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Cancer is the second leading cause of mortality worldwide, 
despite the extraordinary advances in the last two decades due to 
the development of targeted therapies. These target particular 
molecules required for cell growth and tumorigenesis; 
nonetheless, de novo or acquired resistance to therapy often lead 
to patient relapse and disease progression. There is cumulating 
evidence supporting the importance of tumor microenvironment 
(TME)-driven mechanisms in cancer progression and drug 
resistance. Therefore, there is a need for cancer models in which 
critical components of the TME, such as the non-malignant cell 
types and the extracellular matrix (ECM), are represented and 
tissue architecture is maintained. 
The overarching aim of the work presented in this thesis was 
the development of cancer models to address targeted therapies in 
TME-relevant contexts. 
Chapter I reviews the state-of-art, in terms of breast cancer 
(BC) subtypes, available therapies, relevance of the TME for 
therapeutic response, and available experimental and 
computational models. 
In Chapter II, an ex vivo approach was explored to develop a 
BC patient-derived 3D cell model. Our strategy was based on 
encapsulation in alginate, an inert biomaterial, to promote the 
retention of the original TME, combined with dynamic culture, to 
promote diffusion of macromolecules and oxygen. The original 
tissue architecture and microenvironment components, namely 
epithelial, mesenchymal, endothelial, and immune cells, as well as 
an ECM composed of collagen fibers, were retained. Importantly, in 





retention of the TME sustained ERα expression, at gene and protein 
level. Response to ERα stimulation and inhibition was observed at 
the level of downstream targets, demonstrating active ERα 
signaling. Moreover, the challenge experiments with the ERα 
inhibitor fulvestrant, widely used in endocrine therapy, stands as a 
proof-of-concept for the application of the model in the study of 
anti-endocrine targeted therapies. 
In Chapter III, we focused on the biochemical and mechanical 
properties of the alginate capsules, since mechanical cues have 
been reported to influence tumor progression. For this, we 
employed 3D in vitro co-cultures of tumor cells and fibroblasts, a 
model previously established by our group for the reconstruction 
of the microenvironment of solid tumors. We showed that alginate 
encapsulation sustains BT474 BC spheroids phenotype and 
proliferation. Moreover, we observed that the mechanical 
properties of the capsule were affected by its content: the presence 
of cancer cell spheroids reduced the stiffness relatively to empty 
capsules; fibroblasts contributed to a stiffening of the 
microenvironment, when compared to the mono-culture capsules. 
Overall, this study contributed for the characterization of alginate 
capsules, employed by many research groups. 
Finally, in Chapter IV, we addressed antibody transport within 
the TME. We explored the in vitro model system characterized in 
Chapter III to implement an integrated experimental and 
computational framework. The aim of the framework was to 
unravel how the several TME components influence antibody 
distribution. Encapsulated co-cultures were challenged with a 
fluorescent antibody and its location within the alginate capsules 




data was then used to benchmark a computational model, 
developed to simulate a digitized alginate capsule slice. The 
benchmarked model can also be used to generate other capsule 
configurations, according to user specifications. 
In the present thesis, we created and characterized new tools 
to tackle the influence of TME in targeted cancer therapies. We 
explored experimental approaches to establish ex vivo and in vitro 
cancer models, in which key features of the TME could be retained 
or reconstructed, respectively. The in vitro model was 
complemented by in silico approaches to describe transport of 
therapeutics within the reconstructed TMEs. These distinct, yet 
complementary approaches, are tools that can contribute to 
unravel the mechanisms underlying therapeutic response of solid 
tumors and as drug discovery platforms to assess novel targeted 
therapies. 
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O cancro é a segunda principal causa de mortalidade a nível 
mundial, apesar dos avanços extraordinários nas últimas duas 
décadas devido ao desenvolvimento de terapias direccionadas. 
Estas têm como alvo moléculas específicas que são necessárias ao 
crescimento celular e à formação de tumores. No entanto, a 
resistência inata ou adquirida à terapia conduz frequentemente a 
reincidência e à progressão da doença. Actualmente, existem 
evidências que apoiam a importância dos mecanismos moleculares 
relacionados com o microambiente tumoral (TME) na progressão 
do cancro e na resistência aos fármacos. Assim, existe uma procura 
por modelos de cancro em que os componentes críticos do TME, 
tais como tipos de células não-malignas e a matriz extracelular 
(ECM), estejam representados e em que a arquitectura dos tecidos 
seja mantida. 
O objectivo primário do trabalho aqui apresentado foi desenvolver 
modelos oncológicos para abordar terapias direccionadas no 
contexto do TME. 
O Capítulo I revê o estado da arte em termos de subtipos de cancro 
da mama (BC), terapias existentes, a relevância do TME na resposta 
terapêutica, bem como modelos experimentais e computacionais 
já publicados. 
No Capítulo II foi testada uma abordagem ex vivo de forma a 
desenvolver um modelo celular 3D, baseado em tecido tumoral 
mamário de pacientes. A nossa estratégia baseou-se no 
encapsulamento em alginato, um biomaterial inerte, de forma a 





cultura dinâmico que facilita a difusão de macromoléculas e 
oxigénio. A aplicação desta estratégia resultou na retenção da 
arquitectura original do tecido, incluindo os componentes do 
microambiente tumoral (fibroblastos e células epiteliais, 
endoteliais e imunitárias, bem como a ECM composta por fibras de 
colagénio). É de salientar que, no caso de tumores mamários 
positivos para o receptor de estrogénio α (ERα), a manutenção do 
TME reteve a expressão ERα, tanto a nível transcricional e como 
proteico. A resposta à estimulação e inibição do ERα foi observada 
ao nível de genes-alvo a jusante, demonstrando assim que a 
sinalização ERα se encontrava activa. Além disso, as experiências 
com o inibidor de ERα fulvestrant (amplamente utilizado em terapia 
endócrina) representaram uma demonstração da aplicabilidade do 
modelo no estudo de terapias anti-endócrinas. 
O enfoque do Capítulo III foi a caracterização bioquímica e 
mecânica das cápsulas de alginato, dado que alguns parâmetros 
mecânicos têm sido reportados como moduladores da progressão 
tumoral. Para tal, utilizámos co-culturas 3D in vitro de células 
tumorais e fibroblastos, um modelo previamente estabelecido pelo 
nosso grupo para reconstrução do microambiente de tumores 
sólidos. Com este modelo, demonstrámos que o encapsulamento 
com alginato sustenta o fenótipo e a proliferação de esferóides de 
BC, BT474. Observámos ainda que as propriedades mecânicas da 
cápsula foram afectadas pelo seu conteúdo: a presença de 
esferóides de células cancerígenas reduziu a rigidez relativamente 
à de cápsulas vazias; e os fibroblastos contribuíram para um 
endurecimento do microambiente, em relação à cápsulas de mono-




cápsulas de alginato, amplamente utilizado por muitos grupos de 
investigação. 
No Capítulo IV abordámos o transporte de anticorpos no TME. 
Explorámos o modelo in vitro caracterizado no Capítulo III, de 
forma a implementar um framework experimental e computacional 
integrado. O framework teve como objectivo a representação dos 
diferentes componentes do TME e da sua influência no transporte 
de anticorpos. As co-culturas encapsuladas foram tratadas com um 
anticorpo fluorescente cuja localização dentro da cápsula foi 
rastreada utilizando light sheet fluorescence microscopy. Os dados 
obtidos foram então utilizados para treinar um modelo 
computacional, desenvolvido para simular uma fatia digitalizada da 
cápsula de alginato. Este modelo treinado pode ser utilizado para 
gerar novas configurações de cápsulas, de acordo com as 
especificações do utilizador. 
Nesta tese, criámos e caracterizámos novas ferramentas para 
avaliar a influência do TME na reposta a terapias de cancro 
dirigidas. Explorámos abordagens experimentais para estabelecer 
modelos de cancro ex vivo e in vitro, nos quais características 
importantes do TME foram respectivamente retidas e 
reconstruídas. O modelo in vitro foi complementado por 
abordagens in silico, de forma a descrever o transporte de 
fármacos no TME reconstruído. Estas abordagens distintas mas 
complementares, são ferramentas que tanto podem contribuir para 
descobrir os mecanismos subjacentes à resposta de tumores 
sólidos à terapia; bem como podem funcionar como plataformas 
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1. Breast cancer 
Breast cancer (BC) is a pathology which affects the mammary 
gland, characterized by an abnormal growth of cancer cells that 
eventually evolve and invade healthy regions 
1
. The vast majority of 
invasive BCs, and their in situ precursors, originate from the 
terminal duct-lobular unit (TDLU) 
2
. This is a structure in the breast 
composed of a lobule, which is a small cluster of acini, and the 
terminal duct 
3
 (Figure 1.1). BC can spread to other tissues in the 
body, giving origin to metastasis, mainly in lung, bone, lymph 





Figure 1.1: Schematic of segment of breast lobe showing the 




BC represents a major public health problem, since it is the 
cause of the greatest number of cancer-related deaths among 
women 
5
. Although organ-confined disease is mainly curable, 
metastatic and recurrent disease has poor prognosis with a 5-year 
survival of only 27% 
6
. In the USA, about 1 in 8 women will develop 
invasive BC over the course of their lifetime 
7





new BC cases are predicted to be diagnosed and more than 40,000 
people are predicted to die due to BC, in 2020 
7
. In 2008, the 
estimated total productivity loss as a result of premature mortality 
due to BC was $5.49 billion, for young women (aged 20–49) 
8
. 
Metastatic BC represent a significant economic and social burden 
associated with high costs for healthcare systems, with direct costs 
alone accounting for as much as $4.2 billion per year 
9
. In Europe, 
BC had an incidence estimated to be higher than 500,000 cases in 
2018, accounting for €15 billion in 2009, which corresponded to 
12% of the total cancer-related costs 
10
. 
Fortunately, advances in the screening methods (such as 
digital mammography coupled with advanced computer-aid 
detection), early diagnosis, and breakthroughs in treatments have 
increased BC survival rates 
11
. Since 1990, a decline in BC mortality 
started to be observed. This was due to the routine implementation 
of adjuvant therapy (that will be explained later on this chapter, 
section 4) and mammographic screening 
12
. BC research has 
contributed significantly to the discovery of molecular pathways 
involved in tumorigenesis, that are the basis of the targeted 
therapies currently used in the clinics 
13
. Nonetheless, BC relapse is 
still a relevant issue for a high number of patients: the high 
incidence of metastatic disease and drug resistance contribute to 
the high morbidity and mortality indexes 
14–16
. So, it is important to 
uncover the molecular mechanisms which stand behind drug 
resistance and develop novel drugs and therapeutic regimens that 







2. Breast cancer classification 
BC is a genetically, histologically, biologically and clinically 
heterogeneous disease 
17,18
. Given such heterogeneity, different 
response to therapy and outcome are reported 
19,20
 and  various 
classification at histological and molecular levels have been 
purposed to categorize BC 
2,19
. 
Histologically, BC can be divided according with the 
invasiveness status of the disease into: in situ or invasive. In situ 
refers to tumors confined to the ducts (ductal carcinoma in situ, 
DCIS) and lobules (lobular carcinoma in situ, LCIS, Figure 1.2) 
2
. 
DCIS can be further divided in several subgroups according to the 
tumor architecture features 
2
. Regarding the invasive BC group, 
which refers to tumors that are not limited to the epithelial region 
but that have already penetrated into the surrounding stroma 
2
, it 
includes the “no special type” (NST) and “special type” (ST). The ST 
represents 25% of the invasive BC cases and contains tumor with a 
predominant (i.e. >90% of the tumor) differentiation 
2,21
. On the 
other hand, the NST represents the remaining 75% of the cases and 










Figure 1.2: Healthy breast and two BC histological subtypes (ductal 
and lobular). Cancerous region is highlighted in dark purple in the 
mammary overall structure and the cell overgrowth highlighted in the 




It is difficult to establish a relationship between histological 
classification and patient outcome 
22
. The significant differences, in 
terms of treatment and long-term survival, detected among 
patients having the same histological classification, support the 
belief that BC is an heterogeneous group of diseases 
22
. This 
highlights the need for a BC classification based on tumor features 
that can be related with prognosis. In the past decade, microarray‐
based gene expression profiling has been extensively applied to 
the study of BC and led to a classification based on molecular 








The molecular classification of BC was proposed for the first 
time in 2000 by Perou, Sorlie et al. 
23
. It was based on the gene 
expression characterization patterns of a set of 65 surgical 
specimens of BC from 42 different individuals, using 
complementary DNA microarrays covering 8,102 human genes 
23
. 
Patients were clustered into different groups according with the 
overall transcriptome differences. They identified four groups of 
samples: estrogen receptor α (ERα) positive/luminal-like, basal-like, 
Erb-B2+/human epidermal growth factor receptor 2 (HER2) positive 
and normal-like BC 
23
. In a work published one year later, gene 
expression patterns were used as a prognostic marker with respect 
to overall and relapse-free survival 
24
. This work suggested to 
further divide the “estrogen receptor positive” in two distinct 




Currently, the standard molecular classification of BC divides 
tumors into five groups with unique biologic and prognostic 
features: luminal A, luminal B, HER2, basal-like and normal-like 
20,22
. 
Luminal tumors display high expression levels of luminal 
cytokeratins (CK), such as CK8, CK18 and CK19 
25
. Luminal A 
includes ERα-positive and HER2-negative cells with low levels of 
ki67 proliferation marker 
20,22
. Luminal B, with significantly worse 
prognosis than luminal A, includes ERα-positive and HER2-positive 
cells, with higher proliferation rates 
20,22
. The HER2 subtype includes 
cells with high expression of HER2 and low expression of ERα 20,22. 
This highly proliferative and aggressive BC subtype represents 
~15% of all the invasive BC cases 
22
 and usually has an unfavorable 
prognosis. The basal-like BC subtype accounts for up to 15% of all 
BC 
26





and CK14, have low or undetectable ERα and HER2 levels and are 
highly proliferative 
22
. Most basal-like BC have a triple-negative 
phenotype (ERα-negative, progesterone receptor (PR)-negative and 
HER2-negative), but up to 20% express ERα or overexpress HER2 27. 
Patients with this subtype of BC have the worst prognosis among 
all BC subtypes because of the intrinsic aggressiveness and high 
tendency to relapse rapidly. In addition, current therapeutic 
options for basal-like BC are limited to chemotherapy and relapse 
occurs frequently due to drug resistance 
28
. 
A new molecular BC subtype, termed ‘claudin-low’, was 
proposed by Herschkowitz et al. 
29
. Claudin-low tumors are 
characterized by the low expression of genes involved in tight 
junctions and cell-cell adhesion, including claudins 3, 4 and 7, 
Occludin, and E-cadherin 
29
. The “claudin-low” group is 
characterized by inconsistent expression of basal keratins and low 
expression of HER2 and luminal markers, such as ERα and PR 30. 
When compared with other BC subtypes, “claudin-low” highly 
express genes involved in immune response, cell communication, 
cell migration, angiogenesis, extracellular matrix and cell 
differentiation 
30




Despite the high relevance of gene expression analysis, 
namely in grouping and stratifying BC patients, its use on clinical 
samples is resource and time intensive. Therefore, in the clinics, 
immunohistochemical detection of biomarkers of each subtype 
(evaluation of morphology, ERα, PR and HER2 expression status) is 
still the generalized methodology used in diagnosis stage and to 







3. Estrogen receptor signaling in breast cancer 
Estrogen receptor (ER) belongs to the steroid/nuclear 
receptor superfamily and has 2 isoforms in mammals: alpha and 
beta (ERα and estrogen receptor β (ERβ), respectively) 33. The 
isoforms are encoded by two different genes 
33
, mapped on 
chromosome 6 and 14, respectively 
34,35
. Although ERα role in BC 
has been extensively studied, the role of ERβ is still under 
investigation 
36
. ERα is a ligand-modulated transcription factor, 
responsible for the mediation of a plethora of cellular functions 
from development to carcinogenesis, whose structure is 
schematically represented on Figure 1.3 
37,38
. The ER protein is 
composed of several functional domains, associated with specific 
roles. From the NH2 terminal, ER structure consists on an activation 
function domain (AF)-1, followed by a DNA binding domain (DBD) 
and a hinge (H) region. Next to this region is the ligand binding 





Figure 1.3: ER structure. From the N-terminal to the C-terminal: 
activation function 1 region (AF-1), DNA-binding domain (DBD), hinge (H) 
region, ligand-binding domain (LBD), activation function 2 domain (AF-2) 
37
. 
ERα can function both as signal transducer, activating 
various cell signaling pathways, and as transcription factor (TF), 
modulating the expression of several target genes. As signal 
transducer, ER is involved in non-genomic pathways, while as TF is 
involved in the direct and indirect genomic pathways 
39






Figure 1.4: Schematic representation of the different types of 
estrogen receptor alpha (ERα) signaling. Upon estrogen (E) binding to 
ERα, one of three different pathways might be activated: direct genomic, 
in which the E-ER complex binds to estrogen response elements (ERE) 
located in the transcriptional regulatory regions of specific genes; indirect 
genomic, in which the E-ER complex binds to transcription factors (TF) of 
genes that do not have ERE; non-genomic, in which the E-ER complex 





The activation/deactivation of any of the pathway types 
detailed on Figure 1.4 requires the presence of an ERα ligand, that 
interacts with the receptor by binding to the LBD region. In human, 
three different types of physiological estrogens are endogenously 
produced (endoestrogens): estrone (E1), estradiol (E2), and estriol 
(E3) 
40
. They are produced from cholesterol in the sex glands, such 
as ovaries and testes, and in other organs, such as liver and brain. 
E2 is found both in females and males, while E3 is mainly found 
during pregnancy and E1 post menopause 
40
. In addition to 
naturally produced estrogens within the body, a diverse array of 
small organic and inorganic molecules serve as ERα ligands 38. In 





compounds naturally produced by plants), xenoestrogens (non-
natural synthetic chemical compounds with estrogenic effects), 
metalloestrogens (small inorganic compounds in the form of heavy 
metal ions) and several molecules used in therapy, as described 
later in section 4 
38
. ERα ligands can have both stimulatory and 
inhibitory effects 
38
. ERα inhibitors, such as tamoxifen and 
fulvestrant, compete with the estrogen for the binding to ERα and 
block the downstream signaling. This way, they hamper cell growth 
and proliferation and reduce tumor progression 
41,42
. These 
inhibitors will be further explained in the section 4 of this chapter. 
 
The inactive ERα exists in a molecular complex with: 1) 
chaperones – heat-shock proteins (hsp), namely hsp70 and hsp90, 
which bind to the ERα’s LBD region; 2) co-chaperons, such as 
immunophilin and p23, which bind to hsp 
37,43,44
. This complex 
inactivates the transcriptional regulatory capabilities of ER but 
maintains its ability to bind to ligands 
43
. Upon estrogen binding, 
receptor dimerization, dissociation of hsp and association of co-
regulatory proteins occurs 
33
. In these conditions, ERα is able to 
bind to estrogen responsive elements (EREs; which are 13 bp 
palindromic consensus sequence separated by a 3-base spacer 
45
) 
present in the transcriptional regulatory regions of ERα-target 
genes. Here, ERα interacts directly with coactivator proteins and 
components of the RNA polymerase II transcription initiation 
complex, leading to enhanced transcription 
33
 (direct genomic 
pathway, Figure 1.4). Around one third of all estrogen responsive 
genes do not bear an ERE region 
46
. In these cases, the regulation 





(Figure 1.4). ERα interacts with other DNA-bound transcription 




Several genes have been identified as estrogen-responsive 
genes, due to the presence of functional ERE in their promoter 
46
. 
Among them, one can find the trefoil factor-1 TFF1, also known as 
pS2 
47
, and others reported by Lone et al. 
46
. pS2 is an estrogen-
specific response gene, since only estrogen but not progestins, 
glucocorticoids, and androgens, can induce it 
48
. pS2 role is 
controversial, as it has been  reported by different groups to have 
either the capacity to induce or inhibit tumorigenicity 
49,50
. Buache 
et al. performed pS2 gain- and loss-of-function experiments in four 
human mammary epithelial cell lines 
49
. They concluded that 
constitutive expression of pS2 led to an increase in cell migration 
and invasion. Moreover, they observed that tumorigenicity capacity 
of MCF7-pS2 (MCF7 with pS2 overexpression) was the same as the 
parental MCF7. Additionally, they showed that cells with pS2 knock-
down had similar proliferation but higher colony-forming ability. In 
an in vivo mice model, they showed that in pS2 knock-down, 
tumors appeared earlier and had higher incidence than in their 
control counterpart 
49
, suggesting that pS2 inhibits tumorigenesis. 
In a different study, overexpression of pS2 in BC cell lines resulted 
in increased cell proliferation and survival 
50
. Additionally, it also 
increased cell migration and invasion and led to an increase in 
tumor size, in xenograft models. Ablation of pS2 led to a reduction 
in cell viability in vitro and tumor regression in vivo. Then, they 
concluded that pS2 clearly possess oncogenic functions in 







Another relevant gene controlled by ER is the progesterone 
receptor gene (PGR). Progesterone receptor (PR) works closely and 
in a reciprocal manner with ERα. In fact, it is not only an ERα-
induced gene target but also an ERα-associated protein that 
modulates its behavior 
31
. In one hand, PGR only has half ERE region 
in its promoter. The binding of ER to that region revealed to work 
more as an inhibitor than a stimulator, as it is expected when full 
ERE is present 
51
. On the other hand, as described by Mohammed 
et al., progesterone inhibited estrogen-mediated growth, both in 
an in vivo mouse model and in primary ERα-positive BC explants. 
Moreover, they showed that PR boosts the anti-proliferative effect 
of tamoxifen, in a MCF7 BC cell line xenograft model 
31
. They 
concluded that PR controls the chromatin binding and 
transcriptional activity of ERα 31, revealing the combined action 
between ERα and PR. 
In the group of genes regulated through indirect genomic 
pathways 
46
, one can find amphiregulin (AREG). Peterson et al. 
showed that AREG is required for estrogen-dependent growth of 
xenografts generated from the ER-positive cell line, MCF7 
52
. AREG, 
which is a ligand for the epidermal growth factor receptor (EGFR), 




 ER is also involved in non-genomic signaling (Figure 1.4), in 
which estrogen binds to ER located in the cell membrane, leading 
to activation of several protein kinase cascade (e.g. ERK/MAPK, 
p38/MAPK, PI3K/AKT) 
53–57
. This eventually leads to indirect changes 
in gene expression through phosphorylation of transcription 
factors and activation of several pathways 
57
. Mitogen-activated 





family of kinase modules that work by transferring extracellular 
signals to the effectors that control diverse cellular processes, such 
as proliferation, differentiation, migration and apoptosis 
56
. MAPK 
are involved in initiation of cancer and are activated by 
phosphorylation 
56
. p38/MAPK activity can suppress tumor 
development and its signaling is important in cellular responses to 
conventional cancer therapies, including chemotherapy
56
. 
ERK/MAPK has been associated with the ability of cancer cells to 
grow independently of normal proliferation signals and is 
deregulated in approximately 30% of human tumors 
56
. PI3K/AKT is 
an important pathway regulating the signaling of multiple 
biological processes such as apoptosis, metabolism, cell 
proliferation and cell growth 
53
. The AKT signaling cascade, upon 
activation, induce production of phosphatidylinositol (3,4,5) 
trisphosphates (PIP3) by phosphoinositide 3-kinase (PI3K). These 
lipids work as plasma membrane docking sites for proteins such as 
AKT. In turn, AKT, that needs then to be phosphorylated to become 
active, can be inhibited by tumor suppressor phosphatase and 
tensin homolog (PTEN) through dephosphorylation 
53
. 
 In addition to the above-mentioned pathways, ERα can be 
activated in the absence of ligand.  This activation requires 
phosphorylation, in specific residues, that may be induced by 
growth factors, such as epidermal growth factor (EGF) and insulin-
like growth factor. This involves MAPK phosphorylation cascades, 
mentioned above, and guanine nucleotide-binding protein p21ras 
57,58
. 
ER expression itself is regulated by: TFs, DNA methylation, 
histone modification, RNA-binding proteins and microRNAs 
59
. 





translation start site of human ER: estrogen receptor promoter B 
associated factor 1 (ERBF-1), AP2, forkhead box protein (FOXO3a), 
forkhead transcription factor (FOXM1), nuclear proteins recognize 
G-A-T-A nucleotide sequences (GATA-3), zinc finger repressor B-
lymphocyte-induced maturation protein (BLIMP1) and factor 
nuclear kappa B (NF-kβ), which are reviewed in 59. 
ERα is involved in the BC carcinogenesis by controlling cell 
proliferation and metastasis. Among the genes regulated by ERα 
are cyclin D1 and c-myc 
59
, which are proto-oncogenes involved in 
cell proliferation and survival 
60,61
. Estrogen and ERα are also 
involved in the BC metastization process by controlling the 
expression of Snail and e-cadherin 
62,63
. Loss of e-cadherin and 
increased expression of snail is correlated with the epithelial-to-




4. Targeted breast cancer therapies 
BC therapy is typically based on the combination of several 
types of treatments which include non-targeted therapies, such as 
chemotherapy, radiotherapy, surgery and immunotherapy, and 
targeted therapies, which include hormonal therapy, antibodies 




4.1 Hormonal therapy 
Hormonal therapy, also known as endocrine therapy, is 
included in the group of targeted therapy, since it acts only in cells 
carrying a specific cellular target. In the context of BC, hormone 
therapy targets the hormonal receptor ERα and is part of the 





usually during 5-10 years or more 
67,68
. These therapies halt tumor 
progression by blocking either estrogen synthesis or ER signaling 
pathways 
67
. This type of therapy has been shown to be 
advantageous by reducing recurrence rates for almost 50%, when 
comparing with untreated patients 
69
. Hormone therapies are 
divided according to their mechanism of action: aromatase 






Figure 1.5: Types of breast cancer hormonal therapy. BC endocrine 
therapies include 3 different categories of molecules: aromatase 
inhibitors, which inhibit the production of estrogen from androgens; the 
selective ER modulators (SERMs) that agonizes/antagonize ER; selective 
ER down-regulators (SERDs), that fully antagonize ERα 70. 
Aromatase inhibitors, such as the anastrozole, letrozole and 
exemestane, are chemical compounds that hamper aromatase 
activity. These enzymes are involved in the conversion of 
androgens, such as testosterone, into estrogen. By blocking this 
enzyme, it is possible to reduce the amount of endogenous ligand 
(estrogen) available to bind to the receptor (ERα) 70. This type of 
hormonal therapy is only used in post-menopausal women, alone 




Another anti-endocrine therapy approach is based on the 
use of molecules that block specifically ERα signaling named 





such as tamoxifen and raloxifene 
71
. Tamoxifen, also known as ICI 
46 474, is a non-steroidal anti-ER compound, belonging to the 
triphenylethylene chemical group of SERMs, that was developed to 
treat post-menopausal women carrying advanced disease 
72
. 
Nowadays it is used in both pre- and post-menopausal women 
68,70,72
. SERMs have mixed agonist and antagonist activity, depending 
on the target tissue 
70
. In the case of the BC tissue, tamoxifen works 
as an antagonist, blocking transcription of estrogen-regulated 
genes, reducing tumor proliferation 
70
. 
The third type of BC hormonal therapy is based on selective 
ER down-regulators (SERDs), that act similarly to ER modulators but 
have exclusively antagonist effect on the receptor 
73
. Fulvestrant, 
also known as ICI 182 780, is a SERD. It binds to ER, inducing a 
structural change in the receptor that inactivates the AF-1 and AF-
2 domains and inhibits the receptor dimerization. These changes 
lead to an increase in receptor surface hydrophobicity, reducing its 
translocation to the nucleus and promoting consequent faster 
proteasomal degradation 
42,74–76
. So, fulvestrant is both an ER 
competitor and selective estrogen receptor degrader 
77
. Upon 
fulvestrant binding, ER mRNA level is maintained and ER protein 
level is reduced 
78
. ICI 182 780 is currently indicated for the 
treatment of postmenopausal women with metastatic ERα-positive 
BC, after non-steroidal aromatase inhibitor treatment failure 
70
.  
Resistance to endocrine therapy might be intrinsic to the 
patient or acquired during treatment. In this last case are included: 
(1) mutations in amino acids in ERα, resulting in the constitutive 
transactivation of ERα in the absence of the ligand; (2) altered 
expression of ERα co-activators and co-repressors; (3) enhanced 





indirect genomic pathways; (4) microRNA action, for example, 
miRNA 221 and 222, that down-regulate the cell cycle inhibitor 





4.2 Antibody therapy 
With the advances in cancer research, several cellular 
biomarkers have been proposed and their relationship with cancer 
development and progression has been reported. These 
discoveries boosted the development of more specific therapies, 
the so-called targeted anti-cancer agents, such as monoclonal 
antibodies and small-molecule inhibitors 
80
. 
Antibodies have the capacity to selectively target cells 
expressing a specific antigen 
80–82
. Since they are designed to act on 
a specific cellular target, they virtually present higher efficiency and 
less side-effects on non-targeted tissues, when comparing with 
non-targeted therapies 
83
. In the case of BC, examples are the anti-
HER2 antibodies. In the clinical setting, trastuzumab and 
pertuzumab antibodies have been used to target the HER2 receptor 
84
. Trastuzumab was, in fact, the first monoclonal antibody 
approved for the treatment of a solid tumor by the Food and Drugs 
Administration, in 1998 
81
. It is used in both metastatic and 
adjuvant settings 
81
. In clinical studies, combination of trastuzumab 
with chemotherapy and hormonal therapy showed a benefit in 
terms of increased disease-free survival and overall survival 
85,86
. 
Food and Drugs Administration also approved the use of an 
antibody-drug-conjugate (ADC) called trastuzumab-emtansine 
(Kadcyla
®
), which consists on Trastuzumab conjugated with the 





chemotherapy agent maytansine 
87,88
, which blocks microtubule 
polymerization, thus inducing apoptosis in target cells. This ADC 
was approved to be used as an adjuvant treatment of patients with 
HER2-positive early BC who have residual invasive disease after 
neoadjuvant taxane and trastuzumab-based treatment 
87
. 
The major drawback related with anti-cancer antibodies is 
the development of resistance. In fact, the majority of patients who 
achieve an initial response to trastuzumab-based regimens develop 
resistance within one year 
89
. Another drawback is related with the 
fact that several molecules and related pathways that are targeted 
by anti-cancer antibodies are also present in healthy cells, where 
they contribute to cell normal growth and homeostasis 
90
. One 
example is the HER2 which is also present on healthy tissues, 
although at a much lower extent (to 100 vs 2 copies of the gene 




4.3 Small-molecule inhibitors 
 Small-molecule inhibitors (SMIs) are usually ≤500 Da in size, 
which allows them to translocate through the plasma membrane. 
Once inside the cell, they interact either with the cytoplasmic 
domain of cell-surface receptors, such as HER2 or EGFR, or 
intracellular signaling molecules, such as apoptotic proteins 
80
. 
SMIs present several advantages over antibodies such as: (1) oral 
bioavailability, (2) generally good tolerance and (3) due to their 
small size, they can penetrate” sanctuary sites” in the human body 
92
. 
Examples of SMIs approved for the treatment of BC include: 
lapatinib, palbociclib and ribociclib 
93
. Lapatinib is a tyrosine kinase 





of HER2-positive BC 
93,94
. TKI are homologous of the adenosine 
triphosphate (ATP), which allow them to compete for the ATP-
binding domain of protein kinases (present on HER2, for example), 
preventing its phosphorylation and subsequent activation of the 
signal transduction pathways. This results in apoptosis and 
reduction of cellular proliferation 
94
. Lapatinib was approved by 
Food and Drugs Administration as a combination treatment with 
the aromatase inhibitor letrozole in HER2-positive, advanced BC 
patients that have failed standard chemotherapeutic treatment 
80
. 
Palbociclib and ribociclib are cyclin-dependent kinase (CDK) 
inhibitors that have been approved by Food and Drugs 
Administration for the treatment of advanced-stage hormone 
receptor-positive and HER2-negative BC, in combination with 
letrozole 
93,95,96
. Palbociclib inhibits specifically CDK4 and CDK6 
96
, 
that play important role in tumorigenesis since they control the G1-
S phase transition during cell cycle progression 
95
. So, inhibition of 




5. The role of tumor microenvironment in the 
response to anti-cancer therapy 
The tumor mass is not only composed by cancer cells; 
actually, other non-cancerous cells, can be found in the tumor 
environment (TME), such as fibroblasts, adipocytes, endothelial, 
immune cells, pericytes, myoepithelial cells and various progenitor 
cells 
97
. Besides them, several non-cellular components, such as 
extracellular matrix (ECM) and secreted signaling molecules (e.g., 
cytokines and growth factors) are also a part of the TME (Figure 





has been reported to be a critical mediator of anti-cancer drug 
treatment outcome by playing important roles in tumor 
progression 
97,98
. While the TME of early-stage tumors confers anti-
malignancy functions, some cancer cells can tolerate the immune 
suppression and, in turn, reprogram the TME into one exerting pro-
malignancy functions 
99
. So, the understanding of the TME changes 
during this cancer progression is of high relevance when 
developing therapeutic strategies to tackle the tumor at a specific 
stage. 
Some tumors present natural resistance to therapy, not 
responding to the drugs from the beginning (innate resistance)
100
. 
In other cases, an initial response to the treatment is observed 
through cancer progression impairment, but cancer relapses due 
to acquired drug resistance 
101
. Tumor cell-driven mechanisms 
behind this resistance include the activation of DNA-repair 
mechanisms, alterations in drug metabolism and drug transporters 
101
. The latter can be responsible for an increasing drug elimination 
through the ejection of cytostatic therapeutic compounds to the 
extracellular space 
100
 and has a major influence in the failure of 
chemotherapy strategies 
100
. Among those drug transporters are 
ATP-binding cassette (ABC) efflux transporters, such as P-
glycoprotein, which are ubiquitously expressed and normally 
involved in transport of solutes 
100
. 
In this thesis section, the TME components, highlighted in 







Figure 1.6: Breast cancer tumor microenvironment contains tumor 
cells and other cellular and non-cellular components. Non-tumor TME 
cellular components include fibroblasts, endothelial cells, immune cells, 
adipocytes and pericytes. Non-cellular TME components include 
extracellular matrix, (such as collagen fibers and glycosaminoglycans) 




5.1. Cellular components 
5.1.1. Tumor cells 
Tumor cells arise from healthy cells by a progressive series 
of transformations that lead to malignancy 
102
. Together with 
uncontrolled growth, tumor cells are further characterized by 
genomic alteration, increased cell mobility, changes at the cellular 
surface, among others 
103
. However, tumor cells are a 
heterogeneous population with variations at the morphological, 







Tumor cells are the principal component of the TME and the 
primum movens of tumorigenesis and metastasis so, for that 
reason, they are the main target of anti-cancer therapies 
80,105
. A 
multidrug resistance transporter of the ATP-binding cassette 
superfamily of transporters, termed BC resistance protein (BCRP), 
was proposed to be involved in drug resistance 
106
. Overexpression 
of the full-length BCRP cDNA in MCF7 cells conferred resistance to 
mitoxantrone, doxorubicin, and daunorubicin and reduced 
daunorubicin accumulation and retention 
106
. Alternatively, 
continuous exposure of tumor cells to anti-cancer drugs can lead 
to the development of acquired resistance, due to genetic and/or 
epigenetic changes leading to a proapoptotic pathway blockade, 
and/or constitutive expression of anti-apoptotic proteins, as well 






Fibroblasts are mesenchymal cells derived from the 
embryonic mesoderm. They are the pillar of the connective tissue 
that holds the human body together. Fibroblasts produce ECM 
structural proteins (e.g., fibrous collagen and elastin), adhesive 
proteins (e.g., laminin and fibronectin), and ground substance 
(e.g., glycosaminoglycans (GAGs)) 
108
. In healthy tissue, in a wound 
healing scenario, fibroblasts sense and respond to mechanical 
changes and damage signals in the tissue and differentiate into 
activated fibroblasts (myofibroblasts) 
109
. These cells are 
responsible for tissue repair and wound healing through ECM 





There are increasing evidence for the relevance of 
fibroblasts in the TME. In the “tumor is a wound that do not heal” 
theory it is hypothesized that the fibroblasts present on the tumor 
initially act in an anti-tumorigenic manner (by restraining growth 
and eliciting an anti-tumor immune response) 
109
. However, 
fibroblasts are activated by cancer cells to become pro-tumorigenic 
cells, cancer-associated fibroblasts (CAFs) 
110
. CAFs secrete survival 
cues that enhance cancer cell survival, remodel ECM to tumor 
invasion and reshape tumor immunity to generate an 
immunosuppressive environment, promoting tumor development 
109,110
. CAFs are a vastly heterogeneous stromal cell population, 
representing one of the major components of TME. In BC setting, 
CAFs are the most prominent stromal cell type 
109
. 
CAFs origin is controversial; in fact, not all CAFs derive from 
tumor-resident fibroblasts. CAFs have been shown to have diverse 
origins 
110





 and endothelial cells 
113
. CAFs are multiple 
subpopulations that have been divided in several CAFs subtypes: 
F1 tumor-restraining, F2 tumor-promoting, F3 secretory and F4 
ECM-remodeling 
114
. CAFs secretome include, transforming growth 
factor β (TGFβ), EGF, interleukins, fibroblast growth factors (FGFs), 
platelet-derived growth factors (PDGFs), protein ligands in the WNT 
signaling pathways, connective tissue growth factor (CTGF), 
prostaglandin E2 (PGE2), vascular endothelial growth factor (VEGF) 
and metabolites, such as lactate 
110
. Several reports have shown that 
CAFs involvement in pro-tumorigenic functions occurs generally via 
modifications in their secretome 
110
. 
CAFs are key players in therapy resistance and disease 
relapse 
114,115





epithelial-to-mesenchymal transition (EMT), activation of survival 
pathways, immune reprogramming or stemness-related programs 
and metabolic reprogramming in tumor cells 
114,115
. 
CAF-mediated drug resistance can be explained by 
environment-mediated drug resistance (EMDR): (1) based on 
soluble factors which include cytokines, chemokines and growth 
factors secreted by fibroblasts; (2) mediated by cell-adhesion 
between tumor cells and either fibroblasts or ECM components 
116,117
. Within group (1), a study by Straussman et al. used 23 stromal 
cell types to study their ability to influence the innate resistance of 
45 cancer cell lines to 35 anti-cancer drugs 
118
. They suggested that 
anti-cancer drugs capable of killing tumor cells when cultured 
alone, frequently rendered ineffective when tumor cells were 
cultured in the presence of stroma. This effect was particularly 
pronounced with targeted agents compared with chemotherapy. 
They studied in detail the mechanism of stroma-mediated innate 
resistance to the RAF inhibitor PLX4720, in melanoma cells. The 
authors showed that hepatocyte growth factor (HGF) secreted by 
stromal cells induced the activation of the MET receptor tyrosine 
kinase. This lead to reactivation of the MAPK and PI3K/AKT 
pathways, and consequently resistance to RAF inhibition 
118
. Within 
the group (2), it has was reported that adhesion of tumor cells to 
CAFs works as a drug-resistance mechanism, possibly via N-
cadherin homotypic binding, which activates anti-apoptotic protein 








5.1.3. Endothelial cells 
Endothelial cells are the cells lining the blood vessels. In pre-
malignant stages of epithelial tumors, cancer cells are surrounded 
by a basal lamina that separates them from the connective tissue 
121
. In a more advanced stage of the disease, due to the big size of 
the cancer cell clusters and long distance to blood vessel, a hypoxia 
environment is created. This induces cancer cells to release pro-
angiogenic factors, such as VEGFA. Upon binding of this factor to 
specific receptors in neighboring endothelial cells, such as vascular 
endothelial growth factor receptor (VEGFR), angiogenesis is 
triggered 
122
. This process involves an intricate communication 
between endothelial cells and the surrounding matrix, involving 
maturation of primary blood vessels by pericytes and recruitment 
of vascular muscle cells. This results in the formation of immature 
and heterogeneous vasculature characterized by irregular and 
leaky blood vessels 
121,122
. These blood vessels with anomalous 
morphology and excessive branching lead to an increase of 
interstitial fluid pressure (IFP) and irregular blood flow throughout 
the TME, promoting further hypoxia 
121
. This high IFP makes 
difficult the delivery of anti-cancer drugs to target sites within the 
TME and has been correlated with poor prognosis 
105
. 
Anti-angiogenic therapy, which consists on angiogenic 
inhibitors, targets endothelial cells, since: (1) the survival of tumor 
cells is highly dependent on endothelial cells and these cells are in 
much less number so, it is easier to target them than the cancer 
cells; (2) since endothelial cells from different tissues are very 
similar, a unique effective anti-angiogenic drug might be sufficient 
to target those cells in different tumor types; (3) endothelial cells 





to mutation and as a consequence develop therapy resistance 
123
. 
Although in the beginning anti-angiogenic drugs were considered 
to be less toxic than other cytotoxic drugs, it has been shown that 
they may induce severe side effects including lethal hemoptysis 
and intestinal perforation 
123
. 
Since the approval of the first anti-angiogenic therapy 
(bevacizumab to treat advanced colorectal cancer) in 2004, several 
other anti-angiogenic therapies have been approved to be used 
alone or in combination with chemotherapy 
124
. Currently, in the BC 
context, bevacizumab is the anti-VEGF monoclonal antibody most 
extensively evaluated 
125
. It was approved in 2008 by Food and 
Drugs Administration to treat metastatic HER2-negative BC. 
However, in 2011, Food and Drugs Administration withdrew this 
approval due to contradicting lack of overall-survival 
125
. 
Similarly, to cancer cells and fibroblasts, endothelial cells 
have also revealed acquired drug resistance. Gilbert et al. reported, 
using a lymphoma mouse model, that endothelial cells release 
interleukin-6 (IL-6) and tissue inhibitor of metalloproteinase (Timp-
1) in the thymus, upon chemotherapy. This creates a “chemo-
resistant niche”, located in the thymus, that promotes the survival 
of lymphoma cells that can serve as a reservoir for eventual future 
tumor relapse 
126
. Additionally, it has been reported that endothelial 
cells overexpress p-glycoprotein transporter, when compared with 
normal endothelial cells, which confers them resistance to 
doxorubicin and paclitaxel 
127
. Bani et al. showed that TKI and anti-
angiogenic compounds can reverse this resistance in vitro, leading 
to an increase of intracellular drug accumulation 
127
. They 










5.1.4. Immune cells 
The immune system is as intricate and complex system that 
aims to defend the organism from non-self-entities, such as 
bacteria, virus or even cancer 
128
. It involves several types of 
immune cells and their secreted signaling molecules. Altogether, 
the final role is to that neutralize, degrade or induce apoptosis of 
pathogens, infected cells or cells that are not recognized as “self” 
128
. Through a range of mechanisms, the cancer cells tend to escape 
immune surveillance and destruction, leading to tumor progression 
129
. In fact, within the TME, not only anti-tumor immune cells but 
also pro-tumorigenic immune cells can be found, playing distinct 
roles in the different stages of tumor progression 
130
. In the group 
of tumor-antagonizing immune cells one can name: effector T cells 
(including CD8+ cytotoxic T cells and effector CD4+ T cells), natural 
killer (NK) cells, dendritic cells (DCs), M1-polarized macrophages 
and N1-polarized neutrophils 
130
. The group of tumor-promoting 
immune cells consists mainly in M2-polarized macrophages, N2-
polarized neutrophils, regulatory T-cells (T-regs) and myeloid-
derived suppressor cells (MDSCs) 
130
. B-cells have a controversial 
role and so, are not included in neither of those groups 
130
. 
In the tumor setting, DCs are thought to endocytose dead 
neoplastic cells or cellular debris and their main function is to work 
as antigen presenting cells (APC) 
130,131
. They are also involved in 
sensing antigens released by cancer cells. Upon this stimulus, DCs 
become APC, and are transported to the lymph node. There, DCs 





cells become activated effector T-cells (differentiation of antigen-
specific T cells) which have cytotoxic capacity 
131,132
. This process 
involves the MHC, present on the surface of DCs, and the T-cell 
receptor, localized on the surface of effector T-cells surface. This 
interaction triggers a series of proliferative events that lead to the 
expansion of the differentiated effector T cells populations 
132,133
. 
These are trafficked to the tumors mediated by interactions 
between CXC‐chemokine receptor 3 (CXCR3) expressed by T-cells 
with chemokines (such as CXCL9 and CXCL10) secreted by 
dendritic cells 
130,132
. In the tumor site, effector T-cells recognize 
cancer cells through interaction between its T cell receptor and the 
cancer antigen bound to MHC 
134
. After binding to its target, they 
secrete killing molecules, such as death ligands like FasL and TNF-
related apoptosis inducing ligand 
135
. This leads to the release of 
additional tumor-associated antigens that are sensed by DCs, 
initiating the cycle once again 
134
. Each of these steps are the result 
of coordination of stimulatory and inhibitory effects 
134
. This multi-
step process was proposed by Chen and Mellman as the “cancer-
immunity cycle” 
134







Figure 1.7: Schematic representation of the immune-tumor network 
in the “cancer-immunity cycle”. Cancer cells release antigens which are 
sensed by dendritic cells (DCs)/antigen-presenting cells (APCs). These 
cells start presenting cancer antigens on their surface, which are 
recognized by several T-cell types, such as CD8+, CD4+ and activated T-
cells. Upon this contact, they become activated T-cells and are recruited 
from the lymph node to the tumor site. There, they recognize cancer cells 
and release molecules to kill cancer cells 
134
. Immune checkpoint inhibitor 
acts by binding to either programmed cell death protein 1 (PD1) or 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) present of the 




The step of activation and regulation of CD8+ T-cells, upon 
presentation of cancer cell antigens by DCs, requires two signals: 
the first one came from the T-cell receptor (TCR), and the second 
one, co-stimulatory signal from immune checkpoints 
130
. These 
immune checkpoints can have either inhibitory or stimulatory 
effects. Within the inhibitory immune checkpoints, cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) and programmed cell 
death protein 1 (PD-1) are some examples 
130
. Within the 









Another relevant immune cell type present in the TME is the 
macrophage that represents the main immune cell population of 
the TME in most cancers 
137
. Its major functions include 
maintenance of tissue homeostasis, engulfment and digestion of 
foreign substances and clearance of cellular debris and cancer cells 
138
. Macrophages play roles both in innate and adaptative immunity. 
In the cancer context, tumor-associates macrophages (TAMs) are 
obtained by differentiation of monocytes that are recruited to the 
tumor site 
138
 or from embryonic-derived macrophages already 
present in the tumor site 
137
. Upon monocyte recruitment and 
differentiation process, macrophages polarize into: classically 
activated macrophages (M1 macrophages) or alternatively activated 
macrophages (M2 macrophages) 
138
. The phenotype of TAMs is 
plastic and M1 and M2 are only the two extreme phenotypes of the 
several intermediate polarization states in which macrophages can 
be 
138
. M1 macrophages, whose activation can be induced with 
interferon gamma (IFN-γ) and granulocyte-macrophage colony-
stimulating factor (GM-CSF), produce pro-inflammatory cytokines 
with the role to kill non-self-entities 
138
. On the other hand, M2 
macrophage polarization can be obtained by stimulation with 
colony stimulating factor 1 (CSF-1), interleukin (IL)-4, IL-13, IL-10. 
These macrophages are involved in tissue remodeling and 
angiogenesis 
138
. So, TAMs have a dual role in tumorigenesis: they 
can promote tumor progression (by the secretion of IL-6, IL-8, and 
IL-10) or have anti-tumorigenic activity 
138
. 
Macrophages have been reported to be involved in 
resistance against several types of chemotherapy in different types 
of cancer 
139
. In BC, one example of TAM-mediated chemoresistance 
was described by Hughes et al. 
140





show the existence of a subpopulation of M2 TAMs that promotes 
tumor relapse, by accelerating tumor regrowth. These cells, that 
express VEGFA, accumulate near vascularized areas of the tumor 
upon chemotherapy 
140
. Another study by Shree et al. showed an 
increased macrophage infiltration and cathepsin protease levels in 
mammary tumors, in vivo, upon chemotherapy 
141
. Then, using a 
co-culture in vitro assay with BC cell lines with primary bone 
marrow-derived macrophages, they concluded that macrophage-
derived cathepsins prevent tumor cell death upon chemotherapy 
141
. 
Anti-cancer treatment targeting macrophages have been 
proposed by several strategies, such as by PD-1/PD-L1 blockade 




5.1.5. Other cell types 
Other cell types found in the TME includes adipocytes. 
Analogously as it occurs for fibroblasts, normal adipocytes in the 
tumor environment are converted to cancer-associated adipocytes 
(CAAs) 
142
. There, they become storage of ketone bodies, fatty 
acids, pyruvate, and lactate that are seized by tumor cells. 
Additionally, they play roles in inflammation, metabolism and 
exosomes of cancer cells 
142
. In fact, CAAs release several factors, 
such as chemokine (C-C motif) ligand (CCL)2, CCL5, IL-6 and VEGF 
that alter BC cells in terms of p38/MAPK, ERK/MAPK and ER cancer 
cell pathways 
142
. In a study developed by Lehuédé et al., adipocytes 
were shown to promote doxorubicin resistance in both human and 
murine BC cell lines. Adipocytes increase the nuclear efflux of 





mediated by major vault protein (MVP). In fact, co-culture of BC cells 
with adipocytes increased the MVP levels in cancer cells, when 
comparing with cancer cells cultured alone 
143
. Other studies also 
suggest that adipocytes and lipids metabolism can be responsible 




5.2. Non-cellular components 
5.2.1. Extracellular Matrix 
ECM is an interlocking mesh of water, minerals, 
proteoglycans, and fibrous proteins actively interacting between 
them and with the cellular compartment 
145,146
. Based on 
biochemical and structural characteristics, ECM can be classified as 
basement membrane or interstitial ECM 
145
. 
In normal tissues, the basement membrane is a barrier, 
located at the basal side of epithelial or endothelial cells, that 
allows the diffusion of gases and transport of signaling molecules 
145
. This membrane is composed mainly of collagen IV, laminin, 
fibronectin, and several types of proteoglycans 
145
. On the other 
hand, the interstitial ECM, mostly produced by mesenchymal cells 
such as fibroblasts, consists mainly of collagens I and III, 
fibronectin, GAGs and proteoglycans 
145
. In general, healthy tissue 
ECM differs from tumor ECM: this last one usually contains a more 
densely packed network of highly aligned collagen fibers 
147
. 
In the BC setting, ECM components include collagens, 
fibronectin, laminins, GAGs and proteoglycans and non-structural 
proteins, reviewed in 
148
. The predominant component of the ECM 
is fibrillar collagen, whose structure and mechanical properties 
strongly influence tumor cellular phenotype 
145





development both the basement membrane and the interstitial 
ECM suffer modifications. Cancer progression and development of 
metastasis is characterized by the epithelial-to-mesenchymal 
transition (EMT). In this process, epithelial cells acquire a 
mesenchymal phenotype associated with increased motility, 
expression of ECM remodeling enzymes, such as matrix 
metalloproteases (MMPs), and enhanced survival. These MMPs are 
crucial for cancer evasion, since they are enzymes that degrade 
molecules present in both the basement membrane and the 
interstitial ECM 
145
, allowing cell to migrate through the tumor 
interstitium. When cancer cells reach the basement membrane, 
MMP 2 and 9 degrade collagen IV and allow cancer cells to evade 
the tumor site and enter the blood stream 
149
. 
The ECM is responsible for hampering intra-tumoral 
diffusion of therapeutic antibodies and physical masking of target 
receptors on tumor cells 
150
. 
Collagen has been reported to highly influence antibody 
diffusion 
151–153
. Kihara et al. determined the diffusion coefficients 
of biomolecules of various radius (1-10 nm) in a collagen gel 
cultured with fibroblasts. They analyzed the diffusion of those 
biomolecules in collagen gels and they concluded that it is smaller 
near the cell vicinity, when comparing with collagen solution alone. 
Diffusion revealed to be restricted in the proximity of the cells, 
where collagen fibers are highly condensed 
151
. Netti et al., using 4 
different tumor cell lines (colon adenocarcinoma, glioblastoma, 
sarcoma and mammary carcinoma) grown in mice, found a 
correlation between IgG tumor penetration and the extension of 
the collagen network. They concluded that less penetrable tissues 





collagenase treatment. Additionally, they suggested that, possibly 
by binding and stabilizing GAGs, collagen influences the tissue 
resistance to macromolecule transport 
152
. Davies et al. measured 
the diffusion coefficient of nonspecific IgG in three 
rhabdomyosarcoma subclones growing as in vitro multicellular 
spheroids or in vivo. They reported that, the higher the amount of 
collagen and sulphated GAGs, the lower was the antibody diffusion 
coefficient, for spheroids grown in vivo 
153
. On the other hand, Beyer 
et al. performed immunohistochemical studies of tumor sections 
from BC patients and xenografts. They observed co-localization of 
HER2 protein and laminin in HER2-positive BC and ovarian cancer 
biopsies. This suggest that laminin can mask HER2 on the tumor 
cell surface and, as a result, reduce therapeutic antibody access to 
its target site 
150
. 
Hyaluronic acid (HA) is accumulated in most human tumors, 
especially in various adenocarcinomas, such as BC 
154
, and has been 
reported also to play important roles in drug resistance. Ricciardelli 
et al. showed that carboplatin treatment increased the expression 
of production of HA. Also, they proved that HA can regulate the 
expression of ABC drug transporters, in ovarian cancer cells, 
contributing then to chemoresistance 
155
. In another work, Chen 
and Bourguignon showed that HA-CD44 binding is behind a 
chemoresistance mechanism in MDA-MB-468 BC cells 
156
. The 
authors showed that HA binding to CD44 promoted c-Jun nuclear 
translocation and consequent transcription of miR-21 gene (which 
is involved in BC progression). This led to enhanced expression of 
Bcl2 and inhibitors of the apoptosis family of proteins, which were 









Cytokine is a general term which include a large variety of 
chemokines, growth factors, pro- and anti-angiogenic factors, 
adipokines, soluble receptors and extra-cellular proteases 
107
. They 
are involved in several tumorigenic processes related with tumor 
development and metastasis, such as inflammation, angiogenesis, 
cell migration and apoptosis 
107
. 
Cytokines have been reported to play relevant roles in drug 
resistance 
107
. Conze et al. showed that expression of IL-6 increased 
drug resistance by activation of C/EBP transcription factors and 
consequent induction of expression of mdr1 gene (which encodes 
the p-glycoprotein transporter). This lead to a reduction of 
intracellular concentration of anti-cancer drugs 
157
. Another study 
found that, in a multidrug-resistant human BC cell line (MCF7/R), 
both IL-6 and IL-8 proteins levels were increased when in 
comparison with the parental sensitive cell line (MCF7). Drug 
resistance against paclitaxel and doxorubicin was partially 
neutralized upon anti-IL-6 and anti-IL-8 antibody treatment or 
inhibition of endogenous IL-6 and IL-8 with small interference RNA, 




Cytokines have been also reported to induce resistance to 
antibody anti-cancer therapy. Kim et al. reported that AREG, a 
ligand of EGFR, confers trastuzumab resistance to HER2 positive 
BC. They showed that addition of AREG, in a colony-forming assay, 
increased cell proliferation and reduced the anti-proliferative effect 
of the anti-HER2 antibody trastuzumab. Additionally, they state 
that: (1) the mechanism behind this observation involves the AKT 





ERK were phosphorylated upon trastuzumab treatment in the 




6. Breast cancer models 
The study of BC development and testing of new promising 
anti-cancer compounds are conducted in BC models. Broadly, these 
models can be divided into 2 main groups: experimental and 
computational (in silico) models. Within the first group, 3 types can 
be defined according with the biological sources and cell culture 
technique used: in vitro (cell-based approaches), in vivo (animal 




6.1. In vitro models 
In vitro cancer models, based on cell culture of cancer-
derived cell lines, have leveraged the study of tumor-associated 
phenomena, such as tumor cell growth, migration and invasion and 
drug delivery 
161
. Currently, in vitro models range in complexity and 
can be classified into 2-dimensional (2D) or 3-dimensional (3D) cell 
models 
161
. The vast majority of these models are based on cancer 
cell lines commercially available. In the specific context of BC, more 
than 90 cell lines exist 
162
 and several in vitro models have been 












































Figure 1.8: Tumor models used in cancer research can be divided in 
2 main groups: experimental (in vitro, in vivo or ex vivo) and 




6.1.1 2D cell culture 
In vitro 2D cell cultures are the standard models used for 
screening candidate anti-cancer therapeutics 
174
. These models 
include culture of cells directly on flat substrates as monolayers 
175
 
(Figure 1.8). In the 2D cell culture methods, cells are grown in 
unrealistic conditions that do not recreate the physiological and 
pathophysiological situations 
161,175
. Mechanical and biochemical 
signals and cell-to-cell communication sensed by the cells in 2D 
conformations are clearly different from the in vivo situation 
175
. 
Therefore, cells cannot retain their tissue-specific architecture 
since they are forced to be in a flattened and stretched shape, with 
forced polarity 
175
. Despite its simplicity, most cancer biology 
research was based on those models 
175
. The 2D cultures have 
several advantages such as: can be easily implemented, are low 
cost and easily adapted to high-throughput systems 
161,175
. 
Additionally, several cell types, ECM components and soluble 




The transwell systems, considered by many as a 2.5 D 
system, is employed in the assessment of the migration and 
invasion potential of cancer cells, that can be induced by several 
cues, such as chemical attractants
161
. The transwell platform 
comprises two chambers: in the most common setting of migration 
assays, cells are seeded on the top chamber (insert) onto a porous 





added. Cell migration is assessed by evaluation of cell movement 
towards the bottom chamber 
161
. In the case of invasion assays, a 
component mimicking basement membrane is added on top of the 
porous membrane of the insert prior to cell seeding. This allows to 
assess the potential of cancer cells to invade through that 
membrane, as it occurs in the first stages of cancer evasion 
161
. 
Several variations of the transwell system exist and were reviewed 
by Katt et al. 
161
. The transwell system also allows co-culture and 
3D cell culture. It has been employed by several authors to mimic 
cellular barriers, such as the blood brain barrier 
178
. Endothelial and 
epithelial layers can be cultured in the upper and lower side of the 
upper chamber, respectively, while the tumor cells are cultured in 
the lower chamber 
179
. In other configurations tumor or stromal 
spheroids can be included in those chambers 
180,181
. The major 
advantage of the transwell system is that the cellular compartments 
are physically separated, facilitating endpoint analysis in the 
distinct cell compartments. On the other hand, this can also be 
seen as a disadvantage as most of the times these configurations 




6.1.2 3D cell culture 
The growing recognition of the importance of the TME in 
cancer progression and therapy resistance (as referred in section 
5), together with technological and methodological advances, 
contributed to the recent shift from simple 2D flat cell culture to 
complex cell models that include several cell types, ECM 
components and soluble factors 
161
, in conditions physiologically 





variables present on the TME can be included and studied, such as 
different cell types, ECM and biochemical cues 
161
. 
Amongst the 3D cell models available, the spheroids, the 
organoids and the systems based on bioprinting will be discussed 
in further detail. 
 
Spheroids 
Spheroids are the simplest 3D cell culture system. Their 
preparation can be achieved by: (1) stimulating single cells to 
generate spherical colonies by proliferation or (2) inducing single 
cells to aggregate into clusters that later grow in size due to cell 
proliferation 
182
. Techniques to prepare spheroids can be divided 
into dynamic or static methodologies. Agitation-based culture 
systems and microfluidic systems 
183
 (in the dynamic group) 
184
 and 




, microwell arrays 
187
 and embedding in matrices 
190
 (in the static group) have been 
used to prepare spheroids (Figure 1.8, reviewed in 
161,187,191
). 
Agitation-based culture systems include gyratory rotation 
techniques, rotary culture systems and stirred suspension culture 
systems 
184
. In these systems, hydrodynamic forces generated by 
the agitation promote cell collisions, increasing adhesion binding 
kinetics at the cellular and molecular level, leading to spheroid 
formation 
184
. During the aggregation process, stirring rates must 
be controlled to promote cell aggregation while avoiding cell and 
spheroid damage by the shear stress 
184
. These systems allow 
spheroid mass production and long-term culture. However, control 
of size and composition, when preparing spheroids containing 
several cell types, is cell-type dependent and has to be adjusted 
184
. 









Several groups have proposed the use of microfluidics 
technique to prepare spheroids 
192
. One case includes the 
microfluidic-based methodology that uses patterned polymers 
together with PDMS to create molds, or PDMS molds with v-bottom 
microwells, where cells are seeded 
193,194
. Microfluidics methods 
allow to control spheroid size and growth parameters. Moreover, 
they allow performing the aggregation under perfusion condition 
161
, reducing nutrient and oxygen deprivation and waste products 
accumulation. The major drawback of these systems is related with 
the difficulty in collecting the spheroids and the preparation of the 
device itself 
161,195
. The most used type of microfluidic based-
methodology is named microwell-based microfluidic spheroid 
formation chip (µSFC) 
192
. It consists on a chip containing microwells 
connected by microchannels to the inlet. A cell suspension is 
introduced in the inlet, fills the microchannels and then deposit on 
the bottom of the microwells. In each of those microwells, a 
spheroid is formed 
192
. One example of this methodology applied 
in the BC context, was proposed by Wu et al., who established a 
proof-of-concept of the utilization of the platform for MCF-7 
spheroid self-assembly 
196
. The authors claim that this platform 
allows the formation of large amount of uniform spheroids (with 
narrow size distribution) and also the characterization of spheroids 
dynamics. They are formed due to trapping of cancer cells in U-
shape traps and their compactness is assured by a continuous 
perfusion system 
196
. However, validation of the platform with 
additional cell lines is still required considering that aggregation 







Regarding the static culture methods, the liquid overlay 
technique (LOT) is based on a non-adhesive surface and gravity. As 
cells cannot adhere to the substrate, cell-cell interactions are 
promoted by proximity, leading to the formation of spheroids 
185
. 
It is a cost-effective technique that allows easy monitoring of 
spheroid formation. However, spheroid size and cell number 
cannot be controlled 
195
. In the hanging-drop (HD) technique, a 
droplet of single cell suspension is formed and left static, leading 
to cell sedimentation in the bottom of the droplet by gravity. Like 
in the LOT technique, gravity promotes cell-cell contact and 
spheroid formation 
185
. Although HD is cost-effective, it is also time-
consuming and does not allow for long-term cultures 
195
. Microwell 
arrays, which are round-bottom nonadherent 96-well plates where 
cells are seeded, can also be used to prepare spheroids 
187
. 
Commercially available multiwell plates, including round bottom 
nonadherent wells or wells at the micro scale, like the AggreWell™ 
system, can be also used to prepare spheroids. These are simple 
methods that allow easy monitoring of the aggregation process, in 
which co-cultures can be easily implemented 
195
. Due to their 
inherent static nature, these methods can promote nutrient and 
oxygen deprivation and waste accumulation, reducing its potential 
to be used when long-term aggregation periods are needed 
161
. 
Alternative methods include the embedding of single cells in 
scaffolds and hydrogels to give origin to spheroids. Examples 
include AlgiMatrix 
190
 and carboxymethyl cellulose. The later 
compound, when added to culture medium, increases its viscosity, 
preventing the cells from sediment or adhere to the culture device, 
leading to spheroid formation 
185
. Combinations of the methods 





proposed by Frei et al. that presented a platform joining hanging-
drop and microfluidics to prepare spheroids 
198
. 
The abovementioned methods can be applied to a single cell 
type, originating mono-cultures, or to a combination of multiple 
cell types, originating co-cultures 
176,177
. After spheroid preparation, 
they can be cultured per se on the same platform they were 
prepared (e.g. microfluid device, spinner vessel 
175
) or can be 
combined with scaffolds for long-term maintenance (e.g. 





Another type of 3D model widely used is the organoid. The 
term mammary organoid has been used since the 1980s, when 
Mina Bissel seminal work established that functional differentiation 
of mammary epithelial tissue was dependent on 3D architecture 
and interaction with basement membrane 
201
. Recently, organoids 
have been defined as 3D multicellular structures in which cells self-
organize to recapitulate some of the organ functions 
166,202
. Within 
the scope of this current definition, organoids can be established 
from embryonic stem cells, induced pluripotent stem cells, somatic 
stem cells, and cancer cells (in this case are also called tumoroids). 
The establishment of tumoroids starts with cancer cells isolated 
from cancer tissue. Those cells are cultured in basement membrane 
mimetics, in the presence of specific growth factors and small 
molecule inhibitors which expand and differentiate the epithelial 
cell population 
203
. Sachs et al. reported the derivation of more than 
one hundred breast cancer organoids, which recapitulated the 
diversity of the disease 
204
. These organoids were obtained by 





enzymatic digestion cells are placed in basement membrane 
mimetics (e.g., Matrigel) and cultured in the presence of niche 
factors, which in vivo are secreted by the stroma, and have been 
previously reported to be required for the formation of organoids 
205
. 
Organoids have been used to study genetic mutations 
leading to tumor initiation and progression 
206
. Additionally, 
organoids have been applied in drug development 
203
, in particular 
in precision medicine approaches, aiming to determine individual 





Bioprinting is a recently proposed technology with great 
potential to generate not only spheroids but also more complex 3D 
cancer cell models. It consists on printing to a substrate or liquid 
reservoir, in a layer by layer fashion, several components (that can 
include cells, ECM and biomaterials) with a tailored pattern, in 
order to mimic native tissue architecture 
167
. Then, this technology 
allows to reproduce both the structural heterogeneity and 
biomolecule gradients that play important roles in cancer 
167,207
. 
Bioprinting can be achieved using one of three techniques: 
microextrusion bioprinting, laser-assisted bioprinting or inkjet 
bioprinting, which have different spatial resolution, allow different 
cell densities to be printed and different gelation methods 
167
. In 
the case of the microextrusion bioprinting, a continuous flow of 
bioink is generated through pneumatic or mechanical forces. In the 
case of the laser-assisted, a laser is used to guide or induce cell 
deposition. In the case of the inkjet bioprinting, bioink droplets are 
created by a heater or a piezoelectric actuator 
167





cell models using bioprinting, two possible strategies exist: first to 
print the scaffold and then to seed the cells (two-step fabrication) 
or, alternatively, print both at the same time (one-step fabrication). 
An alternative is based on scaffold-free printing, in which only the 
several cell types, capable of producing their own matrix, are 
printed 
167
. One example of the use of 3D bioprinting for generation 
of BC models is the work by Wang et al.. The authors bioprinted 
primary BC cells surrounded by different thicknesses of adipose 
derived mesenchymal stem/stromal cells (ADMSCs), to mimic 
different obesity status and challenged the model with 
chemotherapy to address resistance 
208
. Another example that 
highlights the potential of bioprinting to recapitulate cellular 
organization of the tumor tissue is the work by Langer et al.. The 
authors prepared scaffold-free co-cultures of tumor cells (several 
BC subtypes) surrounded by stromal cells (different cell types) 
209
. 
They demonstrated that the several cell types could be successfully 
co-cultured and that chemotherapy and targeted therapies 





Numerous technologies have been proposed in recent years 
for the generation of advanced in vitro tumor models. One of the 
most relevant examples is the organ-on-chip and human-on-a-chip 
concept 
168
. These consist on the 3D combination and deposition, 
on a microfluidic device, of cells and ECM, which are perfused 
through hollow microchannels with culture medium in order to 
maintain cell viability for long periods of time 
168
, simulating the 
connections between organs by the circulatory system. One 







created a chip containing a layer of epithelial cells on top of a layer 
of fibroblasts, separated by an ECM-derived membrane. On top of 
epithelial cell layer, BC spheroids were deposited to mimic the 
initial phases of BC development (ductal carcinoma in situ). This 
tumor-on-chip model was used as a proof-of-concept to test a 
chemotherapy drug which was perfused in the lower channel to 




6.2. In vivo models 
Animal models are a gold standard in cancer research. 
Mouse is the most used animal, since is easy to maintain and 
handle, has a short reproductive cycle and share genomic and 
physiological properties with humans 
211
. Mouse model can be 
created by genetically engineering strategies, human/mouse 
cell/tissue transplantation or viral/physical/chemical insults 
169
. 
Genetically engineered mouse model (GEMM) are genetically 
modified mice containing in its genome cloned human cancer 
genes (such as the HRas oncogene). This model however fails to 
recapitulate sporadic cancer appearance due to accumulation of 
genetic events in a single cell, as it occurs in human cancers 
212
. So, 
other mouse models have been developed and currently several 
types of GEMM models are available, such as the conditional GEMM. 
In this model, a given allele is phenotypically wild type until 
stimulation, with exogenous chemicals or viruses, is performed in 
a tissue- and time-specific manner. These allow somatic 
inactivation of tumor suppressors or activation of oncogenes, by 
recurring for example to the Cre-lox system 
213,214
. These models are 
germline GEMMs since mice carry genetically engineered alleles in 





steps, such as targeting embryonic stem cells, generation of 
chimeras, germline transmission and complex mice intercrosses. 
Therefore, their development and validation are time-consuming, 
laborious, and expensive 
212
 and so, they are not easily adapted to 
high-throughput translational research and drug testing 
215
. This 
led to the development of non-germline GEMMs (nGEMMs; mouse 
models carrying genetically engineered alleles in somatic cells, but 
not in germline cells) 
212,215
. One example is the clusters of regularly 




Other mouse model is the transplantation mouse or 
xenograft, which it is based on immunocompromised mice lacking 
an effective immune system in order to avoid transplant rejection 
217
. According with the origin of the tissue/cells to be transplanted, 
they can be categorized into: cell line-derived xenografts (CDXs), if 
human established cell lines are implanted; patient-derived 
xenografts (PDX), if human tumor tissue is grafted 
217
. Alternatively, 
syngeneic mouse models (graft using cancer cells from mice) can 
also be prepared 
212
. Transplantation models can also be 
categorized according with the place within the mouse body where 
cells/tissue are/is transplanted: orthotopic (transplanted to the 
same body site from which the tumor was originated), ectopic 
(when transplanted to a different site from the site of origin) and 
intravenous, usually injected in mouse tail-vein, for metastasis 
study in vivo 
218
. The subcutaneously-injected mice model is the 
standard model used in the development and evaluation of new 
drugs in the pharma industry 
219
. 
The representative potential of CDX is low since, contrarily 





populations, an homogenous mass of tumor is injected in mice 
220
. 
To surpass this problem, tumor tissue-transplanted mouse models 
(PDXs) were developed, in order to obtain the different cell 
populations of the original tumor. PDX models allow preservation 
of many relevant features of the primary human tumor, including 
histological features, behavioral characteristics (such as 
invasiveness and metastatic capacity) and most importantly, 
response to therapy 
217
. However, in PDX, human tumor tissue 
availability is as issue. Another important aspect is that PDXs are 
generated in immunocompromised mice, therefore the influence of 
the immune system cannot be addressed. Moreover, the initially 
transplanted human stroma and immune infiltrate tend to be 
replaced by mice stroma over passage 
217
. In order to circumvent 
the drawbacks related to the absence of the immune system, the 
latest developments in mice models have been focused on 
humanized mice, which consists in immunodeficient mice 
engrafted with human cells or tissues, in order to overcome the 
differences between mice and human physiology 
221
. Syngeneic 
mouse models circumvent the need for an immune-compromised 
animal, allowing to evaluate the role of the immune response in 
cancer progression 
218
. These enabled the investigation and 
development of various immune therapies 
222
 nonetheless, they 
may not represent human specific signaling. 
In BC, ER represents a very important receptor, as described 
previously. So, having an ER-positive BC animal model is of high 
relevance. As observed in 2D culture, upon xenotransplantation in 
vivo, the most aggressive cell subtypes tend to overpopulate the 
transplant, biasing these models towards the triple-negative BC 
subtype 
217





generate xenografts in mice and they require estrogen 
supplementation 
223
. The challenges of modelling ER-positive BC in 
mice has been recently reported 
224
. A comparison study of all BC 
GEMM showed that only the Stat1
−/−
 and the Pik3ca-H1047R models 
develop ER-positive tumors 
225
. CDX mouse models of ER-positive 
BC cell lines are based on: (1) BT474 cell line (subcutaneous) 
226
, 
MCF7 cell line (orthotopic transplantation into mammary fat pad) 
227
 and T47D cell line (subcutaneous) 
228
. Xenografts of ER-positive 
BC are typically injected in the mammary fat pad, which leads to 
changes in tumor cell phenotype. In fact, it was demonstrated that 
when luminal tumor cells were injected in the mammary fat pad, 
their characteristics were lost and cells acquired a basal-like 
phenotype 
223
. Moreover, the engraftment rate is very low (2.5%) 
and ER+ tumor cells need exogenous estrogen to grow. Due to all 
of these drawbacks, injection in the milk ducts was proposed by 
Behbod et al. as a more relevant site of injection: intraductal mouse 
models (MIND) 
229
. This system was latter better characterized by 
Sflomos et al. 
223
. The authors observed that tumor cells were able 
to recreate advanced BC stages, such as the breakdown the 
basement membrane and invasion of the stromal space into the fat 
pat. In this case, engraftment rates increases to 30-100% and there 
was no need for estrogen supplementation 
223
. This strategy is a 
great improvement over the models described previously, since it 
allows the engrafted cells to be maintained in a luminal-epithelial 
like phenotype, typical of the ER-positive tumors. However, this 
strategy still has drawbacks, such as the technical difficulties in 
performing the implantation, the long time needed for engraftment 





of immune system, and the exclusive presence of murine cells in 
the stromal compartment 
223
. 
In addition to mice, other animal models that have proposed 
for cancer research, such as zebrafish 
230
. These small fishes have 
high genetic homology to humans, and their embryos are 
transparent, which facilitates analysis of engrafted cancer cell 
growth and metastasis. Zebrafish is easy to maintain and has 
reasonable cost 
230
. Moreover, it allows genetic manipulation at low 
cost and within short time 
230
. Within the BC field, Drabsch et al. 
demonstrate that the zebrafish sustains invasion and metastasis 
upon transplantation of human BC cell lines with different 
metastatic potentials into the blood. Moreover, they showed that 
that animal model can be used to study the role TGF-β signaling in 
BC invasion and metastasis 
231
. Additionally, dogs and primates 




Even though animal models have assisted  the discovery of 
cellular and molecular mechanisms associated to cancer 
tumorigenesis and the drug development process, they are still far 
from being able to recapitulate fully human cancer etiology, 





6.3. Ex vivo models 
Ex vivo models consist on the culture of freshly isolated tumor 
samples with the aim to preserve the original tissue architecture 
and heterogeneity, and the surrounding microenvironment 
172
. The 
most described ex vivo models are based on tissue slice and 





human or animal origin 
236
 and can be cultured: (1) in suspension 
in culture media 
172
, (2) in an air-liquid interface 
237
, (3) in a scaffold 
that mimics the ECM 
238
. 
In the 60s Matoska and Stricker, suggested the culture of 
cubes of tumor tissue combined with a collagen gel support. 
However, problems related with oxygen and nutrient diffusion were 
reported due to the size of the microtissues 
172
. To overcome 
oxygen and nutrient diffusion problems associated with that 
technique, Nissen et al. later adapted the methodology to obtain 
uniform, microscopically controlled tissue slices 
239
. In fact, since 
then several other models were proposed based on these tissue 
slices. An example is the model proposed by van der Kuip et al. 
that used a tissue punch to generate 0.2 mm thick BC tissue slices 
that were cultured for 3 days in suspension. This method was used 
as a drug testing platform to address taxol sensitivity 
172
. 
Several ex vivo BC models were developed which aimed at 
retaining ERα, given its role in BC carcinogenesis and as it is a target 
of endocrine therapy (as described above). Milani et al. 
240
 reported 
the maintenance of epithelial–mesenchymal interactions and 
viability of BC tissue slices for 24h, which were employed to 
evaluate the vitamin D pathway 
240
. To overcome possible oxygen 
and nutrient diffusion problems, due to the size of the tissue slices, 
Parajuli and Doppler proposed the use of precision cut slices, which 
allow to control the slice thickness. They applied this strategy to 
mammary tumor collected from mice and studied the action of 
cytokines and cytotoxic drugs for up to 48 h: apoptotic scores and 
gene expression were assessed in tissue slices treated with IFN-γ 
and cell death was induced by doxorubicin 
241
. Additionally, 





infected by an oncolytic adenovirus and that the virus was able to 
replicate in the slices 
242
. Davies et al. performed a comparison 
study between different strategies to culture of breast tumor 
tissue, among others
237
. They compared tissue slices floating in 
culture medium or placed on a filter support, in direct contact with 
air. Tissue morphology and integrity was better for tissue slices 
cultured on the filters and in the presence of atmospheric oxygen. 
However, the authors observed necrosis and stress biomarkers in 
the area of the tissue in contact with the filter, whereas the area in 
contact with the air was enriched in mitotic cells 
237
. Additionally, 
ERα-positive cells were not efficiently retained  in filter supports 237. 
Naipal et al. reported an optimization that combines manual or 
automated tissue slicing (to obtain an optimized tumor slice 
thickness), specific growth medium and shake-based dynamic 
culture 
243
. Results revealed that cell proliferation was preserved for 
7 days of dynamic culture, without significant morphological 
differences from the original tissue. The authors also showed that 
those tissue slices could be used to study chemotherapy 
243
. Muraro 
et al. reported the use of a perfusion-based bioreactor combined 
with a collagen scaffold to culture BC tissue 
238
. They showed that 
cell viability was higher in perfused tissue when compared with the 
one cultured in static conditions. Even though, in the perfused 
system, after 14 days, viable cells represented only 20-25% of the 
total cells in the tumor fragments. Tissue slices cultured in the 
perfusion system sustained the patterns of cancer driving genes of 
the original tissue 
238
. To show that the system could be used to 
test BC therapies, perfused tissue slices were incubated with 
standard-of-care compounds. When incubated with an ERα targeted 





epithelial cells was observed 
238
. When treated with an antibody 
against HER2, pertuzumab, a reduction of viable HER2-positive 
tumor cells was reported 
238
. However, no ERα or HER2 signaling 
pathways were assessed to verify the functionality of those cellular 
receptors: only cell viability was evaluated. 
The ex vivo ERα-positive BC models described were able to 
maintain cell viability, architecture and hormonal receptor 
expression typically for a week. This brings difficulties when trying 
to use those models for long-term monitoring of disease 
progression and for interrogation of the long-term effects of drug 
treatments. Furthermore, reaching robust conclusions is more 
difficult than when using cell lines due to the inherent 
heterogeneity between patients and material limitation 
244
. In 
regard to analysis endpoints, several techniques routinely applied 
to in vitro models might be difficult to apply on ex vivo tissues, due 
to the limited amount of material 
244,245
. Additionally, some of the 
methodology used to supports BC tissue take advantage of 
collagen scaffolds that are biologically active animal-derived 
biomaterials which bring variability and ethical concerns 
246
. 
Overall, tissue slices and explants seem a promising and 
powerful way to create valuable cancer models, retaining the 
original tumor tissue architecture including the cellular and non-
cellular components of the TME 
244
. This represents an invaluable 
tool to study the role of 3D architecture and stromal interactions 
with the tumor cells 
245
. Since the original features of the tumor 
tissue are maintained, treatment responses are potentially closer 
to ones observed in patients than in in vitro models where tissue 






6.4. In silico models 
In silico refers to analyses “performed in a computer” or “via 
computer simulation” 
160
. It includes both the processing of large-
scale data and the use of computational models that represent key 
features of a physical system, as mathematical equations 
160,247
, in 
order to describe its behavior. 
Computational models used in cancer research can be 
divided in two main groups: probabilistic and deterministic models 
248
. In the former, the events have a certain probability to occur, so 
they are associated with a degree of randomness 
248
. In the latter, 
the events are described by mathematical equations that always 
produce the same output for a given input 
248
. 
A cancer model can represent different biological levels, 
based on the scale of the phenomena to be modeled: (1) molecular 
level, which considers genomic, transcriptomic and signaling 
pathways, together with biochemical reactions; or (2) 
microenvironment and tissue level, in which events are considered 
at the scale larger than the nano-scale 
249,250
. In this last case, the 
representation of the tumor and its components can be achieved 
following several different strategies (Figure 1.9), which differ on 
how cells are represented: continuum masses or as sets of discrete 
elements 
173,251
. Discrete cells can be distributed homogeneously in 
a grid-like pattern, where all cells have a specific number of 
neighboring cells, or heterogeneously, leading to a variable 


















Figure 1.9: Different types of computational models exist to model 
tumors. A) Schematic representation of different mathematical models of 
multicellular systems. (a) in a continuous model, the properties of the cells 
are considered as an average of all the cells of a specific type; (b) in a 
cellular automata model each cell is allocated to a lattice and has 
independent features; (c) in a particle center-based cells are allocated off-
lattice with variable number of neighbors; (d) in cellular Potts each cell is 
allocated to several lattices; (e) in IBCell cells have variable shape with 
different dimensions; B) table summing up the features of each model 




Among the several tumor-related phenomena that have been 
modelled in silico, great relevance can be attributed to models that 
tackle anti-cancer drug delivery and distribution within the TME 
(several TME elements can influence therapy resistance, as 
previously explained in section 5). During tumor drug delivery, 
several steps can be considered from the moment of drug 
administration until this reaches its target cells in the TME 
252
. Here 
we focus entirely on the drug transport phase between leaving the 






Figure 1.10: Schematic representation of drug transport barriers, 
within the tumor interstitium, that hinder drug delivery between the 
vasculature and the target cell. Therapeutic molecules (identified by the 
blue and yellow stars) enter the blood stream after systemic injection. 
Near the tumor site, these molecules cross over the vascular wall and 
reach the tumor interstitium. There they face several barriers, such as 
different cell types (immune cells in purple and fibroblasts in pink) and 
ECM components, e.g. collagen fibers (purple lines), GAGs (red spheres) 
and laminin (light red crosses), until they reach the target cancer cell 
(green cell) 
252
. This transport phase is represented by the dashed black 
arrows. 
 
Within the TME, the preferential drug transport mechanism 
is highly variable, ranging from pure diffusion to a combined 
convection diffusion mechanism. The following contributions use 
diffusion as their core transport mechanism within the TME. Groh 





within the tumor using diffusion-based models 
253
. The tumor was 
modelled by three different approaches: (1) cell-centre model, in 
which the computational nodes surround the central vessel; (2) 
radially symmetric models with circular-compartment regions and 
(3) continuum homogeneous model. In any of the cases, drug 
delivery is performed by a vessel located in the center of the tumor. 
Three-compartments are considered: (1) the extracellular space; 
the intracellular space, which include (2) free and (3) bound 
intracellular drug compartments. In each of those compartments, 
drug balance equations (including diffusion in the continuum 
model) are applied 
253
. Xie et al. developed a hybrid three-
dimensional computational model to study how the environment 
influences drug diffusion and drug-tumor interactions, among 
other features 
254
. Drug concentration over time is calculated by a 
continuum diffusion-reaction model. This is combined with a 
discrete cell automaton model (accounting for the evolution of the 
invasive solid tumor), creating then the hybrid model. The tumor is 
defined by an avascular or vascular circular shape structure that 
include proliferative, necrotic, invasive and quiescent cells and 
deposited and degraded ECM 
254
. Another example is the work 
developed by Hamis et al. who also developed a hybrid model by 
the combination of a cell automaton model with continuum model 
defined by differential equations 
101
. This on-lattice model 
considers intra-, inter- and extra-cellular dynamics to study 
chemotherapy drug by a reaction-diffusion model that includes 
also includes drug diffusion, production, consumption and decay 
rates. The model was defined with cellular resolution and in each 
lattice point a blood vessel, ECM and either sensitive or resistance 







Other contributions on the topic consider instead the 
combined convective-diffusive transport. Venkatasubramanian et 
al. assessed the effect of an heterogeneous environment on drug 
efficacy, using a model based on mass balance equations 
255
. For 
the drug balance equation, diffusive and convective (due to cell 
movement) transport were considered. In this case, the drug 
diffusivity coefficient accounts for combined effects of both 
extracellular diffusion and transmembrane transport (drug binding 
and uptake). Additionally, to account not only for the transport but 
also for the effect of the drug, a pharmacokinetic model was 
applied 
255
. Rejniak et al. studied the role of tumor architecture on 
the interstitial molecule transport by diffusion and advection 
256
. 
For that, they simulated the transport of a drug from a capillary, 
located on one side of the computational domain, with several 
types of tumor architectures (cells with different radius and in 
different amounts) 
256
. Later Karolak and Rejniak improved this 
model by applying a modular approach in which drug concentration 
can be set as continuum or discrete, drug transport can be set 
either as diffusion, advection or combination of both and the 
cellular uptake can occur by membrane diffusion or receptor 
binding 
257
. Mascheroni and Penta investigated the impact of the 
geometry of the tumor vasculature on drug transport 
258
. The model 
they developed considers two different scales: micro- and macro-
scale. While in the macro-scale the domain is homogeneous, in the 
micro-scale the differences in the vasculature are considered. The 
computational solution solves the macroscopic problem of the 
homogeneous domain, assuming the drug is transported by both 








Collagen fibers are one of the most relevant components in 
hindering drug transport within the TME, as explained in Section 5. 
Therefore, the ability to model this ECM element can be crucial in 
understanding its influence in drug distribution. This study is not 
restricted to models tailored specifically towards this problem. In 
fact, some models that were not designed for the study of collagen 
fibers or the transport of drugs can be considered. One example is 
the work developed by Ogston, that studied the transport of 
compact particles through solutions of chain-polymers 
259
. Clague 
and Phillips studied the effect of solute-fiber interaction 
(hydrodynamic interactions) on the hindered diffusion of a 
spherical macromolecule in random media comprised of cylindrical 
fibers 
260
. Stylianopoulos et al. developed a model considering 
steric, hydrodynamic and electrostatic interactions 
261
 between 
fibers and molecules to diffuse. In these models the fibers can be 
seen as the collagen fibers, while the particles are the drug 
molecules. 
To assess if computational models can recapitulate specific 
phenomena, they need to be both calibrated and validated with 
data. These data can be either direct measurements of variables of 
interest in the developed model (obtained experimentally 
262
 or 
from clinical data 
263
) or more complex data, that require additional 
processing to be used, such as images. For instance, the concept 
of using image digitization in order to create inputs for a 
computational model was used by Rejniak and co-workers. They 
apply it to in vivo data, in order to benchmark a pharmacokinetics/ 
pharmacodynamics tumor model 
262,264
 and also to organoid 
cultures to study differences between healthy and malignant cells 
262







. The first group used that data to recreate an accurate 
tumor vasculature where the simulation was applied 
265
 and the 
second group used fluorescence in vivo imaging as reconstructed 
input to the computational framework 
266
. Computational models 
can also be benchmarked by experimental data in the sense that 
any discrepancies between the results of the two models can point 
out important components of the systems that were overlooked in 
the computational model, or even suggest additional experimental 
models and settings to clarify that difference 
247,267
. 
Computational models can run numerous independent 
experiments in a relatively fast and efficient fashion. Data can be 
extracted without interfering with the system evolution and all the 
variables of the system can be controlled or modified 
268
. While 
computational models cannot replace experimental models, they 
can be used as a complementary tool 
160
 to support the reducing, 
refining and replacing (3Rs) animal experiments 
253
. Computational 
models can be used to investigate mechanisms behind 
experimental observations and to simulate many scenarios as a 
basis to select the most relevant experiments and thus reduce 
experimental burden and costs. 
 
7. Aims and scope of this thesis 
The tumor microenvironment is currently acknowledged as 
a potential source of targets for cancer therapy and a driving force 
of clinical drug resistance to targeted therapies. The aim of this 
thesis was to develop and characterize cancer models that 
recapitulate key aspects of the tumor microenvironment, suitable 





therapies. To achieve this goal, we employed in vitro, ex vivo and 
in silico approaches for modeling BC (Figure 1.11). 
In Chapter II, the main objective was to develop a strategy 
for preservation of BC tissue ex vivo, retaining the TME components 
for culture periods long enough to address targeted therapies and 
resistance mechanisms. We developed a strategy based on 
entrapment of BC tissue into alginate and culture under dynamic 
conditions. We reasoned that by using alginate encapsulation to 
promote the original TME retention, while resourcing to dynamic 
culture to guarantee efficient diffusion of nutrients and oxygen, 
tissue microstructures would retain architectural integrity. 
Moreover, we hypothesized that retention of the original 
microenvironment would favor the maintenance of ERα-positive BC 
phenotype and ERα signaling, a driving force of this type of tumor 
and the target of endocrine therapy. Therefore, the second 
objective of Chapter II was to evaluate the presence of ER transcript 
and protein in ex vivo cultures of ER-positive BC and interrogate ER 
signaling. 
In Chapter III, we explored TME in vitro cell models, based 
on alginate encapsulation of cancer cell lines and fibroblasts. The 
objective was to characterize biological, biochemical and 
mechanically those models. We employed an array of 
methodologies, namely atomic force microscopy, scanning 
electron microscopy, immunofluorescence and histochemistry to 













































Figure 1.11: Schematic representation of the research objectives 
pursued in this thesis and the experimental approaches followed to 
attain them. BC: breast cancer; ERα: estrogen receptor α; TME: tumor 
microenvironment. 
In Chapter IV, the objective was to implement a 
computational framework to study antibody transport within the 
TME. The in vitro model characterized in Chapter III was challenged 
with fluorescent antibodies, whose distribution was live-tracked 
using light sheet microscopy. An in silico model comprising 
diffusive transport and saturation mechanisms was calibrated with 
the in vitro experimental data to recapitulate antibody transport. 
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A novel culture method that sustains ERα signaling in human breast 




Estrogen receptor α (ERα) signaling is a defining and driving 
event in most breast cancers; ERα is detected in malignant 
epithelial cells of 75% of all breast cancers (classified as ER-positive 
breast cancer) and, in these cases, ERα targeting is the main 
therapeutic strategy. However, the biological determinants of ERα 
heterogeneity and the mechanisms underlying therapeutic 
resistance are still elusive, hampered by the challenges in 
developing experimental models recapitulative of intra-tumoral 
heterogeneity and in which ERα signaling is sustained. Ex vivo 
cultures of human breast cancer tissue have been proposed to 
retain the original tissue architecture, epithelial and stromal cell 
components and ERα. However, loss of cellularity, viability and ERα 
expression are well-known culture-related phenomena. 
Breast cancer samples were collected and brought to the 
laboratory. Then they were minced, enzymatically digested, 
entrapped in alginate and cultured for one month. The histological 
architecture, cellular composition and cell proliferation of tissue 
microstructures were assessed by immunohistochemistry. Cell 
viability was assessed by measurement of cell metabolic activity 
and histological evaluation. The presence of ERα was accessed by 
immunohistochemistry and RT-qPCR and its functionality evaluated 
by challenge with 17β-estradiol and fulvestrant. 
We describe a strategy based on entrapment of breast cancer 
tissue microstructures in alginate capsules and their long-term 
culture under agitation, successfully applied to tissue obtained 
from 63 breast cancer patients. After one month in culture, the 





were similar to the original patient tumors: epithelial, stromal and 
endothelial compartments were maintained, with an average of 97% 
of cell viability compared to day 0. In ERα-positive cases, fibers of 
collagen, the main extracellular matrix component in vivo, were 
preserved. ERα expression was at least partially retained at gene 
and protein levels and response to ERα stimulation and inhibition 
was observed at the level of downstream targets, demonstrating 
active ER signaling. 
The proposed model system is a new methodology to study ex 
vivo breast cancer biology, in particular ERα signaling. It is suitable 
for interrogating the long-term effects of anti-endocrine drugs in a 
set-up that closely resembles the original tumor microenvironment, 
with potential application in pre- and co-clinical assays of ERα-
positive breast cancer. 
 
Key words: cancer, patient-derived tissue microstructures, 17β-
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Breast cancer (BC) is the most commonly diagnosed cancer 
among women worldwide 
1
. It is a heterogeneous disease with 
distinct biological features and clinical outcomes. Almost 75% of 
diagnosed BC express estrogen receptor-alpha (ERα), being 
classified as ERα-positive (ER+) BC 2. ERα acts as a ligand-dependent 
transcription factor for genes associated with cell survival, 
proliferation, and tumor growth 
3
. Therefore, targeting the ERα-
signaling pathway is the main therapeutic strategy for the 
treatment of ER+ BCs. Nonetheless, the disease often progresses in 
30% of the patients undergoing hormonal therapy due to resistance 
2
. Thus, there is a need to select patients that would respond to 
endocrine therapy and to elucidate the molecular mechanisms 
behind endocrine resistance, as well as to identify biomarkers that 
predict drug response and resistance and novel therapeutic targets 
in resistant tumors. 
When cultured in classical 2D monolayers, ER+ BC cell lines 
fail in recapitulating the typical intratumoral ERα heterogeneity 4 
and, due to cell confluency, cannot be kept continuously for more 
than one week 
5
, hampering the possibility to perform cycles of 
drug treatment for more than one week. Only a few ER+ cell lines 
can generate xenografts in mice, requiring supplementation with 
estrogen 
6
. Recently, an estrogen supplementation-independent in 
vivo model was reported, based on intraductal implantation of ER+ 
tumor cells. The demonstration that the intraductal but not the 
mammary fat pad microenvironment favors epithelial malignant 
cells of the luminal subtype, consolidated the role of the tumor 







there is a report showing that it is possible to propagate normal 
primary breast ER+ cells in 2D 
7
, there are no reports for 
propagation of primary ER+ BC cells using this culture system. In 
fact, ER+ BC primary cells cultured in 2D loose cellularity and ERα 
expression after a short culture period. 
Ex vivo cultures have been explored to sustain ER+ 
malignant epithelial cells within the original BC microenvironment 
8
. Typically, these models retain tissue architecture and 
heterogeneity for short periods of time, around 3 to 4 days of 
culture 
9,10
. Naipal et al. reported extension of culture time up to 7 
days by exploring dynamic culture conditions 
11
. Recently, Muraro 
et al. reported high cell viability and maintenance of ER expression 
up to 14 days in culture, when combining a collagen scaffold and 
a medium perfusion system 
8
. Nonetheless, this methodology 
supports BC tissue maintenance by taking advantage of collagen 
scaffolds, biologically active animal-derived biomaterials which 
bring variability, as well as environmental and ethical concerns 
12
. 
Here, we hypothesized that retention of the original 
microenvironment would favor the maintenance of ER+ BC 
phenotype and ERα signaling. We implemented an ex vivo strategy 
based on the encapsulation of tissue microstructures in alginate, 
an inert biomaterial, combined with dynamic culture, aiming to 
maintain the original tissue structure, cell populations and 
extracellular matrix (ECM). We have recently shown that alginate 
microencapsulation of cancer cell spheroids and TME cellular 
components promotes tumor-stromal crosstalk and retention of 
secreted ECM components towards reconstruction of TME features 
13,14
. Therefore, we reasoned that by using alginate encapsulation to 
promote the original TME retention, while resourcing to dynamic 
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culture to guarantee efficient diffusion of nutrients and oxygen, 
tissue microstructures would retain architectural integrity and 
potentially ER signaling. 
 
2. Methods 
2.1. Ethics statement 
BC samples were collected at the Lisbon Oncology Hospital 
(Instituto Português de Oncologia de Lisboa Francisco Gentil – 
IPOLFG). The use of patient material was approved by the IPOFLG 
ethics committee and all patients have signed an informed consent 
form to agree to donate the material for research purposes. All 
tissues were anonymized before transfer to the laboratory for 
further processing. 
 
2.2. Cell culture 
MDA-MB-231 cell line was obtained from the American Type 
Culture Collection (ATCC). MDA-MB-231 cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) high glucose and 
pyruvate medium (Gibco), supplemented with 10% (v/v) fetal bovine 
serum (FBS, Gibco) and 1% (v/v) Penicillin/Streptomycin (P/S, Gibco) 
at 37 °C in 5% CO2. Mycoplasma contamination was routinely 
checked. 
 
2.3. Collection and processing of patient material 
This study was elaborated on treatment-naïve patient-
derived BC tissue. The method for processing and culture was 
successfully applied to 63 female breast tumors (Table 1). Tumor 
samples were collected during surgery and immediately 





with 1% (v/v) P/S (Gibco) and 10% (v/v) FBS (Gibco). Samples were 
kept at 4 °C and transported to the laboratory within 1 to 3 hours 
after surgery (Figure 2.1A). Sixty-three BC samples were collected, 
with an average weight of 315±225 mg (Figure S2.1). 
Tissue samples were mechanically dissociated with two 
surgical scalpels to obtain pieces of 1 to 2 mm of diameter. 
Subsequently, the minced tissue was resuspended in phenol red-
free DMEM/F-12, HEPES medium (Gibco) containing 0.09 U/mL of 
Collagenase A (Roche), 30 U/mL of Benzonase (Merck Millipore), 
10% (v/v) FBS (Gibco) and 1% (v/v) P/S (Gibco). Digestion was 
performed in an incubator at 37 °C, in a humidified atmosphere 
containing 5% CO2. After 12-15 hours of enzymatic digestion, 
tumor fragments (tissue microstructures, average of 1 mm
3
) were 
sedimented by centrifugation at 100x g for 5 min at 4 °C and 
washed with Phosphate-Buffered Saline (PBS; Life Technologies) 
(Figure 2.1A). 
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Figure 2.1: Alginate encapsulated tissue microstructures maintained 
parental tumor architecture. a Experimental workflow for the 
establishment of long-term cultures of BC patient-derived tissue 
microstructures: samples were collected at the hospital and brought to 
the laboratory within 1-3 hours of surgery. Tissue samples were 
mechanical processed and subjected to mild enzymatic digestion. The 
obtained BC tissue microstructures were encapsulated in alginate and 
cultured for up to one month. Along culture, tissue microstructures were 
interrogated: cell viability assessment, immunohistochemistry analysis 
(IHC), Second Harmonic Generation (SHG) microscopy and estrogen 
receptor α (ER) stimulation and inhibition were performed. b Hematoxylin 
and eosin of biopsy (top row) and corresponding encapsulated 
microstructures at one month of culture (bottom row) (scale: 200 µm). 
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Table 2.1: Clinico-pathological parameters of the breast cancer 




Female tumor samples 63 
Mean age at diagnosis 62 (42-89) 
Hormone receptors   (n) Percentage of tumors 
ERα status 59 94 
PR status 51 81 
HER2 status 11 17 
Triple negative status 1 2 
Histological subtype (n) Percentage of tumors 
Invasive breast 
carcinoma of no-
special type (NST) 
51 81 
Lobular carcinoma 10 16 
Mucinous carcinoma 2 3 
Tumor grade* (n) Percentage of tumors 
1 2 3 
2 50 79 
3 9 14 
Not defined 2 3 
Tumor size** (n) Percentage of tumors 
pT1 38 60 
pT2 22 35 
pT3 3 5 
Lymph node 
involvement status** 
(n) Percentage of tumors 
pN0 41 65 
pN1 21 33 
pN2 1 2 




** Tumor staging (pT and pN) was classified according with the American Joint 







2.4. Tissue microstructure encapsulation and culture 
Tissue microstructures were entrapped in alginate, 
employing protocols previously developed by our team 
14
. Briefly, 
tissue microstructures were dispersed in 1 mL of 2% (w/v) of 
Ultrapure Ca
2+
 MVG alginate (UP MVG NovaMatrix, Pronova 
Biomedical, Oslo, Norway) dissolved in NaCl 0.9% (w/v). 
Encapsulation was performed using an electrostatic bead generator 
(Nisco VarV1, Zurich, Switzerland), with an air flow rate of 10 mL/h, 
at 5.3 V under air pressure of 1 bar, using a 1.1 mm nozzle. The 
resulting alginate droplets containing tissue micro fragments (1-2 
fragments/droplet) were cross-linked in a 100 mM CaCl2/10 mM 
HEPES (pH 7.4) solution for 10 min, washed three times in a 0.9% 
(w/v) NaCl solution and finally equilibrated in culture medium. 
Encapsulated tissue microstructures were then transferred into 6-
well plates and placed under orbital shaking (100 rpm), in a 
humidified incubator, with 5% CO2. Encapsulated tissue 
microstructures cultures were maintained up to 30 days, with 50% 
medium exchange every 3-4 days (Figure 2.1A). Cultures were 
maintained in human mammary epithelial cell (HMEC) culture 
medium: DMEM/F12 phenol red free with 1% P/S (v/v) solution 
(both from Life Technologies), 5 ng/mL Epidermal Growth Factor 
(EGF), 10 μg/mL Insulin, 0.5 μg/mL Hydrocortisone, 0.5 μg/mL 
Transferrin, 0.1 mM Isoprotenol, 0.1 mM Ethanolamine, 0.1 mM O-
Phosphoethanolamine, 70 μg/mL Bovine Pituitary Extract (all 
reagents are from Sigma-Aldrich) and 100 μg/mL Primocin 
(InvivoGen Europe). Non-encapsulated tissue microstructures were 
maintained under the same culture conditions. Encapsulated tissue 
microstructures were assessed for cell viability, architecture, cell 
populations, ECM deposition, ERα presence and signaling, as 
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described below; the extent of assessment performed for each 
sample was determined by the initial sample size. 
 
2.5. Cell viability assessment 
Cell viability was correlated with resazurin reduction 
capacity (PrestoBlue™ Cell Viability Reagent, ThermoFischer 
Scientific), according to manufacturer’s instructions. Encapsulated 
and non-encapsulated samples were incubated for 1 hour with 
PrestoBlue reagent in culture medium, at 37 °C, in a humidified 
atmosphere incubator, containing 5% CO2. Medium was sampled in 
quadruplicate and resazurin reduction evaluated by fluorescence 
detection (ext/em 560/590 nm) in a fluorimeter (Infinite®200 PRO 
NanoQuant, Tecan Trading AG). Resazurin reduction was evaluated 
for 1 month, once a week. Data is represented as fold-change in 
resazurin reduction relative to the first week of the assay. 
 
2.6. Histological and immunohistochemistry analysis 
Samples were collected after 1 month of culture and alginate 
capsules were de-polymerized with 50 mM 
ethylenediaminetetraacetic acid (EDTA) for 5 min at RT. De-
encapsulated tissue microstructures were centrifuged at 300x g, 5 
min at 4 °C, washed with PBS, fixed with formol overnight at RT. For 
paraffin cell-block preparation, the cellular suspension was 
centrifuged for 5 min, at 1270x g, resuspended in 10% (v/v) 
buffered formalin (VWR BDH Chemicals, ref. 9713.9010) to which a 
drop of haematoxylin was added for specimen counterstain, and 
stored in a 1.5 mL microtube. The remaining supernatants were 
subjected to a second centrifugation, for 5 min, at 1990x g. The 





(Thermo Scientific, ref. HG-4000-012) were added to the pellet. 
After gentle homogenization with a Pasteur pipette and 
centrifugation for 2 min, at 1990x g, the sample was placed at -
20 °C for 5 min to solidify. The cone shape solidified sample was 
removed from the microtube, cut along the meridional section and 
placed in a biopsy cassette, which was then immerged in a 
container with buffered formalin to be included in paraffin. After 
processing, the samples were sectioned and stained with 
hematoxylin and eosin (H&E) (Dako CoverStainer for H&E 
equipment, Agilent, Santa Clara, CA, USA). Paraffin blocks were 
sectioned (3 μm) for H&E and immunohistochemical staining. 
Immunohistochemistry (IHC) was carried out using standard 
procedures implemented at IPOLFG; antigen retrieval was done 
using Cell Conditioning 1 (CC1, Ventana) and tissue staining was 
performed using an automated IHC/ISH slide staining Ventana 
BenchMark Ultra (all from Ventana Medical Systems, Inc). 
Antibodies and details on the protocol used are indicated in Table 
S1. Histologic analysis was performed by an expert breast 
pathologist. IHC analysis was performed for cultures derived from 
BC samples of 18 patients. Due to primary material limitations, E-
cadherin, CD45, ki-67, ER and p63 levels were assessed in 8 
different samples; vimentin was assessed in 9 and CD31 in 2. 
 
2.7. Multi-photon microscopy 
Fibrillar Collagen was assessed by multi-photon microscopy. 
After 1 month in culture, encapsulated tissue microstructures were 
collected, fixed in PFA 4% (w/v) in PBS for 30 min, washed thrice 
with PBS and kept at 4 °C until further analysis. Samples were 
imaged with two-photon-excited fluorescence (TPEF), second 
A novel culture method that sustains ERα signaling in human breast 
cancer tissue microstructures 
93 
 
harmonic generation (SHG) and infrared (IR) absorption in a home-
made multiphoton microscope 
15
. The excitation laser was a 
Ti:Sapphire at 810 nm and the laser power, at entrance of the 
microscope, was of 40 mW. Initial tests performed with 100 mW 
resulted in no observable sample damage. The Illumination 
objective was an Olympus 25x 1.05 W. The TPEF signal was 
collected through a photomultiplier tube (PMT) in backward 
direction (using a LP410 filter) while IR absorption and SHG 
(405/25 filter) were collected in forward direction through a Nikon 
25x 1.10 W objective, using a photodetector and a PMT 
respectively. During acquisition, 3-4 images were averaged to 
reduce noise. 
 
2.8. Challenge with ERα agonist and antagonist 
At day 28-30 of culture, encapsulated BC tissue 
microstructures were stimulated with 10 nM 17β-estradiol (Sigma-
Aldrich). Three days before 17β-estradiol challenge, encapsulated 
tissue microstructures were washed thrice with PBS and were then 
kept in phenol red-free HMEC medium without insulin, 
hydrocortisone and EGF, which may trigger activation or 
phosphorylation of ER 
16–21
. Alternatively, a 50% culture medium 
exchange was performed by the time of 17β-estradiol challenge. 
Control wells were also included, in which only ethanol (17β-
estradiol vehicle) was added to a final concentration of 0.001% 
(v/v). After 24h of exposure, encapsulated tissue microstructures 
were collected and alginate dissolved (as described in section 6 of 
Materials and Methods). Challenge with 17β-estradiol was 





different patients, of which 9 in depleted medium and 7 in 
complete medium. 
Encapsulated tissue microstructures were also challenged 
with fulvestrant (ICI182,780), an ER antagonist and degrader. For 
these experiments, 3-5 days after encapsulation HMEC medium 
was supplemented with 1 μM fulvestrant 22,23 (Tocris Bioscience). 
Twice a week, half volume of culture medium was changed and 
fulvestrant was replenished to keep a constant concentration. After 
2 weeks, samples were centrifuged at 300x g, 5 min at 4 °C, washed 
with PBS and processed for IHC (as detailed above) or RT-qPCR 
analysis. Samples for RT-qPCR were stored in RNAlater Stabilization 
Solution (Roche), according with the manufacturer’s instructions, 
until further analysis; samples for western blot were snap frozen at 
-80 °C. Challenge with fulvestrant was performed in encapsulated 
microstructures derived from 8 different patients, of which 7 were 
evaluated by RT-qPCR and 3 by Western Blot. 
 
2.9. Gene expression analysis 
Tissue microstructures were thawed, total RNA was 
extracted in a tissue lyser (Precellys Evolution Homogenizer, Bertin 
Instruments) and purified using the RNAeasy Kit (Qiagen), 
according to the manufacturer’s instructions. Reverse transcription 
was performed using Sensiscript RT kit (Qiagen), also according 
with the manufacturer’s instructions. qPCR was performed in 
triplicates, using the SYBR green I Master kit (Roche), in a 
LightCycler 480 II (Roche). We evaluated expression of ERα (ESR1) 
and its downstream target genes, pS2, AREG and PGR 
24
, and of two 
housekeeping genes, RPL22 
13
 and 36B4 
24
. Primer sequences are 
provided in Table S2. Due to the scarcity of ERα negative BC 
A novel culture method that sustains ERα signaling in human breast 
cancer tissue microstructures 
95 
 
samples, a ERα and PR negative BC cell line, MDA-MB-231, was 
employed as basal expressing control 
25
. Results are shown as fold 
change in mRNA amount compared to the vehicle control (CTRL), 




, considering a geometric 
mean of the 2 housekeeping genes used. 
 
2.10. Western Blot analysis 
Samples were thawed, resuspended in Laemmly Buffer (20% 
Glycerol, 4% SDS in 100 mM Tris Buffer, pH 6.8) and lysed in a 
Tissue homogenizer (Precellys Evolution, Bertin Instruments). BC 
Microstructure lysates were recovered, sedimented to remove cell 
debris, sonicated and stored at -80 °C until use. 
Protein quantification was performed in a Nanodrop ND-
2000C (Thermo Scientific). Proteins were denatured and loaded in 
an electrophoresis gel (NuPAGE 4-12% Bis-Tris Gel) under reducing 
conditions for 50 min (200 V) and then electrophoretically 
transferred using a Bio-Rad wet system (30 V, 18 hours, 4°C) into 
Nitrocellulose membranes. Membranes were blocked for 1 h in TBS 
with 0.1% (w/v) Tween 20, 5% (w/v) non-fat dried milk and further 
incubated with the primary antibodies (Mouse anti-Human ERα, 
1D5 Clone, Dako, final dilution 1:500; Rabbit anti-β tubulin, H-235, 
SC-9104, SantaCruz, final dilution 1:1000, used as loading control) 
and respective secondary HRP-conjugated secondary antibodies 
(Sheep anti Mouse IgG NA931; Donkey anti Rabbit IgG NA934; GE 
Healthcare, final dilution 1:20000). Membranes were developed 
using Amersham ECL Select Western Blot Detection Reagent (GE 






2.11. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 
version 6.0 (GraphPad Software). Data were analyzed as indicated 
in the figure legends. The Mann-Whitney test was performed to 
evaluate statistical difference between conditions. Data are 
presented as mean ± SD, unless otherwise specified. 
 
3. Results 
3.1. Alginate encapsulated tissue microstructures 
maintain parental tumor tissue characteristics for at least one 
month of culture 
To establish an ER+ BC ex vivo model, we investigated the 
possibility of retaining the TME and consequently ERα signaling of 
patient-derived tissue microstructures immobilized within alginate 
capsules and cultured under agitation (Figure 2.1A). Encapsulated 
tissue microstructures were cultured for up to 30 days, showing 
high cell viability, as indicated by maintenance of resazurin 
reduction capacity along culture time (97±28% by the end of week 
4, relatively to the beginning of the culture, Figure S2.2A). 
Moreover, detection of extracellular lactate in culture medium (data 
not shown), as an indicator of high metabolic activity 
27
 
corroborated the high cell viability within the encapsulated tissue 
microstructures. 
The original tumors were very heterogeneous, not only 
between but also within patients (Figure 2.1B): tissue architecture 
varied in epithelial versus stromal content, cell organization and on 
the presence/absence of immune cells (CD45+ cells). A complete 
mixture of malignant epithelial cells and stromal cells was rarely 
observed. Instead, there were islets of tumor cells surrounded by 
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multiple stromal cells (Figure 2.1B, upper panels). These 
histopathological characteristics were maintained in encapsulated 
tissue microstructures cultured for a month (Figure 2.1B, lower 
panels). By day 30 of culture, E-cadherin, vimentin, CD31 and CD45 
were immunohistochemically-detected (Figure 2.2A). The detection 
of membranous E-cadherin indicated that carcinoma cells 
maintained the typical cell-cell adhesions and differentiated 
phenotype 
28
. On the other hand, vimentin detection confirmed the 
presence of stromal cells. CD45, also known as leucocyte common 
antigen, is a transmembrane glycoprotein present in all nucleated 
cells of the hematopoietic lineage 
29
 and has been broadly used to 





 cells were detected in 5 
out of the 8 cases which presented immune cells in the original 
tissue (Figure 2.2A). In two analyzed tissue microstructures, CD31 
positivity confirmed the presence of endothelial cells (Figure 2.2A). 
Absence of cells positive for the basal/myoepithelial marker p63 
was observed similarly to the original tumors (Figure S2.2B). Ki67-
positive cells were also detected at different levels, indicating the 
presence of proliferating cells even after one month of culture 
(Figure 2.2B). Although at low levels, this is consistent with the 
parental tissues, where the median of proliferating cells was 20% 
(Q1=15; Q3=30). Second harmonic generation analysis (SHG) of 
encapsulated BC tissue microstructures revealed dense and 
organized/fibrillar collagen fibers in peripheral regions of the 
samples analyzed, surrounding areas of cellularity (Figure 2.3). As 
a culture control, non-encapsulated tissue microstructures were 
cultured in parallel. A significant decrease in resazurin reduction 





reduced cell viability of these cultures. Remarkably, cell viability 
was increased in encapsulated versus non-encapsulated tissue 
microstructures (Figure S2.2C). 
Altogether, we were able to extend the lifespan of BC explant 
cultures for up to one month whilst maintaining tissue architecture, 
the different cell types of the BC microenvironment, and cell 
viability. 
 
A novel culture method that sustains ERα signaling in human breast 









Figure 2.2: Alginate encapsulated tissue microstructures maintained 
cell populations and contain proliferating cells. a 
Immunohistochemistry analysis of: E-cadherin (epithelial cells); vimentin 
(stromal cells); CD45 (immune cells); CD31 (endothelial cells) at one 
month of culture b Immunohistochemistry analysis of Ki-67 (cell 
proliferation) of encapsulated microstructures at one month of culture 




Figure 2.3: Encapsulated tissue microstructures maintained collagen 
fibrillar structures. Second Harmonic Generation (SHG) microscopy at 
one month of culture: yellow – Two-Photon Excitation Microscopy (TPEF); 
blue - collagen fibers (scale bar: 50 µm). 
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3.2. ERα expression and functionality are sustained over 1 
month of culture 
After one month in culture, ER+ carcinoma cells were still 
detected in the encapsulated tissue microstructures by IHC analysis 
(Figure 2.4A), typically in lesser extent that in the original sample. 
When sample material was not sufficient for IHC evaluation, mRNA 
was quantified, relatively to MDA-MB-231, a human cancer cell line 
which does not express ERα nor PR 25 (Figure S2.3A). All samples 
presented higher expression of the ERα gene (ESR1) than MDA-MB-
231 cells, indicating ERα gene expression after one month of 
culture (Figure S2.3B and Figure S2.5). 
To assess ERα function, encapsulated tissue microstructures 
derived from ER+ BC from 9 distinct patients were stimulated with 
10 nM 17β-estradiol for 24 hours and the mRNA levels of the ER 
target genes evaluated: protein PS2 (also known as Trefoil Factor 1 
-TFF1-, pS2), progesterone receptor (PGR) and amphiregulin (AREG) 
24
. AREG and PGR were upregulated upon challenging with 17β-
estradiol compared to vehicle-controls (mean fold increase in AREG 
and PGR expression of 3.4±5.6 and 6.3±11 respectively, Figure 
2.4B, Figure S2.4A). Strikingly, we detected a generalized 
upregulation of pS2 (in 7 out of 9 tissue microstructures), with a 
mean fold increase in gene expression of 45±45, compared to the 
vehicle-treated control (Figure 2.4B, Figure S2.4A and Figure S2.5). 
In general, there was a trend for a positive correlation between 
ESR1 basal expression and the expression of the three ER target 
genes upon estrogen challenge (Figure S2.4B, R>0 by Pearson 
Correlation), even though not significant, probably due to the 
intrinsic variability of primary tumors and the sample size. Tissue 





also treated with 17β-estradiol and no upregulation of ER 
downstream genes was observed (Figure S2.4C). This data further 
corroborates that the original phenotype is maintained in culture. 
A different set of encapsulated tissue microstructures derived from 
ER+ BC samples of 7 tumors, were maintained in HMEC medium 
until 17β-estradiol challenge. These showed a mild stimulation of 
ERα target genes (on average, 2.3-, 1.8- and 1.2-fold increase 
relatively to vehicle control for pS2, PGR and AREG, respectively, 
Figure S2.4D). 
To further confirm intact ERα signaling in encapsulated 
tissue microstructures, cultures derived additional ER+ BC samples 
were exposed to fulvestrant (or ICI182,720), a ERα full antagonist 
33
 widely used in endocrine therapy 
34
. After 2 weeks of exposure, a 
generalized down regulation of AREG compared to vehicle controls 
was observed (Figure 2.4C). For two of the tumors, we also 
evaluated PGR and pS2 response and observed a strong reduction 
of mRNA levels compared to vehicle controls (Figure 2.4D). 
Additionally, we assessed ERα protein levels in three of the tumors 
and observed a tendency for reduction compared to vehicle control 
conditions (Figure S2.6). Collectively, these results indicate that 
ERα is expressed in encapsulated tissue microstructures derived 
from ER+ BC samples and can respond to stimulation and 
inhibition. 
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Figure 2.4: Estrogen receptor α (ER) expression and functionality are 
maintained in alginate encapsulated tissue microstructures up to 1 
month of culture. a Immunohistochemistry detection of ER in biopsy (top 
row) and encapsulated tissue microstructures culture for a month (bottom 
row) (scale bars: 200 µm for low magnification and 100 µm for high 
magnification). b Encapsulated tissue microstructures were cultured for 3 
days in depleted medium and stimulated with 17β-estradiol; expression 
of ER downstream target genes was assessed by RT-qPCR (amphiregulin - 
AREG, progesterone receptor - PGR and protein PS2 - pS2, N=9). Data are 
shown as fold change in gene expression upon 17β-estradiol challenge 
relatively to vehicle-exposed control (CTRL). c,d Encapsulated tissue 
microstructures were cultured for 3-5 days in complete medium, before 
challenge with fulvestrant for two weeks; ER downstream targets were 
assessed by RT-qPCR (AREG, PGR and pS2, N=7). Data are shown as fold 
change in gene expression upon fulvestrant challenge relatively to 
vehicle-exposed control. Statistical analysis was performed by the Mann-
Whitney test (*p-value<0.001). 
 
4. Discussion 
ERα signaling is considered a defining and driving event 
contributing to ER+ BC carcinogenesis; ERα overexpression in 
primary tumors has been linked to disease progression, influencing 
patient survival 
35–37
. Nonetheless, approximately 30% of patients 
with ER+ BC fail to respond to endocrine therapy 
2
. Several reports 
have shown the intricate relation between response to therapy and 
TME components, such as fibroblasts 
38–40
 and ECM components 
41,42
. 
Therefore, it is paramount to define the biological determinants of 
ERα intra-tumoral heterogeneity and the mechanisms underlying 
therapeutic resistance. However, this knowledge has been 
hampered by the challenges in developing experimental models 
recapitulative of intra-tumoral ERα heterogeneity and in which ERα 
signaling is sustained, essential to address long-term effects of 
tumor-stromal interactions in ERα signaling and drug response 
mechanisms against ER. 
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Here, we propose a culture strategy in which patient-derived 
tissue microstructures retain ER+ carcinoma cells for at least one 
month of culture; of note, these cells still respond to ER stimulation 
and inhibition, therefore constituting a functional ex vivo model of 
ER-positive BC. Tissue microstructures that were entrapped in 
alginate capsules and cultured under dynamic conditions 
maintained high cellularity, low levels of tumor cell proliferation, 
as reported for human ER+ BC 
43
 and parental tissue architecture 
(including epithelial, stromal and endothelial cell compartments 
and deposited fibrillar collagen). Although all interrogation was 
limited to one month of culture, as we have not detected signs of 
tissue microstructure decline in cell viability up to that timepoint, 
we conjecture that the lifespan of encapsulated tissue 
microstructures could be extended for even longer periods. 
We hypothesized that using tissue microstructures within 
the millimeter size range would be more favorable to attain an 
accurate representation of intra-tumoral heterogeneity and TME, 
than more miniaturized ex vivo models. To overcome the major 
limitations of ex vivo cultures – the reduced lifespan and zonation 
due to diffusional gradients 
44
, we resourced to dynamic culture 
conditions. Agitation improves mass transfer, promoting nutrient 
and oxygen diffusion, reducing the formation of gradients typically 
observed for tissue microstructures within the above mentioned 
size range 
45,46
. Moreover, we encapsulated in alginate, a 
biocompatible, inert hydrogel 
47
 since it has defined composition 
and confers support and protection from agitation-induced shear 
stress 
14,48,49
. This contributes to the preservation of tissue 
architecture and cell viability, but also promotes the built-up of 





shown that cells entrapped in alginate capsules, and cultured under 
agitation, accumulate secreted soluble factors (e.g., cytokines) and 
ECM components, promoting homotypic and heterotypic cellular 
crosstalk, cell migration and reconstruction of cancer-related 
microenvironments 
13,14
, such as an immunosuppressive 
microenvironment in a non-small cell lung cancer model 
13
. In terms 
of ECM components, we not only observed the maintenance of TME 
cellular components in the encapsulated tissue microstructures, 
such as the stromal cells, which are involved in the secretion of 
collagen 
50
, but also ECM components as collagen fibers. These 
were detected by SHG microscopy, a technique broadly applied to 
BC tissue 
51
. In all the encapsulated tissue microstructures analyzed 
fibrillar collagen presence was observed. Increased collagen 
density has been shown to directly promote BC tumorigenesis 
52
. 
Moreover, collagen is strongly associated with mammographic 
density used as a measurement of risk of BC 
53
 and is responsible 
for drug resistance since it prevents the penetration of therapeutic 
agents, such as antibodies 
54
. 
The preservation of tumor heterogeneity and TME are critical 
to closely mimic the in vivo situation 
4,55
. We observed a high degree 
of heterogeneity between distinct parental tissues - not only the 
levels of ER-positivity were different, but also the percentages and 
physical distribution of carcinoma and stromal cells - that were 
recapitulated in the derived tissue microstructures. In 5 out of 8 
tissue microstructure cultures derived from tumors with immune 
cell infiltrate, CD45-positive cells were retained even after one 
month of culture, although in low amounts. This is in accordance 
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After 1 month in culture, p63 was not detected in tissue 
microstructures, in accordance with what is reported for luminal 
BC. In fact, the myoepithelial marker p63 is present in basal cells 
of a variety of healthy epithelial tissues 
57
, such as in normal breast 
tissue. However, its expression in BC is rare 
58,59
. On the other hand, 
tissue microstructures presented low levels of Ki-67; in fact, ERα-
positive subtypes have lower proliferative indexes than other BC 
subtypes 
60
. The intrinsic low levels of cell proliferation and the 
reduced amount of patient tissue available to set-up tumor 
microstructure cultures, limit their application in high throughput 
assays. 
The maintenance of ER+ cells in culture is a major 
accomplishment, as ERα ablation ex vivo has been a major issue in 
ER+ BC research 
61
. The sustained expression of ERα is pivotal for 
the study of the luminal A BC subtype, as cell proliferation is ER-
dependent and targeted therapies typically rely on prolonged 
treatment with ERα antagonists 62. After one month in culture, we 
detected ER+ cells in the encapsulated tissue microstructures, 
typically in a less extent than in the original tumor. ERα 
functionality was evaluated by challenging encapsulated tissue 
microstructures, with either activator (17β-estradiol) or inhibitor 
(fulvestrant) molecules. Our results show differential expression of 
PGR, AREG and pS2 in tissue microstructures originated from 
different ER+ BC patients, suggesting that the model reflects inter-
patient heterogeneity. This may be in terms of basal expression 
levels of the target genes analyzed, ER transcriptional response and 
potential presence of ER-independent regulatory pathways 
4,63
. pS2 
is a well-known direct downstream ERα target, which is under the 





before transcription starting site 
64
. Our results show a higher 
upregulation of pS2 when comparing with AREG and PGR. In fact, it 
has been reported for the ER+ MCF-7 BC cell line that, upon 
estrogen exposure, pS2 expression strongly increases compared to 
PGR, at mRNA and also at protein levels 
65,66
. We have also observed 
the effects of fulvestrant at the level of ERα protein, as the drug is 
described to accelerate ERα degradation 33. 
Aiming to retain ER+ cells, we employed a culture medium 
enriched in molecules with reported ER stimulatory effects, such as 
insulin, hydrocortisone and EGF 
16–21
. 17β-estradiol and EGF may 
also be produced by the breast fibroblasts present in culture 
67–69
. 
Our observation of reduced effects upon 17β-estradiol stimulation 
in tissue microstructures cultured in complete medium compared 
with tissue microstructures cultured in depleted medium in the 3 
days preceding stimulation, corroborates the presence of soluble 
ER activators in culture. Further studies are required to understand 
the signaling events that contribute to the maintenance of ERα 
signaling under the culture conditions here presented, which will 
potentially also contribute to further disclose its role in ER+ BC. 
 
5. Conclusions 
Overall, we advocate a new methodology for ER+ BC TME 
modelling, in which the original cell populations, the native ECM 
and tissue architecture are represented, and ER function sustained. 
This ex vivo culture system can contribute to the study of breast 
cancer biology, in particular ERα signaling and 
microenvironmental-driven molecular mechanisms. Moreover, due 
to the extended culture time, the system can be a useful tool to 
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study novel anti-endocrine therapies and other therapeutic 
modalities. 
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Table S2.2: RT-qPCR analysis: primer sequences. 














pS2 Protein PS2/ 





























Figure S2.1: Sample weight. 
 
 
Figure S2.2: Encapsulated BC tissue microstructures do not present 
myoepithelial markers and maintain high metabolic viability. a Metabolic 
activity was assessed along culture. b Immunohistochemistry analysis of 
p63 (myoepithelial cells) at one month of culture; (scale bar: 60 µm). c 
Metabolic activity was assessed in encapsulated and non-encapsulated 
tissue microstructures derived from the same patients. 
A novel culture method that sustains ERα signaling in human breast 




Figure S2.3: a Hematoxylin and eosin staining and 
immunohistochemistry for ERα of MDA-MB-231 (ER-negative cell line) cells 
cultured in 2D (scale: 200 µm). b ERα gene (ESR1) expression in 








See caption in the next page. 
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Figure S2.4: a Encapsulated tissue microstructures were cultured for 
three days in depleted medium before stimulation with 17β-estradiol; 
expression of ER downstream target genes was assessed by RT-qPCR 
(amphiregulin - AREG, progesterone receptor - PGR and protein PS2 - pS2, 
N=9); quantitative evaluation of data shown in Figure 2.3b). b Correlation 
diagrams of expression of ERα gene (AREG) and ER target genes (PGR, pS2 
and AREG). The dots represent the log (mRNA fold change relative to 
control) of each gene for a given BC patient microtissue and the lines 
represent the linear regression (Pearson correlation with R indicated on 
each graph). For all cases, no significant correlation was found (p-
value>0.7). c ER-negative BC encapsulated tissue microstructures cultured 
in complete medium were challenged with 17β-estradiol and expression 
of ER downstream target genes was assessed by RT-qPCR (AREG, PGR pS2, 
N=2). d Encapsulated tissue microstructures cultured in complete medium 
were challenged with 17β-estradiol and ER downstream target genes were 
assessed by RT-qPCR (AREG, PGR and pS2, N=7). Data are shown as fold-
change in gene expression upon 17β-estradiol challenge relatively to 
vehicle-exposed control (CTRL). 
 
 
Figure S2.5: Encapsulated tissue microstructures were cultured for three 
days in depleted medium before stimulation with 17β-estradiol; 
expression of ER downstream target genes was assessed by RT-qPCR 
(amphiregulin - AREG, progesterone receptor - PGR and protein PS2 - pS2). 






Figure S2.6: Encapsulated tissue microstructures were cultured for 3-5 
days in complete medium, before challenge with fulvestrant for two 
weeks; ERα protein was detected by western blot; β-tubulin was used as 
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Cancer is the second leading cause of mortality worldwide. 
Currently there is an effort towards the development of in vitro 
cancer models more predictive of clinical efficacy, such as three-
dimensional (3D) cell models. Biomaterials have been broadly used 
as scaffolds and supports for cells in 3D configurations. Alginate, 
a natural polysaccharide with high biocompatibility and bio-inert 
has been explored by several authors for generation of 3D cell 
models. Alginate encapsulation combined with agitation-based 
culture systems has been proposed by our group as a system able 
to recreate tumor microenvironment features. In this study, 
alginate capsules containing cancer cell spheroids, alone (mono-
cultures) or together with fibroblasts (co-cultures), were produced 
using an electrostatic bead generator. Encapsulated mono- and co-
cultures were maintained in spinner vessels; non-encapsulated cell 
spheroids were also cultured, as control. Analysis by scanning 
electron microscopy revealed the surface porosity of the capsules. 
These retained their sphericity and size during the two weeks of 
culture. Encapsulation sustained the phenotype and proliferation 
of the tumor cells, avoiding the fusion of spheroids observed in 
non-encapsulated cultures. After two weeks of culture, capsule 
stiffness was evaluated by atomic force microscopy. The presence 
of cells decreased the Young modulus of alginate capsules. 
Moreover, capsules containing co-cultures of tumor cells and 
fibroblasts presented higher Young modulus than capsules 
containing tumor cell mono-cultures, in accordance with the 





Collectively, the results presented contribute to the 
characterization of alginate encapsulated cancer cell models. 
 
Key words: 3D cell models, alginate, cancer, cell encapsulation, co-










Cancer cell models based on three-dimensional (3D) culture 
and co-culture of different cell types have been proposed over the 
last years to better represent features of cancer than 2D cell models 
1
. Biomaterial-based 3D cell models have been proposed by 
numerous authors, from naturally-derived (e.g. Matrigel, collagen, 
silk, alginate) to synthetic (e.g. poly-lactic acid, poly-glycolic acid), 
or hybrid and semi-synthetic (e.g. modified hyaluronic acid, 
chitosan-poly-caprolactone) materials
2
. Due to its interesting 
properties, alginate has been widely used, either alone or in 
combination with other biomaterials to create scaffolds for seeding 
or embedding of cells 
3–6
. Alginate is biocompatible and bio-inert 
7
. 
Also, it is a transparent biomaterial which makes it compatible with 
light microscopy techniques 
8
, highly employed in cell biology 
studies. Mechanical properties of alginate hydrogels, such as the 










. Cells and their surrounding microenvironment 
can regulate cell features in a reciprocal manner 
9,15
. On one hand, 
the use of high density of cells can physically interfere with the 
cross-linking reaction, inducing the formation of softer alginate 
hydrogels 
9
. On the other hand, in 3D hydrogels, material stiffness, 
plays a key role by influencing cell phenotype and behavior 
16
. In 
fact, durotaxis, i.e. migration in response to a stiffness gradient, 
generally causes cells to migrate toward stiffer regions 
17
. 
Our group developed an in vitro 3D cell co-culture system 
based on cell immobilization in alginate capsules and dynamic 
culture to recapitulate features of the tumor microenvironment 
(TME) 
6





other cell types found in the TME, such as fibroblasts and immune 
cells, recapitulate specific features, such as the presence of the 
epithelial and stromal compartments, tumor-fibroblast cross-talk, 
e.g. mediated by secretion of pro-inflammatory cytokines and 
extracellular matrix components, such as collagen I 
6
. 
Herein, we focused on the characterization of the 
biomaterial compartment of these models. Alginate capsules (1.1% 
w/v; crosslinked with barium), containing tumor cell spheroids in 
mono-culture or in co-culture with fibroblasts, were generated and 
characterized biologically, biochemically and mechanically. 
 
  




2. Materials and methods 
2.1. Cell lines and 2D cell culture 
BT474 breast cancer (BC) cell line derived from a human 
ductal carcinoma was selected in this study since it is among the 
most frequently used luminal-like BC cell lines. A lung cancer cell 
line, NCI-H157 (#CRL-5802; from now on referred as H157), 
previously characterized by our team as encapsulated cancer cell 
model 
18
, was also employed. Both cells were obtained from 
American Type Culture Collection (ATCC). Human dermal 
fibroblasts (hDFs) isolated from human skin were obtained from 
Innoprot. For the three different cell types, 2D static cultures (in T-
flasks) were maintained at 37 ⁰C in an incubator with humidified 
atmosphere containing 5% CO2 and 21% of O2. Tumor cells were 








cell densities, for H157 and BT474, respectively; hDFs were split 




. For each sub-
culture, cells were trypsinized by exposing the cell monolayer to 
0.05% trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA; 
Invitrogen) for 3-5 min, until total cell dislodging from the 
plasticware surface. Cell were resuspended in complete medium to 
inactivate trypsin and viable cells were counted using trypan blue 
exclusion method 
19
. All cell lines were routinely checked for the 
absence of mycoplasma contamination. They were cultured in 
adherent and static conditions until establishment of the 3D 
cultures (Figure 3.1), using as culture media Dulbecco's Modified 
Eagle Medium (DMEM) low glucose supplemented with 10% fetal 
bovine serum (FBS, Life Technologies) and 100 U/mL penicillin-
streptomycin (P/S, Life Technologies), 2% GlutaMAX (Life 





of 2 g/L or Roswell Park Memorial Institute (RPMI) 1640 with 10% 
FBS and 100 U/mL P/S for BT474, DMEM supplemented with 10% 
FBS, 100 U/mL P/S, 1 mM sodium pyruvate (Life Technologies), 12 
mM HEPES (Life Technologies) and 0.1mM non-essential amino 
acids  (Life Technologies) for H157 and Iscove's Modified 
Dulbecco's Medium (IMDM, Life Technologies) supplemented with 
10% FBS and 100 U/mL P/S for hDFs. 
 
2.2. Generation of alginate capsules 
A solution of 1.1% (w/v) of Ultrapure Ca
2+
 MVG alginate (UP 
MVG NovaMatrix, Pronova Biomedical, Oslo, Norway), dissolved in 
NaCl 0.9% (w/v), was prepared in sterile conditions. 
Microencapsulation was performed using an electrostatic bead 
generator (Nisco Encapsulator) with an air flow rate of 10 mL/h, at 
5.3 volts, with air pressure of 1 bar. Alginate droplets were cross-
linked in a 20 mM BaCl2 bath, adjusted to 290-300 mOsm using 
NaCl, buffered at pH 7.4. The resulting microcapsules were washed 
three times in a 0.9% (w/v) NaCl solution. A nozzle with 0.7 mm 
diameter was employed to generate alginate microcapsules with a 
diameter of approximately 700 μm. 








































Figure 3.1: Schematic representation of the experimental layout. 
Cancer cell lines were expanded, collected and inoculated as single cell 
suspensions in a spinner vessel, for aggregation. The cancer cell 
spheroids formed were encapsulated, either alone (leading to the 
formation of encapsulated mono-cultures), or together with human 
fibroblasts (leading to the formation of encapsulated co-cultures). As a 
control, non-encapsulated spheroids are also maintained in culture. 
Empty alginate capsules were also prepared. Encapsulated and non-
encapsulated cultures were maintained for 14 days under dynamic 
conditions. Biochemically and mechanically characterization of the system 
was performed by scanning electron microscopy, atomic force 
microscopy, immunofluorescence and immunohistochemistry. 
 
2.3. Generation of tumor cell spheroids in stirred-tank 
culture systems 
Twenty-five million tumor cells were inoculated as single cell 
suspension into wall-baffled spinner-flasks with straight blade 
paddle impeller (Corning® Life Sciences), placed on a magnetic 
stirrer in an incubator at 37 ⁰C, with humidified atmosphere 
containing 5% CO2 and 21% of O2 (Figure 3.1), as described before 
20
. To prevent cell attachment to the spinner vessel walls, these 
have been previously coated with 2-3 mL of dimethyldichlorosilane 
(Merck 8.03452, Germany), as described previously 
21
. Stirring rates 
were set as described in our previous report 
20
, according to the cell 
line characteristics, in order to promote initial spheroid formation 
and limiting spheroid fusion. 
 
2.4. Cell microencapsulation and culture in stirred-
tank culture systems 
Tumor cell spheroids were collected for encapsulation once 
compact and spherical spheroids formed (at day 1 and 3 of culture, 
for BT474 and H157 cells, respectively). For mono-cultures, 2x10
4
 
spheroids were collected from spinner vessel culture, washed with 




Phosphate-Buffered Saline (PBS; Thermo Fisher Scientific) and 
dispersed in 1 mL of 1.1% (w/v) of Ultrapure Ca
2+
 MVG alginate (UP 
MVG NovaMatrix, Pronova Biomedical, Oslo, Norway), dissolved in 
NaCl 0.9% (w/v) solution, as previously described 
6,18,20
. 
Alternatively, for the establishment of co-cultures of tumor cells 
with fibroblasts, a single cell suspension of 4x10
6
 hDFs was mixed 
with a suspension of 2x10
4
 tumor cell spheroids and dispersed in 
1 mL of the alginate solution. Encapsulation was performed as 
detailed in section 2.2. The resulting cell-loaded microcapsules 
(diameter of approximately 700 μm) were washed three times in a 
0.9% (w/v) NaCl solution and once in culture medium before being 
transferred to new spinner vessel. At the same time, spheroids 
were also collected from the spinner vessel and directly transferred 
to a different spinner vessel, as non-encapsulated condition. Non-
encapsulated and encapsulated mono- and co-cultures were kept 
in the culture medium of each cell line (section 2.1). Cultures were 
maintained at 80 rpm, up to 14 days. Each 3-4 days, 50% of the 
culture medium was replaced with fresh culture medium. Samples 
were collected throughout the culture period for further 
characterization, at specific time points (See section 2.5). 
 
2.5. Spheroid and capsule characterization 
During BT474 aggregation period, several samples were 
collected (0, 22, 24, 27, 30 and 49 h after spinner inoculation). 
Non-encapsulated and encapsulated mono- and co-cultures were 
also sampled at various time-points: 0, 2, 5, 7, 9, 12 and 14 days 







2.5.1. Cell viability 
Cell viability was assessed by a cell membrane integrity 
assay which uses: the cell permeant dye fluorescein diacetate (FDA; 
Sigma-Aldrich, Steinheim, Germany), which is metabolized into 
fluorescein by cytoplasmic esterases 
22
; the cell impermeant dye, 
propidium iodide (PI; Invitrogen), which binds DNA 
21
. FDA was used 
at 10 μg/mL, to label live cells, and PI at 1 μM to identify dead cells. 
Spheroids or capsules were incubated for 5 min at room 
temperature (RT) with the fluorescent labels and then analyzed 
using a fluorescence microscope (DMI6000 Leica Microsystems 
GmBH, Wetzlar, Germany). 
 
2.5.2.  Spheroid distribution within capsules 
Encapsulated spheroid distribution was evaluated for mono-
culture capsules at days 0, 2, 5, 7, 9, 12 and 14 of culture. At each 
time point, mono-capsules were imaged in a fluorescence 
microscope (DMI6000, Leica Microsystems GmbH, Wetzlar, 
Germany). For the analysis, a group of cells was considered a 
spheroid when individual cells could not be counted. Spheroid 
distribution per microcapsule was analyzed by manually counting 
the number of capsules and the number of spheroids in each 
capsule, present in 1 mL of culture.  
 
2.5.3. Spheroid size  
Spheroid size was evaluated during aggregation and in 
mono- and co-culture capsules at days 0, 2, 5, 7, 9, 12 and 14 of 
culture. Non-encapsulated spheroids were analyzed directly. 
Alginate microcapsules were dissolved in a chelating solution (100 
mM EDTA, 10 mM HEPES, pH 7.4, for 5 min at RT, and washed twice 




with PBS, to harvest the cancer spheroids. Spheroids were imaged 
in a fluorescence microscope (DMI6000, Leica Microsystems 
GmbH, Wetzlar, Germany). Spheroid area and Feret’s diameter were 
measured by adjusting the threshold until the border of each 
spheroid and quantification was performed using ImageJ open 
source software (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-
2018). 
 
2.5.4. Cell phenotype and proliferation 
Samples were collected at day 14 of culture and fixed in 4% 
(w/v) paraformaldehyde (PFA, ≥95%, Fluka) with 4% (w/v) sucrose 
(≥99.5%, Sigma-Aldrich), in PBS, for 30 min at RT. Then, they were 
washed 3 times with PBS and kept at 4 ⁰C until further analysis. For 
cryo-sectioning, samples were dehydrated with 30% (w/v) sucrose 
overnight. Then they were embedded in Tissue-Tek O.C.T. (Sakura, 
Alphen aan den Rijn, Netherlands) and frozen at −80 ⁰C. Samples 
were sectioned at a thickness of 10 μm using a cryo-microtome 
(Cryostat I, Leica, Wetslar, Germany). 
Immunofluorescence (IF) was performed according to 
previously published methods 
23
. In brief, cells were permeabilized 
for 10 min with 0.1% Triton X-100 (w/v) and blocked for 30 min 
with 0.2% (w/v) Fish Skin Gelatin (FSG; Sigma–Aldrich). Primary 
antibodies (Table S1) were diluted in 0.2% (w/v) FSG and incubated 
for 2 h, at RT and secondary antibodies (Table S1) diluted in 0.125% 
(w/v) FSG and incubated for 1 h, at RT. Samples were mounted in 
ProLong Gold Antifade Mountant containing DAPI (Life 
Technologies) and visualized using a fluorescence microscope 





For Ki-67 quantification, ImageJ open source software 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018) 
was used. The percentage of Ki-67 positive cells was obtained by 
diving the number of cells expressing Ki-67 by the total number of 
cells present in the spheroid. This analysis was performed for a 
minimum of three spheroids per experiment, from two 
independent experiments. 
 
2.5.5. Extracellular matrix deposition 
At day 14, encapsulated mono- and co-cultures were 
collected and fixed as described above (Section 2.5.4). Then, 
capsules were embedded in 2% (w/v) high melting temperature 
agarose (Lonza), dehydrated in a graded series of ethanol and 
embedded in paraffin wax (Merck Millipore). Paraffin blocks were 
then sectioned (3 μm thickness) on a rotary microtome (RM 2135, 
Leica). 
Spheroid’s structure and compactness and cell distribution 
were assessed by visual inspection of Hematoxylin and Eosin (H&E; 
Sigma-Aldrich) staining. The presence of collagen fibers was 
assessed by Picrosirius Red (PSR; Polysciences Europe GmbH, 
Eppelheim, Germany) staining. Glycosaminoglycans (GAGs) and 
alginate were stained with Alcian Blue (AB; Polysciences Europe) 
and Aldehyde Fuschin (American MasterTech). Both these stainings 
were performed in accordance with supplier instructions. 
Histological slides were digitalized in a NanoZoomer SQ whole slide 
scanner (Hamamatsu Photonics) and viewed and processed in 
QuPath software. 
 




2.5.6. Capsule morphology 
The surface of empty capsules was assessed by scanning 
electron microscopy (SEM). Capsules were dried on adhesive carbon 
tabs (12 mm, Agar Scientific) or on silicon wafers and coated with 
iridium in order to avoid charging effects during image acquisition. 
SEM was carried out in a Zeiss AURIGA CrossBeam microscope. 
Surface analysis was done on secondary electron imaging mode 
using acceleration voltages of 2 and 5 keV. Pore size was measured 
for 77 different pores. Capsule size was measured in two different 
capsules. Membrane thickness was measured in one capsule. 
 
2.5.7. Capsule’s mechanical properties assessment 
In the last culture day (14 days after microencapsulation), 
capsules from mono- and co-cultures were collected and fixed as 
previously detailed. Atomic force microscopy (AFM)-based 
mechanical dynamic characterization was performed to compare 
the nanoscale elastic properties and behavior of empty, mono- or 
co-culture capsules. Alginate microcapsules were embedded in 1% 
(w/v) high melting temperature agarose (Lonza), forming a thin 
film, which maintained the capsules in a fixed position during AFM 
acquisitions. These capsules were covered with PBS to maintain 
hydration before and during AFM measurements in a MFP-3D Stand 
Alone (Asylum Research) AFM system operated in alternate contact 
mode (AC mode). Elastic behavior was studied through load-unload 
force curves (force spectroscopy) in liquid environment (PBS) using 
commercially available silicon nitride probes (Long cantilever of 
Olympus TR-800PB; f0 = 13 kHz, 0.16 N/m; Olympus Corporation). 
The probes were left to stabilize at least 3 hours prior to calibration 
through Sader’s method 
24





was approximated by fitting Sneddon’s model 
25
 to the force curves 
on augmented reality built-in software packages in IgorPro 
(Wavemetrics). A minimum of 28 force curves were obtained for a 
minimum of three capsules of each condition. For the analysis of 
empty capsules, 3 independent capsules batches were used. For 
the cell-containing capsules, 1 batch of capsules was used for each 
condition. 
2.6. Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 5 
software. All experiments and analysis were performed at least in 
triplicate. The statistical test applied and the considered 




Empty hydrogel alginate capsules were prepared by 
crosslinking of alginate with barium chloride using an electrostatic 
bead generator. Capsule morphology and membrane thickness 
were assessed by SEM. Empty alginate capsules were left to dry on 
carbon tape/silicon wafer, covered with a thin film of iridium and 
then imaged (Figure 3.2A-E). We observed a capsule diameter of 
204±1 µm (Figure 3.2A), which differed from the average diameter 
observed for hydrated capsules (around 700 µm, Figure 3.4). 
Alginate capsules are hydrogels, cross-linked polymeric networks 
which retain a significant fraction of water within their structure 
26
; 
during drying for SEM preparation, capsules loose water by 
evaporation, which probably justifies the observed capsule 
shrinkage. We observed that capsules were composed by surface 
thick membrane (approximately 10 µm, Figure 3.2B). At the capsule 




surface, we could identify pores (Figure 3.2C, D and E), with an 









Figure 3.2: Scanning electron microscopy of alginate microcapsules. 
Alginate capsules were dried on carbon tape, coated with iridium and 
imaged: A) individual capsule, scale bar: 100 µm; B) membrane region of 
a capsule; scale bar: 10 µm; C), D) and E) pore region of the membrane 
of several capsules; (C) scale bar: 10 µm; (D) and (E) scale bar: 1 µm; F) 
pore size distribution. Data is represented as mean ± SD (N=2). In A), B), 







BT474 spheroids were prepared from single cells, as 
previously described by our group 
20
. Spheroids were harvested 
from culture when they reached an average diameter of 120 µm, 
which corresponded to 22 h post inoculation (Figure S3.1). 
Spheroids were encapsulated either alone or with fibroblasts, to 
generate mono- and co-cultures, respectively. In parallel, non-
encapsulated spheroids were also maintained in culture. 
Alginate capsules containing both mono- and co-cultures 
were measured at 2 hours of culture, to allow for equilibration in 
culture medium. The diameter observed for mono- and co-cultures 
was of 755 ± 20 and 780 ± 20, respectively (Figure 3.3). By day 14 
of culture, no major differences were observed, in the average 
diameter of capsules from mono- and co-cultures (672 ± 42 and 
713 ± 26, respectively Figure 3.3). Moreover, capsules retained 
their spherical shape along culture time, with no detectable 




Figure 3.3: Alginate capsule diameter along culture time, in mono- 
and co-cultures. At 2 hours (Day 0) and day 14 of culture, 1 mL of capsule 
suspension was collected and the size of alginate capsules was evaluated. 
Data is represented as mean ± SD (N=2). 
 




Concerning the cellular compartment, typically, 1 to 3 tumor 
cell spheroids were distributed per capsule, with fibroblasts 
organized around them, as previously described by our group for 
another BC cell line 
6
. Both cell types maintained high cell viability 
over the 14 days of culture (Figure 3.4A), without significant 
changes in the number of spheroids per capsule (Figure S3.1A). On 
the other hand, BT474 non-encapsulated spheroids reached a 
diameter of 580 ± 71 µm by day 14, higher that their encapsulated 
counterparts (Figure 3.4B and Figure S3.2B). In both the mono- and 
co-culture encapsulated conditions, spheroid protrusion from the 
alginate capsules was observed during culture, without 
compromising capsule structure (Figure 4A). Compactness and 
roundness of the BT474 encapsulated spheroids were maintained 







Figure 3.4: Non-encapsulated and encapsulated BT474 cell spheroids, 
in mono-culture or in co-culture with fibroblasts. A) At day 0, 7 and 14 
of culture, cell viability was assessed by live/dead assay (FDA-green, live 
cells; PI-red, dead cells) for non-encapsulated spheroids, encapsulated 
spheroids in mono-culture and in co-culture with fibroblasts; scale bar: 
500 µm. Representative pictures of 3 independent experiments. B) At day 
2, 5, 7, 9, 12 and 14, spheroid diameter of non-encapsulated (grey), 
encapsulated mono- (blue) and co-cultures (purple) was evaluated. Data is 
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In terms of tumor cell phenotype, encapsulation did not 
affect BT474 cells, which formed compact spheroids, with BT474 
cells presenting cortical F-actin (Figure 3.5A and B) in the cell-cell 
interaction regions, as previously described for carcinoma cell lines 
27
. Moreover, BT474 cells continued to express the luminal cell 
marker CK-18 
28
, associated with their epithelial nature (Figure 
S3.3). The BT474 cell line is a luminal B BC cell line, which 
overexpresses Human Epidermal Growth Factor Receptor 2 (HER2) 
(Figure S3.3), an important breast carcinogenesis driver, used in 
the discrimination of BC subtypes and as therapeutic target 
29,30
. By 
day 14 of culture, encapsulated spheroids and their non-
encapsulated counterparts presented similar detection of CK-18 
(Figure 3.5C and D) and HER2 (Figure 3.5E and F). Immunodetection 
of the proliferation marker Ki-67, at day 14 of culture, showed a 
low number of positive cells dispersed throughout the spheroids, 
both in non-encapsulated and encapsulated spheroids (Figure 3.5G 
and H). Quantification of Ki67-positive cells indicated that 
encapsulated mono-cultures featured higher levels of proliferation 








































Figure 3.5: Phenotypic characterization of encapsulated and non-
encapsulated BT474 spheroids. After 14 days of culture, non-
encapsulated and encapsulated BT474 spheroids were immunolabelled 
for f-actin (A and B), CK-18 (C and D), HER2 (E and F) and Ki-67 (G and H), 
scale bar: 100 µm; I) Quantification of Ki-67 levels, data is presented as 
mean ± SD (N=6). Statistical analysis was performed using the non-
parametric Mann-Whitney with ** p-value<0.01. 
 
After two weeks of culture, the stiffness of the alginate 
capsules containing mono- and co-cultures were assessed by AFM. 
This scanning probe microscopy has nanometric resolution and the 
YM can be obtained from the data 
31
. 
The YM determined for empty capsules was of 214±112 kPa. 
Capsules from mono- and co-cultures with 14 days presented lower 
YM (Figure 3.6): 16±13 and 40±12 kPa, for BT474 encapsulated 
mono- and co-cultures, respectively. In fact, encapsulated co-


















presence of fibroblasts induced generalized higher stiffness of the 
capsules, we have analyzed encapsulated cultures from another 
tumor cell line (H157). Once again, the YM of encapsulated co-




Figure 3.6: Young modulus of alginate capsules: empty, from mono- 
and co-cultures Young modulus of empty and 14-days cultured capsules 
was analyzed through AFM. BT474 mono and co-cultures represented in 
orange; H157 mono and co-cultures represented in blue). Data 
represented as mean ± SD (N=3). 
 
In a previous study of the lab, we have observed that 
encapsulated co-cultures of H157 cells, fibroblasts and 
macrophages presented increased deposition of extracellular 
matrix (ECM) components in the capsules, namely collagen I and IV 
and fibronectin 
18
. As collagen is described as mainly produced by 
fibroblasts 
32
 and deposition of collagen has been associated with 
stiffening of tumor tissue 
33
, we reasoned that ECM deposition in 




encapsulated co-cultures might be responsible for the stiffening 
detected by AFM. To assess ECM matrix deposition, encapsulated 
cultures were stained for two of the most described components of 
the ECM, collagens and GAGs. 
In encapsulated BT474 mono-cultures, picrosirius red 
staining of collagen was detected within spheroids (pink staining, 
Figure 3.7); there was no detectable collagen deposition within the 
capsules. Under polarized light, collagen fibrillar form was 
detected in very limited regions, in between tumor cells (white 
yellowish staining, Figure 3.7E and F); in accordance, we could not 
detect collagen fibers by second-harmonic generation microscopy 
(data not shown). No differences were observed when comparing 
encapsulated mono- and co-cultures (Figure 3.7). 
GAGs were detected with alcian blue (that stains acidic 
polysaccharides and negatively charged mucins in blue) and 
aldehyde fucshin (that stains sulfated GAGs in purple). A light 
purple staining was observed in BT474 spheroids (Figure 3.7G and 
H), indicating low GAG accumulation relative to H157 spheroids, 
which were strongly stained (Figure S3.4). In all tested conditions, 
no accumulation of GAGs was detected outside of the spheroids, 
except the blue concentric ring surrounding the cells, probably 
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Figure continues on the next page. 
  












Figure 3.7: BT474 mono- or co-culture capsules show low 
accumulation of collagen and GAGs after 2 weeks of culture. After 14 
days of culture, alginate capsules were fixed with PFA and A), B) H&E; C), 
D) Alcian blue/aldehyde fuschin under light microscopy E), F) Alcian 
blue/aldehyde fuschin under polarized light; G), H) Picrosirius red 
histochemical evaluations were performed; black arrows point at the 




Several 3D models of the TME have been developed based 
on the combination of cells and biomaterials. Specifically, alginate 





 and liver cancer 
34
. In this work, we have characterized 3D 
cancer cell models composed of alginate microencapsulated tumor 
cell spheroids together with human fibroblasts. By structural 
analysis, we show that empty alginate capsules have surface 
porosity. By comparison of non-encapsulated and encapsulated 
spheroids, we concluded that encapsulation avoided spheroid 
fusion and sustained cancer cell phenotype, as shown by typical 
epithelial cell markers, and proliferation. Mechanical evaluation of 





presence of cells made alginate capsules smoother and the 
addition of fibroblasts increased capsule stiffness. 
Capsules were cultured in a dynamic system that allow 
culture sampling in a non-destructive manner 
35
. Also, agitation 
contributes to the maintenance of high cell viability by promoting 
a homogeneous distribution of oxygen and nutrients and a reduced 
formation of chemical and thermal gradients
35
. Characterization of 
empty alginate capsules revealed a hydrogel with a non-smooth 
porous surface. This may suggest that the capsule does not hamper 
the diffusion of macromolecules 
6
, including cytokines, released by 
the several cell types, as observed previously by our group using 
alginate co-culture capsules containing MCF-7 cells and fibroblasts 
6
. Additionally, the size of capsule’ pores is higher than antibodies. 
This suggests that these capsules can also be challenged with 
antibodies, which are currently used in clinics as cancer 
therapeutics. The average pore size we measured in the alginate 
capsules, within the nanometer range, is in agreement with the 
reported values on the literature for alginate hydrogels, reviewed 
by Simpliciano et al. 
36
. The surface morphology we observed in the 
empty alginate capsules is in agreement with the observations 
reported by Arica et al. 
37
. The authors prepared empty and 
ibuprofen-loaded calcium alginate beads and analyzed their 
surface morphology by SEM. Results revealed beads with rough 




During two weeks of culture, capsules maintained their 
sphericity and size, without visible damage. In co-cultures, 
fibroblasts arranged themselves around the tumor spheroids 
creating distinct epithelial and stromal compartments, as 




previously observed for co-cultures of MCF7 cells and fibroblasts 
6
. 
Encapsulation sustained the phenotype of the cancer cells, as 
suggested by the sustained detection of CK-18 and HER2. 
Encapsulated spheroids maintained their size over the two weeks 
of culture, compared to non-encapsulated spheroids, for which 
significant higher diameters were observed, concomitant with a 
significant decrease in spheroid concentration. This is probably 
due to spheroid fusion, induced by the agitation in the non-
encapsulated spheroids, and avoided by the space limitation 
imposed by the capsule in encapsulated spheroids. Moreover, we 
observed lower detection levels of Ki-67 in non-encapsulated than 
encapsulated spheroids, suggesting that spheroid fusion, rather 
than cell proliferation explains the increased diameter of non-
encapsulated spheroids over encapsulated ones, for the same 
culture time. Encapsulated spheroids from co-cultures showed 
higher diameter than those from mono-cultures. This is in 
agreement with what has been reported by Jeong et al. when 
culturing HT-29 cells as tumor spheroids in a collagen-matrix 
inside a microfluidic chip 
38
. They compared spheroid diameter 
after 3 and 5 days of culture under mono- or co-culture with 
fibroblasts. In both time points, they observed larger spheroids in 
co-culture compared to mono-culture 
38
. 
To mechanically characterize the alginate encapsulated 
model, stiffness was evaluated through analysis of YM, inferred by 
AFM. The YM depends solely on the intrinsic mechanical properties 
of the materials, being independent of the device geometry 
11
. Cell-
containing capsules were softer that empty capsules, with YM 
obtained for mono- and co-culture BT474 capsules falling within 
the range of BC tissue YM (10-43 kPa) 
39





capsules containing cells could be explained by the time in culture 
medium itself, which can be enough to soften the capsules with 
cells, by influence of culture medium compounds on the alginate 
capsules network. Additionally, the difference of stiffness between 
empty and cell-containing capsules is in agreement with was 
observed by Tian and Chen 
9
. Using alginate hydrogels with varying 
quantity of cells, they concluded that an increase in cell density 
leads to a decrease in scaffold strength. Nonetheless, when 
comparing mono- and co-culture capsules, we observed that the 
latter were stiffer, for both cell lines analyzed, despite the higher 
number of cells encapsulated. This may be explained by the 
secretion of molecules by fibroblasts and tumor cells under the 
influence of the fibroblasts. Secreted molecules, such as collagen, 
can interfere with the overall mechanical properties of the 
hydrogels. In fact, deposition of collagen has been associated with 
stiffening of tumor tissue 
33
. Aiming to elucidate if increased ECM 
deposition in co-cultures could explain the differences in YM 
observed, we employed histochemical methods to detect collagens 
and GAGs. We could not see differences between mono- and co-
culture conditions, as there was no detectable ECM outside the 
cellular compartment of the capsules. Nonetheless, in previous 
works by our group we have detected collagens within capsules of 
co-cultures of several tumor cell lines and fibroblasts, employing 
immunofluorescence and colorimetric methods 
6,18
. A possibility is 
that the processing of the paraffin embedded samples was too 
harsh, as in fact, also fibroblasts were almost not detected. Further 
studies are required to elucidate the presence of ECM components 
within the capsules and their influence on the mechanical 
properties of the system. 





Collectively, the results presented contribute to the 
characterization of alginate encapsulated cancer cell models. These 
models can be a useful tool to study for example anti-cancer 
therapy distribution within the TME. In fact, not only 
chemotherapeutic drugs but also antibodies can be tested since 
alginate capsule’ pore size is bigger than the antibody size 
40
. This 
potential application is studied in more detailed in the Chapter IV 
of this thesis. 
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Figure S3.1: BT474 cell line forms spherical and compact spheroids 
after one day of culture in spinner vessel. A) Spheroid diameter and 
spheroid concentration throughout culture time was measured (N=1); 
data is represented as mean ± SD; B) Live/dead assay (FDA-green; PI-red) 













Figure S3.2: Spheroid distribution per capsule and spheroid 
concentration in non-encapsulated cultures. A) At day 0, 7 and 14 days 
of culture of encapsulated mono-culture, 1 mL of culture was collected 
and the quantity of spheroids inside each alginate capsule was counted 
(N≥2). B) At day 0, 7 and 14, of non-encapsulated culture, 1 mL culture 
was collected and the number of spheroids was counted (N=2). 
  




























Figure S3.3: Immunofluorescence microscopy of BT474 cells cultured 
in 2D. BT474 cells cultured in 2D were immunolabelled for f-actin (A), CK-








































Figure S3.4: GAG detection in encapsulated cultures of H157 tumor 
cells. After 14 days of culture, alginate capsules were fixed with PFA and 
aldehyde fuschin and alcian blue staining were performed to detect 
glycosaminoglycans in general and alginate, respectively (N=1); scale 100 
µm. 
  




Table S3.1: Antibodies used for immunodetection. 
Antibody 
description 
Clone Origin Reference Supplier 
Anti-Ki67 SP6 rabbit ab27619 Abcam 
Anti-CK-18 – FITC 
conjugate 
CY-90 mouse F 4772 Sigma 
Anti-HER2 - rabbit A0485 DAKO 
Anti-phalloidin – 488 
conjugate 
- - A12379 
Life 
Technologies 
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Antibodies revolutionized cancer treatment over the past decades. 
Despite their successfully application, there are still challenges to 
overcome to improve efficacy, such as the heterogeneous 
distribution of antibodies within tumors. Tumor microenvironment 
features, such as the distribution of tumor and other cell types and 
the composition of the extracellular matrix may work together to 
hinder antibodies from reaching the target tumor cells. To 
understand these interactions, we propose a framework combining 
in vitro and in silico models. We took advantage of in vitro cancer 
models previously developed by our group, consisting of tumor 
cells and fibroblasts co-cultured in 3D within alginate capsules, for 
reconstruction of tumor microenvironment features. 
In this work, a computational model of antibody transport within 
alginate capsules was established, assuming a purely diffusive 
transport, combined with an exponential saturation effect that 
mimics the saturation of binding sites on the cell surface. Our 
tumor microenvironment in vitro models were challenged with a 
fluorescent antibody and its transport recorded using light sheet 
fluorescence microscopy. Diffusion and saturation parameters of 
the computational model were adjusted to reproduce the 
experimental antibody distribution, with root mean square error 
under 5%. This computational framework is flexible and can 
simulate different random distributions of tumor 
microenvironment elements (fibroblasts, cancer cells and collagen 
fibers) within the capsule. The random distribution algorithm can 
be tuned to follow the general patterns observed in the 
experimental models. 
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We present a computational and microscopy framework to track 
and simulate antibody transport within the tumor 
microenvironment that complements the previously established in 
vitro models platform. This framework paves the way to the 
development of a valuable tool to study the influence of different 
components of the tumor microenvironment on antibody 
transport. 
 
Key words: antibody diffusion, tumor microenvironment, 3D in 








The value of antibodies as antitumor therapies has been 
largely demonstrated over the last two decades 
1
. Despite the 
generalized success, there are still challenges to overcome, such 
as the largely reported poor tissue penetration and heterogeneous 
distribution of antibodies within solid tumors 
2
. Efficacy of 
therapeutic antibodies is conditioned by several transport barriers, 
from systemic administration until reaching the target cells 
3
. These 
barriers ultimately cause a reduction of the therapeutic molecule 
concentration that reaches the target tumor cells, decreasing its 
therapeutic effect 
3–5
. Specifically within the tumor 
microenvironment (TME), higher heterogeneity is found when 
comparing with healthy tissue: tumors present altered vasculature, 
desmoplastic and inflammatory microenvironment and 
extracellular matrix (ECM) alterations 
6
. Within the ECM, collagen 
fibers and glycosaminoglycans (GAGs) have been previously 
described as influencing the transport of therapeutic molecules 
7–9
. 
So, it is crucial to assess antibody transport within this intricate 
network with high impact on therapy efficiency. 
Experimental (i.e. in vitro, in vivo and ex vivo) and 
computational (in silico) models have been developed to help 
understand how tumor heterogeneity influences drug distribution 
within the TME 
6,10,11
. Those two types of models can and should be 
combined to develop a comprehensive framework to study and try 
to answer that question. 
Several computational models have been developed over the 
years to describe and simulate the transport and interactions of 
drugs within the tumor by considering the main transport 
mechanisms, such as diffusion and convection, degradation and 
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. These models can be used to study the 
complex interaction between several tumor components and drug 
pharmacokinetics and distribution. They can represent the tumor 
with different levels of detail, from a simplistic homogeneous 
tumor mass to complex heterogeneous non-equally distant cancer 
cells. However, they do not consider the impact on antibody 
distribution of specific elements of the TME, such as collagen 




The assessment and tracking of distribution of drugs in vivo, 
in tumor tissue or in tumor-like structures or complex cell 
cultures/tissue mimetics is also technically challenging 
13,17
 and 
typically relies on methods that do not allow real-time tracing of 
antibody distribution 
17–20
 due to limitations of microscopy 
techniques and of the biological sample 
17,21
. 
Our group has been developing modular 3D cell models of 
the tumor microenvironment. These in vitro cancer models, 
comprise cancer cells, and fibroblasts and other cellular 
components, that can be conjugated in different amounts and 
proportions, to mimic features observed in patient tumors 
22,23
. 
In this work, 3D in vitro cancer models were used as an 
experimental platform to assess antibody distribution within the 
TME. Light sheet fluorescence microscopy (LSFM) was implemented 
to perform real-time antibody tracking with high resolution 3D 
imaging over time, together with low photobleaching of the sample 
fluorescence 
24
. An in silico model of antibody diffusion within the 
TME, developed specifically as a complement to the 3D in vitro 
models, was calibrated based on these data. Assuming a purely 





cell surface become saturated over time, Fick’s law was combined 
with an exponential saturation equation. The computational model 
was able to describe the antibody concentration profile observed 
experimentally with very good agreement. Additionally, we show 
this platform can be used to generate random spatial distributions 
of the TME elements (tumor cell spheroids, fibroblasts and ECM 
fibers) inside the capsule, following a tunable stochastic approach. 
 
2. Results 
2.1. Experimental observation of antibody diffusion 
through 3D capsule 
Antibody transport within the alginate capsule was tracked 
using a custom-made LSFM setup. A fluorescent anti-CD44 
antibody was used to challenge the encapsulated co-culture of 
tumor cells and fibroblasts. Over time, fluorescent signal was 
increasingly detected in cells within the capsules, following a radial 
trend from the periphery to the inside of the capsule (Additional 
file 1). The central plane of the 3D capsule acquisition was selected 
to allow visualization and model calibration (Figure 4.1, Additional 
file 2). 
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Figure 4.1: Fluorescence after antibody challenge for a representative 
capsule section. A) 0 min; B) 30 min; C) 90 min; D) 120 min; E) 150 min; 






Image processing was used to trace antibody fluorescent 
signal profiles in defined regions of interest (ROIs), corresponding 
to cell spheroids or clusters of few cells (Figure 4.2A). For cell 
cluster II, close to the capsule periphery, we observed a fast 
increase in fluorescence intensity, which stabilized early into a 
plateau (Figure 4.2C). For cell cluster V, further away from the 
periphery, we observed a delay in the increase in fluorescence 
intensity and the plateau was reached at least 30 min later (Figure 
4.2F). 
The delay time had a positive correlation with the cell cluster 
distance to the capsule periphery, although with a high variability 
(Figure 4.2B-F, Figure S4.A). It is reasonable to expect the presence 
of heterogeneous physical and biological barriers in the antibody 
diffusion path which can influence the delay time. For example, 
cluster III was farther away from the periphery than cluster I, but 
both show a similar delay (Figure S4.A). 
The experimental fluorescence profiles were fitted with 
mathematical models for S-shaped curves, often used to describe 
population growth 
25
. All selected clusters had the best fit, with 
R
2
>0.98, with the Richards model, given by 
"P (t)=
M









- 1 ]  exp(M β t0) (2) 
in which P is the mean fluorescence and α, β, γ and M are constants 
25
. 
The fitted smoothed curves describe well the overall 
fluorescence intensity profiles (Figure 4.2, Table 4.1). Nonetheless, 
for some of the cell clusters, when the fluorescence intensity 
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becomes detectable, the adjusted curve showed a slight bias 
towards a shorter delay than was seen in the experimental data 
(Figure 4.2C, E). Consistently with the previous observations, the 
curve parameters do not follow a clear trend depending on the 
cluster distance to the capsule periphery or the cluster size. 
 
Table 4.1: Properties for selected cell clusters and parameters for the 








 Fitted parameters  
M β γ R2 
I 83.0 232 54.1 6.42×10
-4
 4.40 0.9868 
II 88.1 270 80.2 4.88×10
-4
 15.1 0.9884 
III 115.0 211 55.2 10.1×10
-4
 2.44 0.9980 
IV 124.7 265 109 4.40×10
-4
 1.87 0.9978 
V 127.3 439 75.0 7.09×10
-4







Figure 4.2: Fluorescence profiles for selected cell clusters and fitted 
curves. A) Definition of selected cell clusters (scale bar: 100 µm); B-F) 
Experimental mean fluorescence profiles from LSFM data (red dots) and 
fitted curves (blue lines) for the selected cell clusters I through V, 
respectively. Curve parameters for Eq. (1-2) are shown in the Table 1. 
 
2.2. Computational model emulates antibody transport 
within the capsule 
A digitization approach was used to obtain a capsule section 
equivalent to the one used in the experimental study (Figure S4.2A-
C). The initial diffusivities (Figure S4.2D) were set taking into 
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account the range of values for this parameter reported on the 
literature 
26–28
 and the experimental results over time (Figure 4.1). 
By changing Dmedium the “radially moving front” of the antibody 
distribution can be controlled. Based on experimental 
observations, Dmedium was fixed at 0.15 μm2/s and Dcell was 
subsequently fixed at 0.0015 μm2/s. 
The computational model has antibody distribution profiles 
over time which are very similar to the ones obtained 
experimentally, when looking to diffusion through the extracellular 
intra-capsule space (Figure 4.3, Additional file 3). The model 
diffusivity coefficients decrease over time on the exposed surface 
of the cell spheroids, as imposed by the saturation equation (Figure 







See caption in the next page.  
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Figure 4.3: Simulated antibody concentration profile throughout the 
digitized capsule, over time. Computational images for selected 
timepoints using saturation parameters a = 1, n = 1 and p = 1: A) 0 min; 
B) 30 min; C) 90 min; D) 120 min; E) 150 min; F) 180 min; white 
circumference represents the capsule periphery; scale bar: 100 µm. 
 
Antibody concentration profiles in the cell clusters were 
adjusted to account for binding and saturation of the antigens. To 
fit the computational model, the parameters of the saturation 
equation, Eq. (4), were adjusted by minimizing the root mean 
square error (RMSE) between the normalized experimental and 
computational profiles, for the 5 selected cell clusters (Figure 
4.4A). The proposed model, using Fick’s law combined with 
exponential saturation, was able to represent the experimental 
profiles with an RMSE up to 5% (Figure 4.4B-F and Table 2). The 
best parameters varied between cell clusters, even for clusters with 
similar distance to the capsule periphery such as clusters I and II 






Figure 4.4: Computational antibody concentration profiles after 
fitting of the saturation parameters a, n and p to selected cell 
clusters. Adjusted computational curve: blue line; smoothed 
experimental data: red line; scale bar: 100 µm. 
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Even though a 5% RMSE was considered low, the systematic 
deviation observed consistently in the same direction across cell 
clusters (lower log phase slope for the computational model) 
suggests the influence of biological or biophysical mechanisms not 
considered in the model. Consistently, representing signal delay as 
function of cluster distance to capsule periphery showed that the 
computational delay is smaller than the experimental by 
approximately 10 min (Figure S4.A). Comparing the slope against 
cluster area showed that, with the exception of cluster II, there is 
an approximately constant deviation between the computational 
and experimental models (Figure S4.B). 
The computational model was also tested without the 
saturation equation, Eq. (4). The sigmoidal profile observed 
experimentally cannot be replicated with any combination of the 
adjusted parameters, in this case Dcell and Dmedium (Figure S4.4 and 
Table S4.1), meaning that a purely diffusive model is unable to 




a n p RMSE 
I 1.01 1.73 1.33 0.05 
II 1.00 1.00 1.00 0.01 
III 1.13 0.53 1.34 0.04 
IV 0.43 1.91 1.40 0.03 





2.3. Implementation of a modular framework: tuned 
random distribution of TME elements inside the capsule 
The framework used to create the capsules allows us to 
simulate several distinct but equivalent capsules, i.e. with the same 
number of cancer cell spheroids and fibroblasts, but with different 
distribution. It is based on a tunable stochastic algorithm, which 
mimics the observed experimental distributions. Along with the 
cancer cells and fibroblasts, we also included a representation for 
collagen fibers. Some examples of the versatility of this framework 
are shown in Figure S4.5. 
This framework was tested in silico by creating two identical 
capsules, one with and one without collagen fibers (Figure 4.5A, 
scenarios i and ii respectively). The diffusivity coefficient for the 
collagen fiber was set as zero (total barrier), as it has been reported 
that this ECM component hinders antibody diffusion 
7–9
, while the 
remaining TME elements maintained the previously described 
diffusivity parameters (Figure 4.5B). Antibody concentration 
distributions were compared for both capsules for the second and 
last time frames (Figure 4.5C-D). For the capsule without fibers, the 
antibody diffuses radially and homogeneously to the interior of the 
capsule (Figure 4.5C-D, scenario i). When fibers are added, 
antibody distribution throughout the capsule is highly 
heterogeneous as fibers perpendicularly aligned to the diffusion 
direction retain the antibody (Figure 4.5C-D, scenario ii). This 
difference is also clear in the antibody concentration profiles for 
the three selected clusters in each scenario (Figure 4.5E). Cluster 1 
is near the periphery and the antibody diffusion profile is very 
similar for both settings. Cluster 2 is in the internal portion of the 
capsule and is surrounded by fibers that impede diffusion, which 
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in turn virtually nullifies the antibody concentration. Finally, cluster 
3 displays an intermediate situation, the antibody concentration 
profile in the presence of fibers follows a similar trend than in the 
absence of fibers but with lower total. 
 
 






Figure 4.5: Example of a tuned stochastic computational capsule with 
and without fibers. Simulation with Dmedium=0.15 μm2/s, Dcell=0.0015 
μm2/s, a=1, n=1, and p=1, for two scenarious: (i) without fibers and 
(ii) with fibers. A) Graphical representation of one random tuned capsule, 
with the indication of the selected clusters; B) Initial diffusivity coefficients 
throughtout the capsule; C-D) Antibody concentration for two different 
time points (30 and 180 minutes, respectively); E) Antibody concentration 
profile for the three cell clusters identified in A (blue – cluster 1, orange – 
cluster 2, green – cluster 3); scale bar: 100 µm. 
 
3. Discussion 
In the present work, we developed a computational model 
that reproduces in silico antibody transport within a 3D in vitro 
cancer model. The in silico model was trained with live tracking 
data of a fluorescent antibody, generated by LSFM. This 
microscopic technique allowed us to assess which cells within the 
alginate capsules, were binding to the antibody and to what extent. 
LSFM overcomes the limitations of classical fluorescent microscopy 
techniques, as it provides a good optical sectioning for volumetric 
rendering, being less aggressive to fluorophores and sample, 
reducing photo-bleaching and phototoxicity 
24
. 
Experimental results show that the time delay until a 
detectable fluorescence intensity was attained for each cell cluster 
has a weak linear correlation with cell cluster distance to the 
capsule periphery. This hints at the capsule interior being an 
anisotropic medium with some degree of heterogeneity. Molecules 
secreted by the cells, such as collagens and glycosaminoglycans, 
cannot be detected under the microscope and cause antibody 
retention 
7–9
, being likely responsible by some of the observed gaps 
between the computational and experimental models. Additionally, 
it may be associated with heterogeneous antibody presentation, in 
particular because there are 2 cell types being analyzed together. 
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We assumed a purely diffusive mechanism of antibody 
transport, i.e. antibody transport is controlled exclusively by 
concentration gradients. Convection was considered negligible 
since no significant flow of culture medium was imposed on the 
experimental setup. The lack of significant flow implies a near zero 
Péclet number 
29
 and, therefore, corresponds to a diffusion-driven 
transport. However, convection could be incorporated in the model 
for different experimental conditions. 
Kinetic equations for antibody binding described in the 
literature 
30,31
 require a priori knowledge of kinetic parameters, 
such as binding and dissociation constants. Because these values 
are not always available, we opted for a simpler approach, where a 
generic exponential equation was used to describe the saturation 
of binding sites as the antibody concentration increases and less 
antigens become available. Our simulated antibody distribution 
profiles showed that binding site saturation can be correctly 
represented using this approach. The saturation parameters a, n 
and p control the shape of the sigmoidal curve (Figure S4.6). 
Parameters n and p change the sigmoidal curve by controlling its 
slope. So, n and p can be biologically correlated with ease of 
antibody binding to the cell cluster. As n increases, a longer time 
is needed to observe any reduction in the diffusivity coefficient. As 
such, n can be correlated with the initial contact of the antibody to 
the cell cluster, when the antibody concentration is very small. 
Conversely, p controls the stages closer to saturation, when a much 
higher antibody concentration is present on the cell clusters. 
Parameter a controls mainly the time required to reach the plateau. 
Thus, a can be correlated with the amount of available binding sites 





smaller a value require a higher antibody concentration to bind to 
all the available binding sites.  
Computational model parameters were optimized to fit each 
selected cell cluster. This means that, for each fitted model, all 
clusters were given the same a, n and p parameters as the selected 
cluster. Following this procedure, we observed that different 
parameters fit different clusters. It was not possible to find a 
combination of a, n and p that provided a good fit (RMSE<5%) for 
all the cell clusters simultaneously. A modest but systematic 
deviation was observed in the simulated fluorescence profiles for 
all cell clusters, which suggests mechanisms that are not being 
considered are interfering with the antibody transport. 
This framework can be used as a basis for future work, 
where further improvement can be attained by going from a 2D to 
a 3D in silico representation of the capsule. This will allow for a 
more relevant and realistic study of the antibody transport 
throughout the capsule. 
 
4. Conclusions 
We describe a computational model that reproduces 
antibody transport within an in vitro tumor microenvironment 
model, containing different cellular components. Moreover, we 
showed that the combination of 3D in vitro cell models and light 
sheet fluorescence microscopy enables the experimental 
assessment of therapeutic antibody distribution within the tumor 
microenvironment. Drug molecules with different properties 
(different sizes and charges), ranging from small molecules such 
as chemotherapeutic drugs, to larger molecules such as antibodies, 
can be studied using the same approach. 
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Ultimately, the combined experimental and computational 
framework can be employed not only to decipher how different 
elements within the TME can influence drug transport, but also, 
once that influence is understood, to work as a predictive tool. This 
would help reducing experimental burden and costs by performing 




5.1. Experimental setup, data collection and processing 
5.1.1. Cell lines and 2D cell culture 
NCI-H157 (#CRL-5802; from now on referred as H157) Non-
Small Cell Lung Carcinoma (NSCLC) cell line was obtained from 
American Type Culture Collection (ATCC). Human Dermal 
Fibroblasts (hDFs) isolated from human skin were obtained from 
Innoprot. Cells were cultured under 2D static conditions, 
maintained at 37 ºC in an incubator with humidified atmosphere 
containing 5% CO2 and 21% of O2.  





 and maintained in Tumor Cell Culture 
Medium, composed of Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 1 mM sodium pyruvate (Life Technologies), 12 
mM HEPES (Life Technologies) and 0.1 mM non-essential amino 





 and cultured in Iscove's Modified 
Dulbecco's Medium (IMDM, Life Technologies) supplemented with 







5.1.2. Cell microencapsulation and stirred suspension 
culture  
H157 cell spheroids were generated in all-baffled spinner-
flasks with a straight blade paddle impeller (Corning Life Sciences), 
according to the aggregation protocol previously established in-
house 
32
. Spheroids were collected 3 days after spinner inoculation 





 spheroids were mixed with a single cell suspension 
of hDFs and the mixture was dispersed in 1.1% (w/v) of Ultrapure 
Ca
2+
 MVG alginate (UP MVG NovaMatrix, Pronova Biomedical), 
dissolved in 0.9% (w/v) NaCl solution 
22,23
. Microencapsulation was 
performed using an electrostatic bead generator (Nisco 
Encapsulator) with an air flow rate of 10 mL/h, at 5.3 V with air 
pressure of 1 bar, to generate capsules of approximately 700 μm; 
alginate droplets were cross-linked in a 20 mM BaCl2 bath. 
Encapsulated co-cultures were cultured for 2 weeks under agitation 
(shake flasks, 80 rpm), with medium exchange twice a week (half 
of the volume replaced by fresh Tumor Cell Culture Medium). 
 
5.1.3. Light sheet fluorescence microscopy setup 
All the images were acquired with a custom-made LSFM 
system, an improved version of the SPIM-fluid system 
33
. The 
illumination path consists in three CW lasers with excitation 
wavelengths of 488, 561 and 637 nm (Cobolt; MLD 50 mW, DPL 
100 mW and MLD 150 mW, respectively). Laser beams are 
expanded using a telescope system, composed of two achromatic 
doublets (Thorlabs, AC254-050-A-ML (f = 50 mm) and AC254-200-
A-ML (f = 200 mm)), creating a flat top Gaussian beam profile. The 
light sheet is created by a pair of galvanometric mirrors (Thorlabs, 
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GVSM002), which pivoting planes are properly conjugated with the 
back focal aperture of the objective lens (Nikon, 4x PlanFluor NA 
0.13). Double side illumination is achieved by duplicating these 
elements and adding a 50/50 beamsplitter cube (Thorlabs, CCM1-
BS013). A relay lens set, with two achromatic lenses (Thorlabs, 
AC254-075-A-ML (f = 75 mm)) is used as a bridge, so optical planes 
are properly conjugated in the right arm. In the detection path, a 
water dipping objective (Nikon 10x 0.3) is used to collect the 
generated fluorescence from the top of the incubation chamber, as 
in an up-right microscope configuration. An achromatic doublet 
with focal distance of 200 mm (AC254-200-A-ML) is used to form 
the image onto the sCMOS camera chip (Hamamatsu Orca 
Flash4.0). Different emissions are selected using a motorized filter 
wheel (Thorlabs, FW102C), equipped with three filters (Chroma and 
Semrock: 520/15 (GFP), 590/50, 638LP (Cell tracker deep red)). 
The scanning of the sample is performed by translation of the 
whole physiological chamber with a motor (PI M-501.1DG) through 
a fixed horizontal light sheet plane (Figure S4.7). The Flexi-SPIM 
microscope features a custom developed software based on 
LabVIEW (National Instruments). This software allows the user to 
access settings of the various devices on a single graphical user 
interface. An Arduino UNO board, connected via USB to the 
workstation, is integrated in the LabVIEW software providing 
control of the shutters, bright-field illumination and sample 
rotation. The custom-made LSFM allows for different possibilities 
for the sample mounting. In order to provide flexible, fast and easy-
to-use sample loading capabilities, an imaging chamber was 
designed and 3D printed using fluorinated ethylene propylene 





CO2 permeable. So, it allows for live imaging on specimens using 
water-dipping objectives. Prior to imaging acquisition, samples 
were loaded into FEP tubes and transported towards the detection 
objective field of view using a programmable syringe pump (Tecan, 
Cavro Centris). Once here, the two motors can rotate the sample, 
in order to choose the view of interest. This mounting system offers 
the possibility to easily insert, aspirate and discard the specimens 
without the need of agarose, enabling the possibility for high-
throughput studies with relatively big samples (up to 1 mm 
diameter). 
 
5.1.4. Antibody challenge, image acquisition and 
processing 
The fluorescent antibody (anti-CD44 Monoclonal Antibody 
(IM7), PE, eBioscience) was diluted in Tumor Cell Culture Medium, 
to a final concentration of 13 µg/mL, close to the range of 
therapeutic antibody concentration found in patient serum 
34,35
. 
Individual capsules were harvested from culture and loaded 
into the microscope tube in order to obtain a control image of the 
intrinsic autofluorescence and to assess general capsule features 
(in the bright-field). The capsule was then removed from the FEP 
tube, immersed in the antibody solution and reloaded in the 
microscope. Fluorescence was acquired in the 561 nm laser line. A 
3D stack of the capsule containing 235 planes separated by 3 µm, 
covering 705 µm, was acquired every 2 minutes. Acquisition was 
performed over a total of 3 h. 
The fluorescence intensity profiles for selected cell clusters 
(Figure 1-2) were obtained from the central plane of the capsule. 
Each cluster was marked using a ROI defined by a circular domain. 
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The fluorescence intensity over time was integrated and converted 
to a profile. All image processing was performed using Image J 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018). 
Further details on image processing are described in the 
Supplementary Materials and Methods. 
To smooth the experimental data noise, the five cluster 
profiles were fitted to growth curve models 
25
 and the model type 
showing the best fit (highest R
2
) was selected. For comparison 
between the profiles of the selected clusters, the delay time and 
the slope of log phase of the curve were calculated. The first of 
these parameters can be seen as a measurement of the time 
required for the antibody to reach that cell cluster in sufficient 
concentration to be detected. It was calculated as the time interval 
from the beginning of the experiment until the mean fluorescence 
value became larger than 5% of the total achieved fluorescence for 
that selected cluster. The slope of the log phase was obtained by 
calculating the slope of a linear fit, adjusted for this phase alone. 
For consistency, we assumed log phase of the curve to correspond 
to the portion of the model that takes place when the measured 
value (i.e. fluorescence and antibody concentration) corresponds to 
15% to 85% of its maximum observed value. 
 
5.2. Antibody diffusion model within the alginate capsule 
Antibody transport within the alginate capsule was assumed 
to be purely diffusional. In fact, assuming the capsule is immersed 
in a static fluid, no relevant convective transport is expected to 
occur 
36
. This diffusive behavior is modelled by Fick’s second law, 




















in which D is the diffusion coefficient (Dmedium for the medium and 
Dcell for the cells), C is the concentration of the antibody, t is the 
time, and x and y are the Cartesian coordinates. 
Cells detain a limited number of antigens where antibodies 
can bind. So, as the antibody binds, the number of available 
binding sites on the cell surface is reduced until reaching 
saturation, in which all or the vast majority of the binding sites are 
bound to an antibody molecule. This biological effect can be 
translated in terms of variation of diffusivity of the antibody in the 














in which a, n and p are adjustable parameters, Dcell is the diffusivity 
coefficient in the cells and Cnorm is a normalized concentration. The 
latter takes into account the fact that the concentration at which 
the cells get saturated is much smaller than the antibody 








in which Cinj is the antibody concentration of injection and C
t
i,j is the 
concentration of antibody in a cell localized in the position i,j. 
The model proposed here works under the following 
assumptions: (i) no significant antibody degradation occurs; (ii) the 
initial antibody concentration inside the capsule is zero; (iii) cell 
growth and death are not relevant; (iv) cell movement is neglected; 
(v) ECM formation, degradation or re-structure is negligible within 
the time interval of the experiment; (vi) initial Dcell was set as being 
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100 smaller than initial Dmedium for all cells (single cells, cancer cell 
spheroids and fibroblasts) and (vi) Dmedium is constant over time and 
through the extracellular space inside the capsule. 
Additionally, we also consider that antibody diffusivity 










 is the diffusivity coefficient of a cell in the spheroid 
whose distance to the cancer spheroid center is d, Dcell
max
 is the 
diffusivity coefficient of the cells located in the outer layer of the 
spheroid and rsph is the spheroid radius. 
 
5.3. Computational model fitting and simulation 
5.3.1. Definition of the initial setup: capsule domain 
The computational model and all simulations were 
implemented and run in Python (version 3.7). To numerically solve 
Fick’s second law in Eq. (3), the finite differences method was 
applied. This method to solve differential equations requires a 
discretized domain. So, a two-dimensional square grid (mesh) with 
200×200 equally spaced nodes and a 1000 µm side was created. 
Method convergence was evaluated as described in Supplementary 
Materials and Methods section and Figure S4.8. Each element 
(node) was assigned a range of intrinsic attributes (coordinates: x 
and y; type: cancer cell, fibroblast or ECM; diffusivity; and 
concentration). This grid is further split between two major 
domains: a central circular domain, representing the alginate 
capsule (centered in the mesh and with a radius of 350 µm) and its 
surrounding medium, representing the culture medium outside the 





capsule two alternative approaches were performed: one based on 
capsule digitization and another one based on tuned random 
distribution of TME elements (Figure 4.6A and B, respectively). 
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Figure 4.6: Experimental and computational workflow. A) 
Methodology applied in the digitized capsule approach (LSFM: light sheet 
fluorescence microscopy). B) Methodology applied in the tunable 
stochastic approach on an example. 
 
5.3.2. Capsule digitization from experimental 
capsule images 
Digitization of the capsule allowed to reproduce the 
experimental capsule in silico, with cancer cell spheroids and 
fibroblasts localized in the same positions. Based on the last frame 
of the experimental antibody diffusion video for a specific capsule 
slice (Additional file 2), Python Imaging Library (PIL) was used to 
convert the figure into a binary input (Figure 4.6A). The cancer cell 
spheroid was added manually, according with the contrast phase 
images acquired experimentally. 
 
5.3.3. Tunable random distribution of TME elements 
A stochastic framework, in which the TME elements are 
randomly distributed inside the capsule was also implemented. 
This process is tunable by the user who can set the total number of 
each TME element to include in the capsule (Figure 4.6A). From 
images of several capsules, two circular regions of cell distribution 
can be identified inside the capsule. So, first, the capsule domain 
was divided in two rings, with the inner ring corresponding to 80% 
of total radius. Cancer cell spheroids were defined as circular 
entities with a selected radius, whose localization can be set by the 
user or randomly. Since antibody cell targets might not be present 
in all cells, targeted and non-targeted cells can be considered in 
the model. The pre-defined number of cancer cells and fibroblasts 
(as single cells or small clusters) were randomly distributed with a 
preference towards the outer ring, as the experimental results 
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showed they were more prevalent in this area. Fibroblast average 
radius was assumed to be 11.5 µm as single cells 
37
 or 17.5 µm in 
the cluster form (measured from the experimental images). 
Collagen fibers can also be included and randomly distributed 
within the capsule domain. These fibers were assumed to have 30 
μm length 38, to have 4 possible orientations (0, 45, 90, 135º) and 
zero diffusivity. The overall process of model development is 
schematized in the workflow in Figure S4.9 and Figure 4.6. 
 
5.3.4. Benchmark of the computational model with 
experimental data 
Experimental fluorescence profiles and computational 
antibody concentration profiles were normalized so as to vary 
between 0 and 1 and thus allow their comparison (Figure 4.6A). 
The benchmarking of the computational model by the 
experimental data was performed by implementing the Broyden-
Fletcher-Goldfarb-Shanno (BFGS) optimization algorithm to find the 
saturation parameters a, n and p of Eq. (4) which minimize the root 
mean square error (RMSE) for a set of selected cell clusters. The 
RMSE between the experimental and computational normalized 












in which n is the number of points in which computational and 
experimental values are compared, ŷi is the predicted value from 






All cells were assumed to be target cells of the antibody, 
since CD44 is detected in both hDFs 
39




5.3.5. Boundary conditions 
The capsule external domain was defined as having a fixed 
antibody concentration of 13 μg/mL, as in the experimental setup. 
We assume that, for the modelled timeframe, the depletion of the 
medium is not significant since the volume of antibody solution is 
two orders of magnitude higher than the capsule volume. 
 
6. List of abbreviations 
BFGS: Broyden-Fletcher-Goldfarb-Shanno; ECM: extracellular 
matrix; FEP: fluorinated ethylene propylene; GAG: 
glycosaminoglycan; hDFs: Human Dermal Fibroblasts; LSFM: light 
sheet fluorescence microscopy; NSCLC: Non-Small Cell Lung 
Carcinoma; PIL: Python Imaging Library; RMSE: root mean square 
error; TME: tumor microenvironment 
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12. Supplementary information 
Table S4.1: Fitted Dcell and Dmedium by application of the BFGS algorithm, 













Figure S4.1: Comparison of profile features (delay time and slope) 
with cell cluster features (distance to capsule periphery and section 
area) obtained experimentally and for the computational model. A) 
Experimental delay vs distance to periphery. B) Slope of log phase of the 








I 0.164 0.126 0.06 
II 0.659 0.110 0.09 
III 0.712 0.156 0.11 
IV 0.151 0.103 0.04 






Figure S4.2: Definition of the initial setup by application of Python 
Imaging Library (PIL) tool. A) Read-out from Fiji of the last frame for the 
selected capsule section; B) digitized capsule obtained by application of 
PIL tool to A); C) component distribution and aggregate placement in 
accordance with B) and identification of the selected cell clusters 
equivalent to the experimental capsule section (Figure 2A); D) Diffusivity 
coefficient distribution within the capsule in the computational model for 
the digitized capsule. 
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Figure S4.3: Diffusivity coefficient on the computational model over 
time, for the digitized capsule. Computational model was run for a=1, 








Figure S4.4: Comparison of best fittings obtained considering only 
Fick’s law (blue curve) or Fick’s law combined with exponential 
saturation (orange curve) to the experimental data (red curve). 
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Figure S4.5: Tunable stochastic computational model examples. A 
modular tuned stochastic computational framework was developed and 
its versatility allows the user to set a defined amount of cancer cells 
aggregates and fibroblasts as single cells or clusters and also collagen 
fibers. First column shows models with varying amount of single and 
small clustered cells. Second column shows capsules with different 
number of aggregates. The third column shows variation in cancer 
aggregate radius. The fourth column shows the inclusion of several 







Figure S4.6: Exponential saturation equation for several different 
inputs. 
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Figure S4.7: Schematic representation of the LSFM acquisition portion 
with a photography showing a zoom on the FEP chamber. Lasers 
illuminate the sample (loaded on a TEP tube) from two directions. The 








Figure S4.8: Mesh convergence study: 100x100, 200x200 and 
300x300. Initial and final time-points for the model run with the specific 
mesh size. 
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Figure S4.9: A flow diagram of the tunable stochastic computational 
framework. The model starts by defining the mesh and creation of the 
domain. Then, verifies if fibroblasts, cancer aggregates and fibers are to 
be included in the model. Then, the remaining free space in the mesh is 
defined as the extracellular space and the diffusivity for all the parts of 
the system is set. Then, it calculates the concentration of the antibody in 
each node of the mesh by using the discretised second Fick’s law. With 
these new values, it calculates the new cell diffusivity coefficients. This 
process runs iteratively until reaching the maximum time, in which it 






Supplementary Materials and Methods 
S1. Image processing procedure 
All image processing was performed using Fiji, ImageJ 
software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018). 
Data collected from LSFM experiments were sets of sequential 
images of the fluorescence of several sections of each alginate 
capsule over time. For further analysis, only one capsule section 
corresponding to middle plan was selected. First, we selected 
regions of interest (ROI) corresponding to the areas where cluster 
of cells were identified. The image was converted to 8-bit, a 
threshold mask was applied and the image was transformed into 
binary. The diffusion profiles (mean grey values over time) were 
obtained using the Z-axis profiler plugin. Five representative cell 
clusters of one capsule were selected for this analysis. 
 
S2. Method convergence with varying mesh size 
A method convergence study was performed choose the 
mesh size. Different mesh sizes were tested to assess if the 
obtained antibody concentration profiles were not significantly 
affected by increasing the mesh step. The step process was the 
following: 1) create a mesh using the fewest, reasonable number 
of elements and analyze the antibody concentration profile inside 
the capsule; 2) recreate the mesh with a denser element 
distribution, and compare the new obtained antibody 
concentration profiles to those obtained with the previous mesh. If 
the final antibody distribution throughout the capsule is equivalent 
in the tested conditions, then the mesh size selected for the study 
was thin enough to give accurate results. In this study, we 
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compared meshes with size (number of nodes in x and y) of 
100x100, 200x200 and 300x300, maintaining the 1000 µm side 
(Figure S8). 
 
13. Additional files 
All additional files can be found in: 
https://osf.io/yd5vu/?view_only=93e411b15dba44249811d82d7
4d9162a 
Additional file 1: Video of the LSFM maximum intensity projection 
for all acquired frames, corresponding to 3h (AVI, 6044 kb) 
Additional file 2: Video of the LSFM selected capsule central plane, 
corresponding to 3h (AVI, 4865 kb)  
Additional file 3: Video of the simulated antibody concentration 
over the 3 h time interval (MP4, 483 kb) 
Additional file 4: Video of the evolution of simulated diffusion 
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Cancer is the second leading cause of mortality worldwide, 
despite the extraordinary advances in the last two decades due to 
the development of targeted therapies. These therapies target 
specific molecules required for cell growth and tumorigenesis; 
nonetheless, resistance often leads to patient relapse and disease 
progression. This resistance can be partially explained by the 
crosstalk and modulation by the several tumor microenvironment 
(TME) cellular and non-cellular elements. To study this intricate 
network, cancer models incorporating TME features have been 
proposed. 
This thesis aimed to establish and characterize ex vivo, in 
vitro and in silico TME models, as tools to study cancer targeted 
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Figure 5.1: Aim and achievements of each research chapter of the 
thesis. BC: breast cancer; ECM: extracellular matrix; ERα: estrogen 
receptor α; TME: tumor microenvironment. 
 
1.1. Development of long-term ERα-positive breast cancer 
ex vivo model 
Estrogen receptor α (ERα) represents one of the most 
relevant receptors in breast cancer (BC), since it a main driver of 
tumorigenesis in ERα-positive BC and, for that reason, is the focus 
of endocrine therapies. Despite the application of several of these 
therapies in the clinics for the treatment of ERα-positive BC, tumoral 
therapeutic resistance is an issue. To study the mechanisms that 
underly the resistance BC models in which ER signaling is sustained 
are needed. 
We hypothesize that by combining alginate encapsulation 
and agitation-based culture, it would be possible to maintain BC 
tissue architecture for longer periods of time, with retention of the 
cellular components and, therefore functionality of ERα. When 
applied to partially digested ERα-positive BC tissue (tissue 
microstructures, Chapter II), we verified that this strategy allowed 
for the culture of microstructures with high cell viability, that 
maintained the original tissue architecture for at least one month. 
ERα expression and functionality were also assessed by protein and 
mRNA detection and by inhibition with a standard-of-care 
compound and stimulation with estrogen (an ERα ligand) and 
evaluation of ERα-targeted genes. We reported that gene 
expression of the individual ERα-targeted genes varied in BC 
microstructures from different patients, when the same stimuli was 
applied. This might be explained by the inherent heterogeneity 





Centenera et al. observed a very heterogenous PgR mRNA level on 
patient-derived explants upon estrogen stimulation 
1
. Gohno et al. 




In the present thesis, the components responsible for the 
maintenance of the ERα signaling in the ex vivo model were not 
assessed. Though, we hypothesize that the maintenance of the 
TME, and specifically the stromal cells, greatly contribute to the 
preservation of ERα signaling. As a matter of fact, stromal cells are 
known to produce the enzyme aromatase, which increases intra-
tumoral estrogen levels and, consequently, contribute to the 
activation of the receptor 
3,4
. Additionally, in an in vivo mouse 
model of intraductal engraftment of ERα-positive cells, it was 
shown that the TME plays an important role in maintaining ERα-
positive cells. While the mammary fat pad environment induces a 
basal phenotype on the implanted cells, an intraductal 
transplantation results in the maintenance of ERα-positive cells 5. 
The relevance of our model is evident when comparing with 
both BC gold-standard 2D monolayer cell culture and mice models. 
In the first, both cell viability and ERα expression/functionality are 
kept, however, cells lack not only heterogeneity but also the three-
dimensional (3D) architecture found in tumor tissue 
6
. Most mice 
models are based on genetically engineered animals that develop 
ERα-negative tumors. In the case of xenograft mice models, 
hormonal supplementation is usually required, leading to 
unphysiological estrogen levels in mouse serum 
5,7
. One exception 
can be found in Sflomos et al., which reported an intra-ductal 
mouse model that does not require estrogen supplementation for 
the maintenance of transplanted ERα-positive cells 5. 
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Our results showed that alginate encapsulated 
microstructures have higher and more homogenous cell viability 
than their non-encapsulated counterparts. This may suggest that 
the alginate capsule has both a protective role against shear stress 
and a structural role in maintaining the TME inside the capsule. 
Additionally, the cultured microstructures revealed dense and 
organized/fibrillar collagen which hints that the developed culture 
method also allowed the maintenance of the extracellular matrix 
(ECM) elements. Both cell viability and ECM deposition were 
sustained for at least one month in culture. Some previously 
published explant models employed bioactive collagen as 
biomaterial 
8,9
. One of these described culture under perfusion, 
attaining high cell viability  sustained up to two weeks 
8
. In this 
same report, tissue slices were treated with an anti-ERα drug and 
cell viability was assessed but, however, ERα signaling was not 
evaluated 
8
. In other scaffold-free models, cell viability was 
maintained for only up to four 
10
 or seven days 
11
. This reduced time 
hinders the use of these models to test of the long-term effects of 
ERα-targeted therapies. 
The developed BC ex vivo model represents the longest 
reported culture time of BC tissue with maintenance of the ERα 
signaling and can be used to study the mechanism of resistance 
development against several hormonal therapies (e.g. reduction of 
ERα levels or upregulation of HER2 12). We challenged this model 
with fulvestrant, but other hormonal therapies could also be tested, 
namely selective ER modulators such as the clinically used 
tamoxifen. In addition, it can be used to study ERα-related signal 
transduction pathways, such as MAPK/Ras and PI3K/AKT signaling 
pathways 
13





medicine tool since an individual patient’s tumor can be challenged 
with several therapies prior to treatment, allowing for the selection 
of the best course of therapy. These models can aid in the discovery 
of novel therapeutic targets. In the future, the developed model can 
be better characterized in terms of the other BC relevant cellular 
receptors, such as progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2). Such a study may 
include the challenging of encapsulated microtissues with 
standard-of-care therapies that target these receptors, namely the 
pertuzumab therapeutic antibody. 
Finally, some already available platforms to culture 3D in 
vitro cell models can be applied to patient-derived microtissues. 
Microfluidic techniques are suitable to be used with these, as the 
techniques are designed to work with small amounts of biological 
material. The tumor-on-a-chip strategy could be implemented with 
tumor tissue, rather than cell-based reconstruction of the TME. The 
flow of culture medium would promote both nutrient and gas 
diffusion and drug challenges can be easily implemented through 
the inlet channel. Additionally, the application of microfluidic 
techniques would allow for a reduction of reagent consumption. 
Further improvement can be attained by creating the more complex 
body-on-a-chip, in which tissue from several organs can be 
combined in a single chip. This could be used in the study of 
metastasis by including one tumor tissue and several healthy 
tissues in the chip. Bioprinting can also be used in combination 
with patient-derived tissues, since that technique allows to print 
ECM components in specific regions. This combination could be 
used to study how specific ECM elements can influence several 
cellular processes. 
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The work developed in Chapter II shows that the 
combination of alginate encapsulation with a dynamic culture 
system is a good strategy for long term maintenance of ERα-
positive BC explants, ex vivo, and for the interrogation of the drug 
treatment effects on a culture setting more similar with the in vivo 
situation. 
 
1.2. Experimental and computational cancer model as 
tools to study antibody targeted therapy 
TME has been reported to play a role in anti-cancer therapy 
efficacy. For instance, ECM components such as collagen fibers and 
GAGs have been previously described as key influencers on the 
transport of therapeutic molecules 
14–16
. The study of the role of 
several TME components on drug distribution can be achieved with 
the use of both computational and experimental models. 
Several in silico models have been reported that describe 
and simulate tumors at different levels, ranging from molecule to 
tissue scale 
17
. Previous contributions to the topic discuss drug 
distribution to and within the TME 
18–20
. However, a computational 
model that can detail on the influence exerted by the amount or 
distribution of different individual TME components on antibody 
transport is still inexistent. As such, in Chapter IV, we developed 
a computational framework to tackle this problem. 
Our group has been developing in vitro models of TME that 
include several non-cancer cell types, such as fibroblasts and 
immune cells, and ECM accumulation 
21,22
. These models consist of 
alginate capsules containing the several cell types: tumor cells from 
distinct tumor types (such as breast, and lung cancer) and stroma. 





including cell maturation and polarization; secretion and 
accumulation of cytokines and ECM, among others 
21,22
. However, 
the mechanical characterization of these models is also relevant, 
as mechanotransduction can heavily influence cancer features 
23–25
. 
Consequently, in Chapter III, we characterized our in vitro TME cell 
models. The mechanical properties of the alginate capsules were 
assessed in terms of their stiffness. Cell-filled capsules were softer 
than empty capsules, regardless of their cellular composition. This 
may be explained by the fact that the occupation of the capsule by 
cells interferes with alginate crosslinking, which reduces the 
number of binding sites between alginate and the counter-ion, 
finally leading to the formation of a softer hydrogel 
23,24
. Different 
stiffnesses were also observed between mono- and co-culture. 
Nonetheless, the stiffness of capsules containing mono and co-
cultures was within the range reported for BC tissue 
26
. 
We further evaluated capsule surface’s porosity by scanning 
electron microscopy. Results showed the commonly used alginate 
capsules are hydrogels with surface porosity, as it was already 
suggested in the literature 
27,28
. In turn, this porosity allows for both 
gas and nutrient exchange 
28
. We concluded that the average pore 
size in alginate capsules was c.a. 100 nm, 1 order of magnitude 
larger than antibodies (14.5 nm x 8.5 nm x 4.0 nm). As these are 
the largest therapeutic molecules 
29
, this would suggest that the 
capsule is not a physical barrier and that the in vitro model may be 
used to address antibody-based therapies. In fact, in Chapter IV, 
we developed a framework to study antibody transport consisting 
of an in silico model, benchmarked with experimental data 
acquired using Light Sheet Fluorescence Microscopy (LSFM) applied 
to the in vitro model characterized in Chapter III. To the best of 
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our knowledge: (1) this work represents the first usage of LSFM to 
live track antibody distribution within the TME; (2) no study exists 
detailing the influence of the amount or distribution of different 
individual TME components on antibody transport. As a matter of 
fact, routine assessment and tracking of antibody distribution 
within the spheroids or xeno-transplanted tumors is performed by 
either: a) incubation of antibodies or fragments followed by 
detection using avidin-biotin method and peroxidase 
30
, or b) by the 
use of fluorescence labelled antibodies and detection by 
immunohistochemistry using microscopy techniques 
31,32
. We 
started by comparing confocal microscopy and LSFM. The selection 
of LSFM technique agrees with the conclusions of Lazzari et al., in 
which they show that it is preferable to confocal microscopy on the 
assessment of drug distribution in tumor co-culture aggregates. As 
the latter only allows scanning up to a depth of 100 µm, 
information on deeper layers is lost, a problem that is circumvented 
by using LSFM 
33
. When analyzing the fluorescence profiles for 
several cell clusters within the alginate capsule, we observed a 
weak correlation between cell cluster distance to capsule periphery 
and the time needed to detect a fluorescence signal. This might be 
explained by either different amounts of antigen on the surface of 
different cells or that the capsule interior has some degree of 
heterogeneity caused by localized ECM accumulations. 
In Chapter IV, the transition from experimental to 
computational models derive from two key assumptions regarding 
antibody distribution. Firstly, we assumed that antibody transport 
is purely diffusive under Fick’s law; and secondly, that antigen 
saturation during antibody binding follows a generic exponential 





section of a co-culture alginate capsule, obtained using LSFM. To 
this digitized section, we applied what can described as a “hybrid” 
model, similar to the majority of recently developed models 
34
 of 
antibody transport. We used a combination of an on-lattice model 
(i.e. cell distribution) with continuous model techniques (i.e. 
solving the diffusion equation with a finite difference approach). 
Using the developed model, we created predictive computational 
profiles that closely mirror the observed experimental ones. As we 
used the experimental data to benchmark our computational 
model, any discrepancies between the two models hint at the 
absence of important components of the system in the 
computational model. The lack of discrepancies allows us to 
conclude that, as we previously assumed, antibody diffusion is the 
main transport mechanism within the alginate capsules. The 
benchmarked code was further used to generate virtual capsules. 
For this, we applied a stochastic tuned approach, which allows the 
user to set specific features and assess antibody diffusion patterns 
under different initial conditions. With this approach, we tested the 
influence of collagen fibers on antibody distribution profiles for the 
two identical capsules. As collagen fibers act as perfect barriers, 
our results show that their presence severely hinders the ability of 
the antibody to reach the target cells, as was experimentally 
demonstrated by Davies et al. and Kihara et al. 
14,16
. 
In Chapter III we also evaluated ECM accumulation. This 
could clarify the differences observed between the stiffness of 
mono- and co-culture capsules (observed in Chapter III). 
Furthermore, it would help in the confirmation of the existence of 
a heterogeneous medium (an inherent physical barrier to antibody 
transport) present on the co-culture capsule (assessed in Chapter 
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IV). In fact, fibroblasts are the major producers of collagen in the 
TME 
35
. Collagen has been linked to an increased stiffness 
36
 and to 
biomolecule hindered diffusion 
14,16
. Collagen and GAGs deposition, 
which were assessed by immunohistochemistry were low in mono- 
and co-culture capsules. Conversely, we had observed higher levels 
using other detection techniques in other 
21,22
. It should be possible 
however to increase ECM accumulation by implementing 
modifications in the alginate itself. Alginate alone does not 
promote cell adhesion, due to lacking of binding sites 
28
 which 
might be limiting ECM production. However, when alginate is 
combined with other polymers (e.g. chitosan) or ECM components 
(e.g. fibronectin peptide arginine-glycine-aspartic acid), cell 
adhesion is enhanced 
28
. This helps promoting a tissue-like 
environment, where cells are adhered rather than in suspension. 
The in vitro model characterization presented on Chapter 
III furthered the knowledge on both surface porosity and 
mechanical features of alginate capsules, which are extensively 
employed in several applications 
21,22,37,38
. The model can be further 
improved by adding extra cell types (endothelial cells or immune 
cells) and assess how these variations can influence the mechanical 
properties of alginate capsules. Further testing would be required 
to verify the influence of cell types and/or ECM deposition on the 
surface pore size distribution. Additionally, as electrostatic charges 
can also play a role in drug-TME interactions, the alginate capsule’s 
electrical charge should be also evaluated.  
In Chapter IV, we showed that a combination of LSFM 
applied to 3D in vitro cell models and computational modelling is 
a stepping-stone to study therapeutic antibody distribution within 





tool”, in which potential experimental conditions can be tested 
before being pursued experimentally. This model can also work as 
a predictive tool, hinting at which specific TME conditions produce 
a given drug diffusion output. In the future, the computational 
framework could be further developed (and benchmarked) to 
account for the complexity of the ex vivo model developed in 
Chapter II. This in turn would imply a further knowledge on the 
diffusion barriers that exist in real tissue, as opposed to a 
reconstructed one. In the ex vivo model, a plethora of cell types 
and diffusion barriers (e.g. significant fibrillar collagen deposition 
as shown in Chapter II) are inherently present. By contrast, in in 
vitro models only some cell types are available, and ECM is not in 
its native form. 
The in silico model could be enhanced by coupling it with a 
detailed measurement of the diffusivity coefficient by fluorescence 
recovery after photobleaching (FRAP) or fluorescence correlation 
spectroscopy (FCS). These can be performed in different regions of 
the capsule over time and would allow a better description of the 
experimental data, helping to decipher intra-capsule 
heterogeneity. In the developed computational model, we assumed 
a constant antibody diffusivity in the TME but this might not be the 
case. Having clear data on the spatio-temporal evolution of this 
coefficient would result, thus, on higher predictive power for the 
computation framework. We developed the in silico model in 2D 
conditions, due to computational power constraints. While 3D 
modelling would be more conclusive, using purely 2D models we 
were able to hint at a non-radial antibody diffusion. Labeling of 
cells with a fluorescence tracer prior to antibody challenging would 
allow to discern between cells with bound and unbound antibody. 
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This can help identify both possible regions where preferential 
diffusion of antibody occurs and regions where the antibody cannot 
reach. 
 
2. Final Remarks 
With this thesis we proposed three different types of TME 
models that can be used as mutually complementing tools for the 
assessment of targeted drug response. Overall, this work expanded 
the knowledge in the fields of experimental and computational 
cancer models and targeted cancer therapies. 
Both experimental models described in the thesis were 
maintained in a dynamic system in which culture progression can 
be evaluated using non-destructive sampling 
39
. Likewise, agitation 
helped sustaining high cell viability by ensuring a homogeneous 
distribution of both oxygen and nutrients as well as a reduced 
thermochemical gradients 
40
. The ex vivo model maintained all the 
TME components architecturally organized as in the human 
tumors. Due to its human origin, the amount of tissue that can be 
obtained is a major problem. This in turn can be a major 
disadvantage in drug screening assays. Conversely, the in vitro 
model is based on virtually unlimited cell sources, which makes it 
suitable for assays requiring large numbers of cells. In these 
models, interpreting results is facilitated due to the easier 
separation and consequent analysis of the several components of 
the model. However, since the tumor is “reconstructed” in the lab, 
native tissue architecture is difficult to replicate. Finally, in silico 
models are cost-efficient when compared with cell and tissue 





conditions before pursuing them experimentally. Nonetheless, 
they cannot simultaneously mimic all the biological and chemical 
processes that naturally occur in cancer.  
To conclude, ex vivo, in vitro and in silico models should not 
be seen as separate tools but pieces of a larger puzzle. While strong 
as individual approaches to the study of cancer, they are at their 
finest when integrated in a larger framework. 
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